including all mature teratoma components, IMP3 may serve as a potential tissue biomarker to distinguish metastatic teratoma from its benign mimickers, especially in the setting of status post chemotherapy for germ cell tumors.
Main renal vein (MRV) involvement was noted in 6/15 cases by expert radiologist but in 9/15 by patholgists. The 3 discrepant cases involved the left kidney.
When compared with radiology images the 3 involved veins were large primary tributaries of the MRV. Conclusions: 1) Sinus involvement is not routinely mentioned by radiologists 2) Sinus involvement is usually detectable by CT/MRI (9/12) when present 3) Unrecognized sinus invasion by radiologists may lead to overestimate of tumor size and understaging that can be corrected by education on pathologic features of RCC 4) Discrepant MRV involvement by radiologists versus pathologists affecting the left kidney is due to differing definitions of what constitutes the MRV. 
Conclusions:
Our study demonstrates that the majority of rare carcinomas of cervix, including NE variants are positive for high-risk HPV which may suggest a unique carcinogenic pathway induced by the virus. This finding may have a role in tailoring HPV sub-type selection for vaccine and also theraputic strategies. Our data also suggest that tumors with serous type morphology and p53 expression are possibly derived from uterine corpus and should be treated accordingly.
993
HPV DNA In-Situ Hybridization, p16 and p53 in a Cohort of 128 Vulvar Squamous Cell Carcinomas. G Allo, AM Mulligan, D Ghazarian, M Tsao, H Mackay, BA Clarke. University of Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; St. Micheal's Hospital, Toronto, ON, Canada. Background: Vulvar squamous cell carcinomas may develop via two different pathways: the most common pathway is HPV negative well differentiated keratinizing squamous cell carcinoma arising in elderly women, often in a background of lichen sclerosis and differentiated vulvar intraepithelial neoplasia; HPV positive vulvar squamous cell carcinoma occurs in younger women in association with usual vulvar intraepithelial neoplasia. P53 is typically over-expressed in the former and p16 in the latter. We analyzed p16, p53 and HPV integration in a cohort of 128 cases of squamous cell carcinoma of the vulva and determined the prognostic significance of these biomarkers. Design: An annotated, duplicate core tissue microarray of 128 cases of vulvar squamous cell carcinoma was constructed. HPV DNA in situ hybridization and p16 and p53 immunohistochemical staining were performed. Statistical analysis was performed using JMP v8.0.2 (SAS institute, Carey, NC USA). Conclusions: LBC Pap test results of HSIL were associated with 50% of 508 histopathologic CIN2/3 diagnoses, followed by ASC-US in 19%, LSIL in 16%, and ASC-H in 13%. Over a three year period preceding CIN2/3 diagnoses, a significant number of isolated negative Pap (58.6%) or negative HPV test (17.6%) results were noted, supporting the value of combined cytologic and HPV co-testing.
Factors Predicting Response to Progestin Treatment for Complex Atypical Hyperplasia/Well Differentiated Endometrial Carcinoma in Premenopausal Patients.
C Aoyama, K Penner, N Ostrzega, J Rao, C Walsh, O Dorigo, I Cass, B Balzer, C Holschneider. Olive View-UCLA Medical Center, Sylmar, CA; UCLA Medical Center, Los Angeles, CA; Cedar-Sinai Medical Center, Los Angeles, CA. Background: Response rates of complex atypical hyperplasia (CAH) and/or Grade 1 endometrial carcinoma (G1EAC) to progestin treatment are approximately 70 % with median time to resolution being 5 months. Little is known about factors associated with patient's response to this hormone therapy. Purpose: To establish clinical and histologic indicators for predicting response to progestin treatment in premenopausal patients with CAH and/or G1EAC. Design: In 40 premenopausal patients with CAH and/or G1EAC, clinical data (age, ethnicity, parity, BMI) and histologic features from pre-and first-on-(minimum 8 weeks of progestin)-treatment endometrial sampling (ES) were analyzed for distinguishing Responders from Non-Responders. ESs were reviewed by 2 pathologists independently, and the diagnosis, architectural abnormalities (papillary; polypoid; cribriform; backto-back; budding), nuclear abnormalities (nuclear stratification; nucleolus; N/C ratio >0.67), cytoplasm eosinophilia, cytoplasm squamoid changes, and decidual changes were recorded. Responders were defined by absence of atypia or carcinoma in 2 consecutive ESs and/or hysterectomy.
Results:
Variables associated with Response in univariate analysis Conclusions: Non-response to hormone treatment in CAH and G1EAC was associated with (1) Pre-treatment ES with significantly abnormal architecture; (2) First-treatment ES with diagnosis worse than simple hyperplasia (SH); (3) First-treatment ES with persistent abnormal architecture; (4) First-treatment ES with persistent nuclear atypia (nucleolus, mitosis > 2/10 glands) and (5) First-treatment ES with >1mm lesion.
were selected with similar criteria as group 2 but with negative sampled lymph nodes. Group 4 patients were those with primary peritoneal serous carcinoma with lymph node metastasis (n=13). Median follow up was 72 months (range 1 to 144 months). Patients with primary ovarian serous carcinoma with regional lymph node metastasis without peritoneal involvement had better recurrence free survival (RFS) and overall survival compared to the rest of the groups (p=0.026). Survival was also better in patients with primary peritoneal serous carcinoma with lymph node metastasis than in those with primary ovarian serous carcinoma with peritoneal involvement and lymph node metastasis. There was no significant age variation and all tumors were histologically high grade. Pelvic lymph nodes were more frequently involved in peritoneal carcinoma versus aortic lymph nodes in ovarian carcinoma.
Conclusions: 1-Patients with primary ovarian serous carcinoma with lymph node metastasis without peritoneal involvement have better survival than those with peritoneal involvement. 2-Patients with primary peritoneal serous carcinoma with lymph node metastasis have better survival than those with primary ovarian serous carcinoma with peritoneal involvement and lymph node metastasis. Based on this study, stage IIIC ovarian cancer patients need to be stratified to reflect these significant prognostic differences. Background: Ovarian/peritoneal high grade serous carcinoma typically presents at advanced stage and has a low 5 year survival rate. Optimal surgical debulking and tumor sensitivity to platinum-based chemotherapy are two well-established prognostics. Molecular markers that identify more clinically aggressive tumors would allow for the development of individualized treatment options. PTEN is a key negative regulator of the PI3K signaling pathway. Loss of PTEN expression in endometrial carcinoma is associated with endometrioid histology; women with endometrioid tumors have a better prognosis than those with non-endometrioid tumors. In breast cancer, loss of PTEN is associated with resistance to Herceptin. Thus, measurement of PTEN expression has the potential to provide important prognostic information. Currently, there is no established clinical scoring system for assessing PTEN expression by immunohistochemistry (IHC). Therefore, we first established a useful PTEN IHC scoring system and then determined if PTEN expression was associated with relevant clinical variables in ovarian high grade serous carcinoma. Design: PTEN IHC (Dako, clone 6H2.1) was assessed in 126 women with stage III, high-grade serous carcinoma of the ovary/peritoneum who were treated with surgery and then a platinum plus taxane regimen. A 3-tiered scoring system was developed (negative, reduced, positive) based on tumor expression of PTEN in relation to stroma, which was always strongly positive. Immunohistochemistry for anti-phosphorylated (serine 235/236) S6 ribosomal protein (pS6) was performed to validate the PTEN scoring system. PTEN expression was assessed in relation to clinical characteristics using Cochran-Armitage trend test, Fischer's exact test and log-rank trend test. Results: 11% of the cases had complete loss of PTEN by IHC. The presence of significantly increased pS6 expression in these cases helped to validate the PTEN IHC scoring system. PTEN protein expression was not associated with platinum resistance or surgical debulking status. Positive PTEN expression, which was present in 58% of the cases, was significantly associated with decreased recurrence free survival compared to tumors with negative or reduced PTEN expression (18 months vs. 29 months; p=0.0009).
Conclusions:
We have developed a clinically useful scoring system for PTEN IHC in ovarian cancer which can be used for assessing patient eligibility for treatment with PI3K inhibitors. Importantly, positive PTEN expression is associated with decreased survival. This may help to identify patients who can receive more aggressive therapy.
Preinvasive Stage in the Endometrium: Relation and Role of Clonal Expansion and PTEN.
H Baloglu. GATA Haydarpasa Training Hospital, Istanbul, Turkey. Background: Physiologic endometrium may undergo proliferation under unopposed estrogenic stimulation that progress to hyperplasia. Some of the hyperplastic glands gain capacity to generate monoclonal proliferation and stromal invasion. The role of PTEN gene in this process still remains uncertain, although there are many theories. In this study, we investigated a neoplastic transition spectrum in 80 cases model to understand the place of clonal expansion and its relation to PTEN functional loss (mutation or promoter methylation) in the way of progression to invasive carcinoma process. Design: Endometrial samples of 80 hysterectomy specimens diagnosed as benign (n=20), hyperplasia (30 with atypia, 10 without atypia) and endometrioid carcinoma were studied. Due to the performance of applied techniques like laser micro dissection, DNA extraction, PCR, clonality analysis, DNA sequencing and methylation analysis, 25 cases were excluded from the study and replaced by new cases. All hyperplasia cases were selected on the basis of the absence of concomitant carcinoma. Epithelial components were collected by laser micro-dissection. After DNA extraction, clonality was determined by human androgen receptor gene assays based on methylation-specific PCR (HUMAR-MPS). PTEN gene exons were amplified by PCR and sequenced.
According to the clonality and PTEN mutation results, cases of only monoclonal and PTEN wild type hyperplasia were submitted to methylation detection procedure. Results: All benign endometria were polyclonal (PC) and all carcinoma were monoclonal (MC). Glandular proliferation was MC in 31 and PC in 9 cases of 40 hyperplasia. Five of 10 cases of hyperplasia without atypia were PC and remaining 5 were MC. In 30 atypical hyperplasia cases, 26 were MC whereas only 4 were PC. None of the benign endometrial samples -which represented atrophy, secretion, proliferation and polyprevealed PNEN mutation. In atypical group, only one of 10 hyperplasia cases without atypia revealed PNET mutation whereas PTEN mutations were seen in 8 cases. Four of each low and high grade carcinomas were PTEN-mutated. None of the PC samples were consistent with PTEN mutations. In all 51 MC lesions, 17 were PTEN-mutated and most of the PTEN mutations were in exon 5 and 7. In all 22 monoclonal hyperplasia cases with wild type PTEN, 13 revealed PTEN promoter methylation. Conclusions: Our findings suggest that there is strong evidence that functional loss of PTEN, either because of mutations or promoter methylation, occurs following monoclonal expansion in the endometrial glandular neoplastic transformation.
Conclusions:
The molecular alterations found in our ECSs suggest that, together with p53, two main pathways could be implicated in the pathogenesis of this neoplasia, like the PIK3CA-AKT and the EGFR-NRAS-KRAS pathways. Immunohistochemical staining for CD68 (DakoCytomation, Carpinteria, CA) was performed on each tumor. The number of TAMS was counted, averaged over 10 high powered fields, and stratified into those associated with tumor epithelium or stroma. The data was then analyzed for correlation with various prognostic factors. Results: There were 22 endometroid, and 18 serous or clear cell carcinomas included. The number of TAMS in the epithelium and stroma was correlated with tumor characteristics (Table 1) . Conclusions: Although our study did not show statistically significant correlation between TAMS and any of the prognostic factors in EAC, we concluded the following:
There is an overall greater number of TAMS seen in tumor related stroma than in the epithelium. More TAMS (epithelial and stromal) are seen in tumors showing myoinvasion and/or lymph node metastasis. Finally, there are a slightly increased number of epithelial associated TAMS seen in tumors with LVI than those without. Background: Microsatellite instability (MSI) arises due to loss of function of mismatch repair (MMR) proteins, commonly MLH1, MSH2 and MSH6, either through genetic loss or epigenetic silencing. There are only a few and conflicting reports on the prognostic value of MSI in endometrial cancer. The aim of this study was to investigate this parameter in endometrioid endometrial tumors with the emphasis on early vs. advanced stage disease. Design: Immunohistochemistry for MMR proteins, MLH1, MSH2 and MSH6, was performed in 100 endometrioid carcinoma cases. The patients, aged 28-92, had no known history of HNPCC. Immunohistochemistry was scored as positive or negative. Tumors with loss of any one of the three MMR proteins were classified as having MSI, with the remainder classified as microsatellite stable (MSS). Patients were grouped as early (I and II) and advanced (III and IV) stage. Outcomes including depth of myometrial invasion (MI), lymphovascular invasion (LVI), lymph node (LN) status, relapse free survival and overall survival were examined.
Microsatellite Instability in Advanced Stage

Results:
The results are summarized in tables 1 and 2. MSI was identified in 31 patients (28 MLH1, 1 MSH2, 2 MSH6). Patients were of similar age in the early (59) and advanced stage (61) groups. Unlike the early stage tumors, advanced stage tumors with MSI had significantly shorter overall survival and relapse free survival rates, as well as a greater depth of MI. They also showed a trend toward a higher incidence of LVI and LN metastases. In addition, MSI was significantly more common in grade 3 tumors (58%) than in grade 1 and 2 tumors (30%) (p=0.0441). Conclusions: Advanced stage endometrioid endometrial carcinomas with MSI are associated with a worse prognosis than their MSS counterparts. MSI may predispose tumors toward an accelerated pace of acquisition of new mutations, leading to more aggressive tumor behavior in advanced stages. As such, identification of MSI in endometrioid endometrial tumors may be instrumental in guiding patient management.
Differential Expression of Survivin and γ-H2AX in Vulvar Squamous Epithelial Lesions.
H Brustmann. Landesklinikum Thermenregion, Moedling, Lower Austria, Austria. Background: Survivin inhibits apoptosis, is involved in the regulation of cell cycle progression and the mitotic spindle formation. It is overexpressed in many cancers. The histone γ-H2AX is a marker of activated DNA damage and is overexpressed in different cancers and their precursor lesions. It also forms early during apoptosis. Design: Formalin-fixed, paraffin-embedded archival tissues of 55 patients were immunostained with antibodies to surviving and γ-H2AX to determine their expression in normal squamous vulvar epithelia (NE, n=25), lichen sclerosus (LS, n=10), highgrade classic vulvar intraepithelial neoplasia (VIN, n=16), differentiated VIN (D-VIN, n=16) and vulvar invasive keratinizing squamous cell carcinoma (ISCC, n=20). Immunostaining for both factors was scored for moderate and strong intensities in two cohorts of quantity. Statistical analysis was done by chi-square and Fisher's exact test. Results: Nuclear survivin expression increased from NE and LS to VIN and D-VIN to ISCC significantly (P=0.0001) and followed the distribution of immature squamous epithelial cells. γ-H2AX reactivity was found in nuclei of cells in all diagnostic cohorts except for NE in any epithelial level and was seen in horn pearls in ISCC, without relevant statistical distributions. Immunoscores did not differ between FIGO stages I and II, grade 1 and grades 2/3, and did not indicate prognosis. Conclusions: Expression patterns were different for both factors, suggesting their involvement in different biological mechanisms. Expression of survivin in vulvar squamous neoplastic tissues culminating in ISCC and comparably low and insignificant γ-H2AX reactivity reflects the resistance to apoptosis in the oncogenic development of these lesions. University of Chicago, IL; Vanderbilt, Nashville. Background: Sertoli-Leydig cell tumors (SLCTs) of the ovary are composed of sexcord derivatives resembling those of the testis and a stromal component containing variable amounts of Leydig cells. Based on morphology the sex-cord derivatives have traditionally been regarded as Sertoli cells. However, the pathogenesis has yet to be elucidated and it is unclear if these cells are true Sertoli cells. FOXL2 is a member of the forkhead-winged-helix family of transcription factors and one of the first genes expressed in the development of the female gonad. It is required for proper differentiation of granulosa cells during folliculogenesis. The transcription factor SOX9 is an intermediate downstream target of SRY and is required for testis development by formation and maintenance of (pre-) Sertoli cells. The aim of our study was to further characterize the differentiation of the sex-cord derivatives by evaluating the expression of these two counteracting transcription factors and SRY. Design: Paraffin embedded material of 10 SLCTs, one Sertoli cell (SC) hamartoma arising in a background of testicular feminization, and a TMA containing 38 granulosa cell tumors (GCTs) were examined by IHC for the expression and localization of FOXL2, SOX9 and SRY.
Results:
The sex cord-stromal derivatives revealed strong nuclear staining for FOXL2 in 10/10 cases and were negative for SOX9 expression. Leydig cells were devoid of FOXL2 and SOX9 expression. The SC hamartoma exhibited strong positivity for SOX9 and did not express FOXL2. All GCTs revealed nuclear staining for FOXL2 and SOX9 negativity. SRY was not expressed in any component of the SLCTs, the SC hamartoma or the GCTs. Conclusions: FOXL2 actively suppresses SOX9 throughout adult life via an upstream regulatory element, leading to mutually exclusive expression of these two transcription factors. Based on consistent FOXL2 expression in all SLCTs and GCTs, our findings support that the sex-cord derivatives of SLCTs are of granulosa cell lineage. SOX9 expression in the SC hamartoma is consistent with a true Sertoli cell component in this tumor. The encountered SRY negativity in the SCST is in concordance with previous studies. Of interest, SRY was not expressed in the SC harmatoma, however SRY activates SOX9 and might not be co-expressed. Our study suggests that the sex-cord derivatives of SLCTs are of granulosa cell and not of Sertoli cell lineage and may represent a morphologic variant of GCTs.
The Sertoli Cell Associated Molecule Doublesex and Mab-3 Related Transcription Factor 1 (DMRT-1) Is Not Expressed in Sertoli-Leydig Cell
Tumors of the Ovary. R Buell-Gutbrod, A Montag, O Fadare, E Lengyel, K Gwin. University of Chicago, IL; Vanderbilt University, Nashville. Background: Sertoli-Leydig cell tumors (SLCTs) of the ovary are composed of sex-cord derivatives resembling those of the testis and a stromal component containing variable amounts of Leydig cells. Based on morphology the sex-cord cells have traditionally been regarded as Sertoli cells. However, true Sertoli cells are not present in the adult female gonad and the origin of these cells is unclear. Doublesex and mab-3 related transcription factor 1 (DMRT1) is a key regulator of male development and is expressed in Sertoli cells of the developing and adult male gonad. Mutations in the DMRT1 gene result in defective testicular development and XY feminization. Design: Archival paraffin embedded material of 10 SLCTs, 3 Leydig cell tumors, one Sertoli cell (SC) hamartoma arising in a background of testicular feminization, a TMA containing 38 granulosa cell tumors (GCTs), and normal ovarian and testicular tissue as controls, were examined by IHC for the expression and localization of DMRT-1.
Results:
The sex cord-stromal derivatives of the SLCTs revealed no expression (0/10) of DMRT1. Two cases showed weak cytoplasmic staining in the Leydig cell component. Two cases of Leydig cell tumors were negative for DMRT1 expression, with weak cytoplasmic staining in one case. All 38 GCTs were devoid of DMRT1 expression. The Sertoli cell hamartoma showed moderate (2+) nuclear expression. Sertoli cells in adult testis showed moderate to strong nuclear expression while no expression was seen in the granulosa cells of normal adult ovaries. Conclusions: DMRT1 is a transcription factor with a Zinc finger-like DNA-binding motif (DM domain) that is a highly conserved component of the male vertebrate sexdetermining pathway. Its expression has been demonstrated in Sertoli cells of the testis by ISH in the past. We show that it is also expressed by IHC in Sertoli cells of adult testes and in Sertoli cell hamartomas, but is not seen in so called Sertoli-Leydig cell tumors of the ovary nor is it seen in GCTs or normal granulosa cells of the ovary. This suggests that the sex-cord derivatives of SLCTs are not of Sertoli cell lineage but may be of granulosa cell lineage. FOXL2 is a member of the forkhead-winged-helix family of transcription factors and is expressed early in the female gonad. It is required for differentiation of granulosa cells during folliculogenesis. The transcription factor SOX9 is an autosomal downstream target of SRY and is required for formation of Sertoli cells. The aim of our study was to characterize the differentiation of the sex cord cells in SCTAT by evaluating the expression of these two counteracting transcription factors. Design: Archival paraffin embedded material of 2 SCTATs were examined by IHC for expression and localization of FOXL2 and SOX9. Both cases were unilateral tumors and occurred in adult females (43 and 49 years of age). There were no stigmata of Peutz-Jeghers syndrome in either of the patients and both cases were thus considered sporadic.
Sex Cord Tumor with Annular Tubules (SCTAT)
:
Results:
The sex cord cells revealed strong nuclear staining for FOXL2 in 2/2 cases and were negative for SOX9 expression. Conclusions: SCTAT is a rare sex-cord derived tumor made up of cells variably described as Sertoli or granulosa like. Expression of FOXL2, which is found in granulosa cells and actively suppresses the Sertoli associated SOX9 throughout adult life via an upstream regulatory element, supports a granulosa cell origin for these cells. These findings suggest that sporadic SCTAT may be best classified as a variant of granulosa cell tumor.
Comparison of Fluorescent In Situ Hybridization (FISH), p57
Immunohistochemical ( Background: Distinguishing early complete hydatidiform mole (CHM), partial hydatidiform mole (PHM) and hydropic abortus (HA) can occasionally be difficult on a morphologic basis. A variety of ancillary methods (p57 IHC and DNA ploidy analysis by Flow Cytometry and more recently molecular techniques including FISH and molecular genotyping) are utilized to aid in difficult cases. There is limited literature comparing these various methodologies on a single study set of products of conception (POC) cases. The aim of this study was to evaluate the utility of FISH compared to relatively well-established p57 IHC and FC, including accuracy and turnaround time in a community hospital setting. Design: Thirty-two cases of products of conception (POC) were retrieved from the pathology files at our institution for the time period January 2010-August 2010. All of these cases had morphologic findings that prompted further work-up with either p57 IHC (1:1000; Thermo Fisher, Fremont California), DNA ploidy by flow cytometry and/ or FISH. We retrospectively performed IHC and FISH on all cases to complete the cohort. P57 IHC was considered positive when villous trophoblasts and stromal cells showed strong positivity. FISH procedure utilized 4 centromeric probes (chromosomes 1, 17, X and Y; Abbot Molecular). Trisomy 1 and 17 is incompatible with fetal implantation, unless it is part of a triploidy and this was the rationale in picking these FISH probes over others. X and Y chromosome probes in addition to confirming the findings, allow detection of the sex chromosome complement. DNA ploidy by FC was performed using flow cytometer (BD FACSCanto II) following DNA extraction of paraffin embedded material.
Results:
Final The fallopian tube fimbriae are the major site of localization of the earliest forms of hereditary pelvic serous cancer. Occult cancers in the fimbriae are also common in women with sporadic ovarian or peritoneal serous carcinoma. Bilateral salpingo-oophorectomy is effective in markedly reducing the risk of hereditary pelvic cancer. However, not all such tubal tumors are localized to the fimbriae. Anatomic distribution of early tubal carcinoma carries implications for technique of risk reducing surgery. This study evaluated the topography of occult tubal carcinoma, emphasizing incidence of cases exclusively involving the non-fimbrial tube. Design: Bilateral tubes were evaluated with an enhanced dissection protocol in 212 women presenting for a variety of benign and malignant gynecologic indications. Tubes were first formalin-fixed. The fimbriae were amputed from the ampulla and sectioned parallel to the fimbrial length. The ampulla was dissected in cross-section. Slice thickness was 2 to 3 millimeters. All slices were examined microscopically. Results: Tubal carcinoma was present in 15/212 patients. 3 patients had carcinoma exclusively in the mucosa of the tubal ampulla/isthmus whereas 12 patients had carcinoma involving fimbriae. Among the 3 non-fimbrial tumors, 2 were invasive high grade serous carcinoma and 1 was a non-invasive but exophytic high grade serous carcinoma. None were grossly visible. Size was 0.1 to 1.0 cm. None had lymphovascular invasion. Among the 3 patients with exclusive ampullary involvement of the tube, 2 had primary peritoneal serous carcinoma and 1 had primary ovarian carcinosarcoma. Conclusions: While grossly occult tubal carcinoma most commonly involves the fimbriae, the more proximal tube may occasionally be the exclusive site of involvement. This suggests that the benefit of risk-reducing surgery is maximized if all of the tube, not just the distal portion, is completely removed. Additionally, attention to thinsectioning and complete histologic examination should be directed to the entire tube, not just the fimbriae. The importance of ribosome function and translational control is based on the regulation of ribosome production and the initiation of protein translation by several oncogenes and tumor suppressor genes including p53. Previous work from our laboratory has demonstrated that the expression of the RP Rplp1 immortalizes primary cells and is involved in transformation. This is an acidic RP that belongs to the termed P proteins and is crucial for the efficient assembly of the functional GTPase-associated center of the ribosome. Design: To investigate the role of the P proteins in tumorigenesis, we examined the messenger RNA expression levels of Rplp0, Rplp1, and Rplp2 in a series of 32 patients with gynecologic tumors. In addition, a total of 140 biopsies of gynecologic cancers (46 endometrioid and 94 ovarian) were studied to evaluate the expression of the P proteins and p53 by immunohistochemistry.
The messenger RNA expression level of all 3 P proteins was significantly higher in the tumor tissue, compared with normal tissue. An up-regulation of P protein expression was observed by immunohistochemistry in an average of 27% of the tumors, as compared with normal tissues. Moreover, the level of P protein up-regulation correlated significantly with p53 expression in serous ovarian cancers. This is an important fact because the level of overexpression of the P proteins correlated with the presence of lymph node metastases in serous ovarian cancers. We also observed that endometrial carcinomas that had invaded the myometrium overexpressed P proteins in the invasive frontat a higher level. In addition, we found that the P proteins are up-regulated in a considerable number of patients with the most common types of cancer. Conclusions: Our study shows that P proteins are involved in human cancer, and indicates that the expression level of these proteins could be useful as a prognostic marker in specific subtypes of gynecologic tumors. Importantly, the fact that the P proteins are preferentially located in the infiltrating margins of endometrial tumors suggests that they could represent a novel molecular marker of tumor invasiveness. p120, vimentin, SPARC,  fascin and caveolin-1 was studied in a group of 76 ECS by immunohistochemistry. Real-time PCR was used to measure differences in the expression of 384 miRNAs, E-cadherin, SPARC, SNAIL, ZEB1, ZEB2, TCF4, TGFß1 and TGFß2 between the epithelial and mesenchymal component of 23 ECS.
Results: A loss of epithelial characteristics, including cadherin switching and the acquisition of a mesenchymal phenotype, was accompanied by changes in the profile of miRNA expression and the upregulation of all the E-cadherin repressors analyzed. There was a more than 5-fold difference in the expression of 14 miRNAs between both neoplastic components. Members of the miR-200 family are involved in epithelial differentiation and they were downregulated in the mesenchymal part of the ECS. In addition, miR-23b, miR-29c, which are involved in the inhibition of mesenchymal markers, and miR-203 that is involved in the inhibition of cell stemness, were also downregulated. Upregulated miRNAs included miR-155, miR-369-5p, miR-370, miR450a and miR-542-5p The average mTOR staining score for grade I tumors was 4.6 (σ=2.8), grade II was 6.2 (σ=3.5), and grade III was 5.8 (σ=3.2). There was a diversity of staining patterns regardless of FIGO grade as indicated by the range of scores. In benign proliferative endometrium there was moderate diffuse mTOR expression, while secretory endometrium epithelium showed strong diffuse mTOR expression.
Conclusions:
In this study mTOR expression did not have a significant association with grade in UEC. Of note, previous studies from our laboratory did not find significant association of either PTEN or PIK3CA mutations with grade. It should be noted that mTOR was expressed in non-neoplastic proliferative and secretory endometrium. Further studies to determine the association of mTOR expression with other prognostic factors and correlation with molecular genetic alterations (e.g., PIK3CA and PTEN) are needed to determine the utility of this putative biomarker. Design: Patients with uterine adenosarcomas from our archive between 1991 and 2010 were retrieved. Parameters including age, follow up period, presence of sarcomatous overgrowth, homologous or heterologous elements, and staging information (as per 2010 AJCC criteria: depth of invasion, extrauterine spread, and lymph nodes status) were extracted. The time interval of recurrence was calculated from initial diagnosis to documented first recurrence of disease. Results: Thirty-nine cases of uterine adenosarcomas with sufficient staging and followup information were identified within the specified study period. The mean patient age was 59.2 years (range: 36-97, median: 58). Twenty-one cases were staged as pT1a, 13 as stage pT1b, 1 as stage pT1c, 1 as stage pT2a, 2 as stage pT3a, and 1 as stage pT3b. Sarcomatous overgrowth was present in 19 cases (49%), and heterologous elements identified in 5 cases (14%). The average follow-up interval was 44 months (range: 1-185, median 25). Seven cases (5 in stage pT1a, 1 in stage pT1b and 1 in stage pT1c) recurred in 4-116 months. All 7 cases exhibited sarcomatous overgrowth, and one of them also had concurrent heterologous elements present. Conclusions: In this limited study, there was no definitive correlation between recurrent disease and stage as defined by the 2010 AJCC staging criteria. We identified a strong association between disease recurrence and the presence of sarcomatous overgrowth in uterine adenosarcomas. A multi-institutional study with a larger cohort may be required to validate the 2010 AJCC staging criteria for uterine adenosarcomas, particularly with respect to long-term overall and disease-free survival outcomes. Background: Dysgerminoma, the ovarian counterpart of seminoma, is the most common type of malignant ovarian germ cell tumor. The role of KIT mutation and amplification in the development of dysgerminoma is not currently established. We analyzed alterations of the KIT gene in a large series of dysgerminomas and correlated the findings with clinicopathologic parameters. Design: Dysgerminoma cells from 22 patients were analyzed for KIT mutations at exon 17 codon 816. KIT amplification and chromosome 12p anomalies were investigated by dual color fluorescence in situ hybridization. KIT protein expression was also examined by immunohistochemistry. Results: KIT exon 17 codon 816 mutations were detected in 6 cases (27%) of dysgerminomas, KIT amplification was detected in 6 (27%) cases and KIT expression was detected in 87% of the dysgerminomas. The KIT mutation was associated with advanced pathological stage (P<0.05), and KIT amplification was associated with elevated KIT protein expression (P<0.05). Chromosome 12p anomalies were found in 82% of the dysgeminomas and did not correlate with KIT abnormalities. Conclusions: KIT mutations occur in approximately one third of cases of dysgerminomas and are associated with advanced stage at presentation. KIT is a potential therapeutic target for those dysgerminomas that have the mutation. Background: Translocations resulting in gene fusion are often seen in ESTs, particularly endometrial stromal nodules (ESNs) and low-grade endometrial stromal sarcomas (ESSs). While JAZF1-JJAZ1 gene fusion is most common, EPC1-PHF1 and JAZF1-PHF1 gene fusions have been rarely reported. Translocations have not been reported in ovarian endometrioid stromal sarcomas (Ov-ESS). We investigated the frequency of rearrangements involving JAZF1, JJAZ1, EPC1, and PHF1 in ESTs and Ov-ESS and correlated molecular and histologic findings. Design: 57 patients were included. A tissue microarray was made from 62 tumors, including 19 ESNs, 27 primary ESSs, 14 metastatic ESSs, and 2 Ov-ESSs. Of these tumors, 5 and 2 metastatic ESSs samples belonged to one patient each respectively (primary tumor not available). Variant histologic patterns, including smooth muscle (7), fibrous and/or myxoid (7), sex-cord (6), glandular (3), epithelioid (1), skeletal muscle (1), and fatty (1) differentiation were seen in 7 ESNs, 10 primary ESSs, and 6 metastatic ESSs. FISH was performed on all tissue microarray samples using breakapart and fusion probes for JAZF1, JJAZ1, EPC1, and PHF1 genes. Results: FISH was successful in 51 samples. Rearrangements of JAZF1, JJAZ1, EPC1, or PHF1 were detected in 31 tumors (61%), including 10/14 ESNs (71%), 12/23 primary ESSs (52%), 7/12 metastatic ESSs (58%), and 2/2 Ov-ESS (100%) of classic (78%) and variant morphology (35%). JAZF1-JJAZ1 gene fusion was found in 21 (68%), including 9 ESNs, 9 primary ESSs, 2 metastatic ESSs, and 1 Ov-ESS. JAZF1-PHF1 gene fusion was found in 1 primary ESS (<1%); EPC1-PHF1 gene fusion in 1 primary ESS and 1 metastatic ESS (1%). 7 cases showed rearrangements of JAZF1 and PHF1 with no apparent fusion partner. Gene rearrangement status in patients with multiple metastatic ESSs remained unchanged. Translocations were not detected in 20 cases. No correlation was found between different translocations and morphology of tumors. Conclusions: Our results confirm that translocations are present in many ESTs and can be seen in Ov-ESS. JAZF1-JJAZ1 gene fusion is the most common rearrangement, but EPC1-PHF1 and JAZF1-PHF1 gene fusions can rarely be found. Of note, JAZF1 and PHF1 appear to have fusion partners which have yet to be identified. Although no apparent correlation between morphology and specific gene rearrangements was found, gene fusions are more common in tumors of classic morphology than EST variants. Background: The origin of pelvic serous carcinomas is a source of continuing controversy. Several recent studies of patients undergoing primary surgery for ovarian, primary peritoneal, and even uterine serous cancer have indicated the value of complete fimbrial sampling in order to detect occult serous tubal intraepithelial carcinoma (STIC). The presence or absence of STIC in specimens from interval surgery after neoadjuvant treatment has not yet, to our knowledge, been addressed. Design: Fourteen consecutive cases of interval surgery after neoadjuvant chemotherapy were reviewed, using both H&E and, as needed diagnostically, immunohistochemistry for p53 and MIB-1, for the presence or absence of serous tubal intraepithelial carcinoma. Tubal sampling varied among the fifteen cases. Nine archived cases had non-standard sampling of the tubal fimbriae while 5 cases had complete evaluation of the tubal fimbria using a protocol for sectioning and extensively examining the fimbriated end (SEE-FIM). Results: Residual tumor involved the endosalpinx in five out of nine (55%) cases with non-standard tubal sampling and STIC was identified in one of these. STIC was identified in four out of five (80%) cases with complete fimbrial sampling. Interestingly, p53 positive in situ tubal lesions included both proliferative regions with histologically bizarre cells consistent with chemotherapy effect, and non proliferative regions with minimal to no histologic evidence of chemotherapy effect.
KIT Gene Mutation and Amplification in
Conclusions:
The origin of pelvic serous carcinoma is an area of current controversy. Several lines of evidence indicate that a significant proportion of pelvic serous carcinomas may arise from in situ lesions on the distal fallopian tube. These results are expected to improve the quality of pathologic evaluation by providing data driven recommendations for sampling in interval surgery cases. These results indicate that serous tubal intraepithelial carcinomas can persist through neoadjuvant chemotherapy and can be readily identified during microscopic examination. These results also show the value of a systematic approach to grossing of the fallopian tube. Background: Recent studies have demonstrated the important role of platelets in metastasis. Tumour cell induced platelet aggregation (TCIPA), where circulating tumour cells (CTCs) may become 'cloaked' with platelets, has implications for chemotherapeutic efficacy, CTC-endothelium adhesion and CTC extravasation. CTC-platelet cloaking kinetics are poorly understood. We examined (A) platelet-cancer cell adhesion, (B) the role of vascular shear in platelet cloak formation and (C) the impact of platelet cloaking on chemotherapeutic responses. Design: A: Cell lines representing normal ovarian epithelium and a spectrum of ovarian cancer were studied. Gel filtered platelets were prepared from whole blood from healthy volunteers, loaded with calcein AM dye and applied to cell lines for 45 minutes. Total fluorescence and residual fluorescence following three washes, indicative of platelet adhesion, was recorded. Adhesion was calculated against total fluorescence and a fibrinogen positive control. P-selectin expression as a measure of activated platelets was also assessed by flow cytometry. B: Cone and plate viscometry was used to examine shear and non-shear effects on platelet cloaking of cancer cells. Patients with this disease typically develop multiple hamartomatous tumors and are at increased risk for breast, thyroid and endometrial cancers. Mutations of PTEN are present in up to 83% of spontaneous endometrial adenocarcinomas, making it the most frequent molecular genetic alteration seen with these tumors. Additionally, deficiencies in mismatch repair proteins are frequently seen with endometrial carcinoma. Recently, we encountered a patient with Cowden syndrome who developed an atypical polypoid adenomyoma (APA) of the uterus which prompted an investigation of the prevalence of loss of PTEN and mismatch repair protein( MHL1 and MSH2) expression in APAs. Design: A series of APAs were reviewed and diagnoses were confirmed. These included a mixture of curettage and hysterectomy/polypoidectomy specimens. PTEN, MLH1, and MSH2 expression was examined using immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Cases were considered to be PTEN reactive if they demonstrated cytoplasmic staining of the glandular component of the APA and non-reactive if there was no cytoplasmic staining of the glandular component but the stroma or other internal control tissues was reactive. Similarly, MLH1 and MSH2 were considered positive with nuclear staining of the neoplastic cells, and negative if the neoplastic cells were negative but an internal control was positive. Results: Immunohistochemical staining for PTEN demonstrated a total of 12 of 20 (60%) cases with staining of the glandular component of the lesion. A total of 7 of 20 cases demonstrated stromal and/or squamous metaplasia positive for PTEN but no staining of the glandular component. All of the cases retained expression of MLH1 and MSH2. Conclusions: PTEN expression is lost in a subset of APAs, albeit less so than is seen with endometrial carcinomas. There was no loss in the expression of mismatch proteins. Uncommonly, APAs develop in patients with Cowden disease. Background: The prognosis of epithelial ovarian cancer (EOC) is poor, in part due to the high frequency of chemoresistance. The Toll-like receptor-4 pathway is thought to mediate some of this resistance, particularly via the adaptor protein MyD88. We previously described different clinicopathologic features associated with TLR-4/MyD88 expression in EOC, including predominance of MyD88 expression in serous carcinomas and significantly reduced survival if MyD88+. We examined the expression of MyD88 in chemosensitive and chemoresistant EOC cells, together with two microRNAs that regulate the TLR-4/MyD88 pathway (miR-21 & miR-146a), to assess the direct association between biological behaviour, MyD88 and its molecular regulators. Design: Archival paraffin-embedded EOC samples (n=22) were divided into type 1 (MyD88+) or type 2 (MyD88-) based on previous immunohistochemical (IHC) expression. Pure tumour samples were obtained using laser capture microdissection, and RNA extracted for gene (n=22) and miRNA analysis (n=18). RNA was extracted from 8 human cancer cells lines, EOC lines 59M, SK-OV-3, A2780 & IGROV-1, and cervical cancer cells KB-3-1, as well as chemoresistant cancer cells A2780cis (Cisplatin-resistant), IGROV-1CDDP (Cisplatin & Paclitaxel-resistant) and Background: The development of uterine malignancies during and after the use of tamoxifen is a well-documented phenomenon. The purpose of the study was to determine if there was a correlation between the duration of tamoxifen therapy, the development of these malignancies in relation to cessation of the drug, and tumor type and/or grade. In addition, we sought to determine any recurrent morphologic features present in these tumors. Design: All women with a history of breast cancer treated with tamoxifen who subsequently developed a uterine malignancy between 1980 and 2005 were included in the study. Results: A total of 119 such patients were identified. The distribution of tumor type was as follows: 64 FIGO 1-2 endometrioid carcinomas (EC), 7 FIGO 3 endometrioid carcinomas, 28 serous carcinomas or mixed endometrioid and serous carcinomas, 3 clear cell carcinomas, 2 undifferentiated carcinomas, 13 carcinosarcomas (MMMT) and 2 leiomyosarcomas. There was a higher incidence of high grade tumors in patients who received tamoxifen for 5 years or more (59%), compared to those who used tamoxifen for less than 5 years (26%). Low grade tumors also appear to develop more frequently early on after the use of tamoxifen; the frequency of high grade tumors was more in cases where the interval between cessation of tamoxifen therapy and diagnosis of endometrial carcinoma was more than 1 year (58%) compared to less than 1 year (38%). In the slides available for review, a number of recurrent morphologic features were noted including prominent squamous/morular metaplasia, background polyps and/or polypoid tumors, background endometrial atrophy (also seen in endometrioid tumors) and presence of prominent ovarian stromal hyperplasia. Conclusions: Patients treated with tamoxifen therapy for breast carcinomas can develop a spectrum of endometrial malignancies of all histologic subtypes. Patients who received long duration of tamoxifen therapy had a tendency to develop higher grade tumors, and these often developed later on after tamoxifen cessation. In contrast, patients who used tamoxifen for shorter time periods were more prone to developing lower grade tumors that often presented early after discontinuation of tamoxifen use, with the exception of carcinosarcomas that often presented early. Background: Glioma-associated oncogene 2 (Gli2) is a zinc finger transcription factor whose nuclear expression has been associated with aggressive behavior and invasiveness in melanomas and urothelial carcinomas. Downregulation of Gli2 is associated with the inhibition of proliferation. Gli2 is generally regarded as an effector of the hedgehog signaling pathway but can also be induced by the transforming growth factor-beta/Smad3 signal transduction. Its role in myometrial tumors has not been previously studied. Design: We examined the expression of Gli2 in a spectrum of uterine smooth muscle tumors. A tissue microarray block was assembled from 11 uterine LMS, 16 smooth muscle tumor of uncertain malignant potential (STUMPs), 14 leiomyomas (LM) and 11 normal myometria. Morphoproteomics uses bright-field microscopy and immunohistochemistry to study the signal intensity, subcellular compartmentalization and extent of distribution in a tumor of protein analytes in signal transduction pathways.
Immunohistochemical stains were performed using antibody against Gli2. The intensity (1-3+) and percentage of chromogenic signal was determined, and a composite score (CS), the product of the intensity and percentage was calculated. The significance of difference in means was determined by one way ANOVA. Results: Gli 2 expression was localized to the nucleus. Gli 2 was positive in 81% (9/11) uterine leiomyosarcomas and majority of Gli2 positive LMS {8/9 (89%)} show moderate to strong (2-3+) signal intensity. The average CS of LMS is 140 (range 0-300). LGSC was identified in supraclavicular (2), cervical (1), periaortic (1) and intramammary (1) LNs, either preceding (by 7 months), concurrently, or following (up to 24 months) the diagnosis of ovarian SLMP. In 3 cases, pelvic and periaortic LNs were collected during the ovarian tumor resection, with nodal SLMP and endosalpingiosis identified in 3 and 2 cases respectively. In the remaining 2 cases, lymph node dissection was not performed. All except one patient received adjuvant platinum-based therapy. Follow up ranged from 1 to 20 years (average 7 years). None of the patients recurred in the pelvis. 3 patients are free of disease. However, one patient with cervical nodal LGSC developed brain metastases and died. Another patient with supraclavicular nodal LGCS is currently living with bilateral malignant pleural effusions. Both patients had pelvic/periaortic nodal SLMP and extensive nodal endosalpingiosis.
For the first time, we present a case series of patients with ovarian SLMP and nodal LGSC. Despite no evidence of LGSC in the pelvis, or any pelvic recurrences, the patients developed extrapelvic nodal LGSC. These patients also had nodal endosalpingiosis and SLMP, suggesting that SLMP/LGSC tumors in LNs may arise independently of the ovarian primary, progress along their own timeline and undergo metastatic spread. Therefore, in patients with ovarian SLMP and extensive pelvic/periaortic nodal SLMP and/or endosalpingiosis, examination and follow-up of extrapelvic LNs is warranted. INK4a (p16) immunostain is a useful objective adjunct in diagnosis of CIN 2. We studied the use of p16 in cervical biopsies from women enrollled in MECCS II. Design: MECCS II was conducted in 2 sites in Michoacán, Mexico. Pts. ages 30-50, non-pregnant, with varied histories of screening, no history of hysterectomy or pelvic irradiation participated. All pts. had direct samples obtained for HPV testing (Qiagen HC2, Gen-Probe Aptima) and a ThinPrep Pap (Hologic). Pts. + on any test were recalled. At the 2 nd visit VIA was done to rule out large (>3 quadrants) pre-invasive disease or cancer, colposcopy and biopsy followed using the POI directed and random biopsy protocol (>5biopsies/patient). All HC2 positive subjects eligible by VIA triage were treated with cryotherapy. P16 immunostaining (Cintec) was performed on all CIN biopsies. P16 was considered positive in CIN 2+ when diffuse, strong staining was seen. Results: 503 pts. with a +HPV test or abnormal Pap were re-called for secondary screening and treatment (34 lost to follow up). 2,350 biopsies were reviewed and many showed marked acute and chronic cervicitis. Table 1 summarizes Pap test results, HPV status and p16 results in patients with CIN 2+. Of 9 patients with CIN 2 and negative p16, 3 were HPV -, 4 had NILM Paps and 5 had CIN 2 in 1 biopsy only. Table 2 shows a comparison of sensitivy, specificity and positive predictive value with and without p16 results. Conclusions: P16 was helpful in identifying CIN 2 in our study and enhanced the sensitivity of HPV testing and cervical cytology. Pts. with CIN 2 in a single quadrant biopsy were more likely to be HPV -and p16 -than those with multiple quadrant CIN 2. P16 was helpful in the setting of markedly inflamed biopsy samples. All patients with CIN 3 were HPV positive and p16 positive. (8); IV (1). 7 tumors were pure PNET; 11 were combined with mature teratoma (4), immature teratoma or yolk sac tumor (3), carcinoma (3), and carcinosarcoma (1).Histologically, all PNETs were characterized by small, round to spindle shaped cells predominantly in a patternless sheet.Other histologic features included: pseudopapillary structures (4), myxoid background (4), fibrillary background (7) and rosettes (true, 6; HomerWright, 7).In PNET combined with immature teratoma, recognition of the PNET was facilitated by an absence of primitive neurotubules and the presence of disorganized sheets of cells.The most commonly used IHC to facilitate diagnosis included: keratin, 2/13 pos;synaptophysin, 2/12 pos;neurofilament 9/9 pos;CD99 2/7 pos;GFAP 4/9 pos;CD56 6/7 pos;and S100 4/7 pos.FISH for EWSR1 demonstrated a translocation in 1 of 2 pts tested.Follow up ranging from 3-107 mos (median 18.5) was available for 16 pts:dead of disease, 9; alive with disease, 2; no evidence of disease, 5. 4 of 5 pts alive without disease were stage I at presentation with 1 currently completing adjuvant chemotherapy.All 5 pts received chemotherapy with 2 treated as neuroblastoma and 2 treated as Ewings sarcoma. Conclusions: PNET of the adnexal region is aggressive and tends to affect young adult women.It is more commonly encountered in combination with other tumor types, particularly teratoma.Keratin, synaptophysin, and neurofilament are most useful in distinguishing PNET from other entities in the differential diagnosis.The low expression of CD99 suggests that adnexal PNETs more closely resemble central type PNET. Background: Preclinical analyses strongly implicate the phosphatidylinositol 3' kinase-Akt-mammalian target of rapamycin (P13K-Akt-mTOR) signaling pathway in smooth muscle tumorigenesis and differentiation, indicating that this pathway may be a suitable molecular target for the development of anti-cancer chemotherapeutic agents. The purpose of this study is to define the frequency and patterns of expression of 3 proteins in this pathway [mTOR, Akt and phosphatidylinositol 3' kinase (PI3-K)], in smooth muscle tumors of the uterine corpus, and to establish whether the expression of any of these proteins has independent prognostic significance. Design: The expression of mTOR, pan-Akt, and PI3-K was evaluated by immunohistochemistry in 31 uterine leiomyosarcomas and 10 leiomyomata, and were correlated with clinicopathologic parameters. Associated peritumoral normal myometrium was present in 27 cases. Cases were scored by multiplication of staining intensity (on a 0-3+ scale) and the extent/distribution of immunoreactivity (on a 0-4+ scale) for potential scores that ranged from 0 to a maximum of 12. Cases with scores of 4+ to 12+ (moderate, 4+ to 8+; high, 9+ to 12+ immunoreactivity) were considered positive.
Results: All 31 leiomyosarcomas were pan-Akt positive with 80.6% of positive cases displaying high scores, whereas all 10 leiomyomata and 27 normal myometria were entirely pan-Akt negative. High pan-Akt scores were associated with high tumor grade but not with advanced stage or outcome. Every tumoral and non-tumoral sample evaluated showed immunoreactivity for mTOR. PI3-K was positive in 20 (64.5%) of the 31 leiomyosarcomas but in none of the leiomyomata. High scores of PI3-K were associated with late pathologic stage (p=0.0022). High PI3-K scores, high pan-Akt scores and PI3-K positivity were not independently associated with reduced diseasespecific survival on multivariate analysis. Conclusions: These findings suggest that relative to normal myometrium, there is indeed dysregulation of the P13K-Akt-mTOR pathway in uterine smooth muscle tumors, and especially in uterine leiomyosarcomas. The expression patterns of proteins in this pathway, especially pan-Akt, may be of diagnostic utility in separating benign from malignant smooth muscle tumors. Pan-Akt, mTOR and PI3-K expression lacked independent prognostic significance in this pilot study, but additional and larger corroborative analyses are required. Background: There are several grading systems for ovarian serous carcinoma (OSC), mostly ternary systems. The Silverberg grading system is based on a composite score of architectural pattern, cytologic atypia and mitotic index. A nominal binary system (high-grade/low-grade) has been proposed reflecting that these are distinct entities rather than a disease spectrum. All high grade OSC correspond to Silverberg grade 2 and 3. Grade categories should reflect therapeutic, prognostic or biologic difference. We have previously shown no prognostic difference between Silverberg grade 2 and 3 OSC and there are no therapeutic differences. It has been suggested that subclassifying high-grade OSC is not relevant, however, molecular studies comparing Silverberg grade 2 and 3 OSC are limited. We analyzed a publicly available microarray dataset of 285gynecological tumors. We compared Silverberg Grade 2 and Grade 3 OSC to determine if they are molecularly distinct entities. Design: We included 140 arrays in our analysis: 49 Grade 2 and 91 Grade 3 OSC. Data analysis was performed in R (version 2.9.1) using BioConductor. Pre-processing employed the RMA algorithm, and quality-control with boxplots, principal components analysis and clustering indicated that all samples were of good quality. Non-expressed genes were filtered for and excluded based on Y chromosome signals. Two-sided, unpaired, unequal variance t-tests were used to compare grades, followed by an empirical Bayes moderation of the standard error. False-discovery rate adjustments were used to control for multiple testing.
Results: Differential gene expression was not identified between Grade 2 and Grade 3 tumors at either stringent (1% FDR) or relaxed (25% FDR) thresholds. As a control we compared Grade 1 and Grade 3 tumors, and hundreds of genes showed differential expression. We applied a naive p-value threshold of <0.001 to assess functional enrichment. Even at this level only 38 genes were found to be differentially expressed and there was no functional enrichment based on Gene Ontology enrichment analysis.
Conclusions: Based on the current data set, Silverberg Grade 2 and Grade 3 OSC do not differ molecularly (gene expression or pathway analysis), even in a very relaxed statistical analysis. These findings support the use of a two-tier classification system which is in keeping with clinical differences, molecular and morphologic evidence and therapeutic decisions and has been shown to be highly reproducible in practice. We have previously shown that histologic artifacts including vascular pseudo-invasion (VPI) are significantly more common in laparoscopic than nonlaparoscopic hysterectomies and specifically in cases in which a uterine manipulator (UM) is used. Whether or not VPI occurs intraoperatively or is a post-operative grossing artifact is unknown. The aim of this study was to assess the influence of grossing techniques in introducing artifacts including VPI in a subset of prospectively accrued laparoscopic hysterectomies (LH) utilizing a UM. The specimens were processed using an alternative approach aimed at reducing mechanical transport at the time of grossing. Design: The previously recommended alternative grossing technique was used in 16 LH as follows: the uterus was bivalved on receipt to permit overnight fixation. In contrast to the standard approach of sectioning from mucosa to serosal surface, the uterine wall was sectioned from the serosal aspect towards the mucosal surface with care to clean the scalpel blade between sections. The presence of artefactual changes including nuclear crush artifact, endomyometrial clefting, debris (inflammatory or tumor fragments) in fallopian tube (FT) lumen and VPI, were evaluated and compared with those from 57 LH grossed in the standard way using the Fisher exact test. The number of vessels involved by VPI was compared between the groups using the Student t-test. Results: No significant difference between the groups was identified for any of the artifacts [ Table 1 ]. In cases with VPI the number of vessels involved ranged from 1 to 13 (average 5.25) in specimens grossed using the standard technique and from 1 to 2 (average 1.25) in specimens grossed using the alternative technique (P=0.04).
Vascular Pseudoinvasion in Laparoscopic Hysterectomies
Conclusions:
Use of the alternative grossing technique described herein was not effective in eliminating the presence of artifacts; however, the extent of VPI was significantly less in these specimens. While the data is limited by small numbers, the findings suggest that adopting this technique may help to reduce VPI and should help to minimize potential misinterpretation of prognostic parameters in these specimens. We intend to accrue more cases to ensure the study is adequately powered.
Biomarkers of Invasion in Cervical Squamous Cell Carcinoma.
A Felix, F Silva, S Dias. Instituto Português de Oncologia e Faculdade de Ciências Médicas, Lisboa, Portugal; Instituto Português de Oncologia, Lisboa, Portugal. Background: The capacity of neoplastic cells to invade and metastasize depends on different factors, namely on the ability to establish new complex interactions of cellular adhesion molecules and the extracellular matrix (ECM) components. Laminin γ2 chain (lamγ2) plays an important role during tumor invasion and integrins are primary receptors mediating ECM remodeling. Our aim was to identify biomarkers of invasion in cervical squamous cell carcinomas.
Design: Laminin5 (Lamγ2) α2; α3; α5 and αV integrins immunoexpression was evaluated in a tissue microarray (TMA) constructed with representative regions (formalin fixed and paraffin embedded tumor samples) of 81 cervical squamous cell carcinomas (11 being in situ and the remaining 70 were invasive) and appropriate controls. Staining was evaluated both in cells and in the ECM. Results: Lamγ2 was present in the ECM (basement membrane) in all in situ carcinomas (CINIII) and also in the cytoplasm of very few cells, in two cases. In contrast, intracytoplasmatic lamγ2 was present in 59 cases of invasive SCC (see table 1 ). This difference was significant (p<0.0001). Regarding integrins, we found that α5 integrin was overexpressed in invasive tumor. This finding was also significantly correlated with invasion (p=0.0043). In invasive tumors α5 and αv (cell membrane) integrins were significantly correlated with the presence of intra-cytoplasmatic lamγ2 expression (p= 0.0009 and p=0.0053, respectively). Background: S100P is a 95-amino acid isoform of the S100 protein family with restricted cellular distribution, first purified from placenta. It activates ERK and NFkB pathways via the receptor for advanced glycation end-product to promote cellular proliferation and survival. Its expression has been reported in breast, prostate, lung and gastrointestinal malignancies. Recent complementary DNA studies of human endometrium showed S100P is expressed in the postovulatory endometrium. The expression of S100P in endometrial adenocarcinoma (EAC) is largely unknown. We evaluated the expression of S100P in EAC, proliferative endometrium (PE), and secretory endometrium (SE) in this study. Design: Biopsy and hysterectomy specimens were retrieved from the Department of Pathology archives at Lyndon B. Johnson General Hospital. and a formalin-fixed, paraffin-embedded tissue microarray containing 31 EAC, 29 PE, and 21 SE was constructed. Immunohistochemistry was performed using a mouse monoclonal antibody against human S100P (1:20, R&D Systems, Inc. Minneapolis, MN, USA). S100P expression was semi-quantified by light microscopy regarding staining pattern (cytoplasmic vs nuclear), percent of staining cells (0-100%) and intensity of staining (0-3+). Positive staining is defined as at least 1+ concurrent nuclear and cytoplasmic staining. Cytoplasmic staining alone is regarded as negative. Results: S100P is expressed predominantly within the nucleus but is also present within the cytoplasm. Minority of EAC (3/31, 9.7%) showed strong (2-3+) and focal to patchy (3 to 50% of cells) S100P staining. Majority of SE (17/21, 81%) showed positive (1-3+) and patchy to diffuse (30 to 90% of cells) S100P staining. All mid to late secretory endometrium (≥ day 20) showed strong and diffuse S100P staining and most (4/6) early secretory endometrium (< day 20) showed negative S100P staining. Minority of PE (5/29, 17%) showed positive (1-2+) and variably distributed (5 to 80% of cells) S100P staining. EAC showed statically significant lower frequency of positive S100P expression compared to SE (P <.001) but not compared to PE (P = .47); and SE showed statically significant higher frequency of positive S100P expression compared to PE (P <.001) by Fisher's exact test. Conclusions: Majority of EAC do not show S100P overexpression but S100P expression is consistently present within benign SE. These findings indicated S100P expression may be utilized to differentiate difficult cases of EAC and SE with highly complex glandular architecture. Furthermore, S100P immunohistochemical staining may also be an adjunct study in endometrium dating for infertility workup. Germline BRCA1 mutations were present in 3.8% "Not compatible" and 26.2% "Compatible." The sensitivity and specificity of "Compatible" morphology were 55.0% and 88.2%, respectively; while the sensitivity and specificity of combined "Compatible" and "Possibly compatible" morphology were 67.9% and 77.5%, respectively. The presence/absence of a dominant mass, fallopian tube mucosal involvement, and uterine cornu involvement did not predict BRCA1 status.
Conclusions:
A combination of serous/undifferentiated histology, marked nuclear atypia, high mitotic index, giant, bizarre nuclei and prominent intraepithelial lymphocytes appears to be highly specific for germline BRCA1 mutation positive ovarian cancer (negative predictive value >95%) in this catchment area. Ovarian tumor specific histology may help identify women for BRCA1 mutational analysis in the appropriate clinical setting.
Investigation of Human Papillomavirus Infections in Vulvar Intraepithelial Neoplasia by Polymerase Chain Reaction, Chomogenic In Situ Hybridization and Immunohistochemistry. J-A Gardner, K Cooper, V Rajendran, CS-C Adamson, MF Evans. Fletcher Allen Health
Care, Burlington; University of Vermont, Burlington. Background: Several studies suggest there are two distinct types of vulvar intraepithelial neoplasia (VIN) that can progress to vulvar squamous cell carcinoma (VSCC): usual VIN (uVIN) is associated with high-risk (hr) human papillomavirus (HPV) infections and lichen sclerosus/differentiated VIN (LS/dVIN) is rarely associated with hrHPV. This study extends the investigation of HPV in these conditions by combining polymerase chain reaction (PCR), chromogenic in situ hybridization (CISH), and p16 INK4a and p53 immunohistochemistry (IHC) assays. Design: Random cases of uVIN (VIN grade II/III, n=50) and LS/dVIN (n=50) were collected from Fletcher Allen Health Care archives. HPV genotyping was performed by PCR using GP5+/GP6+ primers followed by cycle sequencing. CISH was performed using a biotinyl-tyramide-based assay. IHC was performed using a polymer detection system. Results: HPV was detected by PCR in 48 (96%) uVINs (1 low-risk HPV, 6 hrHPV types) and in 11(22%) LS/dVINs (3 hrHPV INK4a staining was noted in 33 (66%) LS/dVINs. Suprabasal staining for p53 was noted in 26.5% uVIN and p53 basal layer staining was noted in 50% of LS/dVINs. The uVIN patients (median age=48.5) were significantly younger than the LS/dVIN patients (median age=60) [P<0.0001]. Conclusions: These findings support the existence of two distinctive pathways. uVIN is HPV driven and occurs in younger women, whereas LS/dVIN is most likely hrHPV independent and occurs in older women: the CISH and p16 IHC data suggest that hrHPV detectable by PCR in 22% of the LS/dVINs may be incidental to the lesions. The uVIN CISH data indicate that chronic infections may evolve into lesions containing only integrated HPV. p16
INK4a and p53 staining may be used qualitatively to distinguish uVIN from LS/dVIN.
The Accuracy of an Intraoperative Diagnosis of Ovarian Borderline
Tumor Varies by Histologic Subtype. K Garg, K Shih, R Barakat, N Abu-Rustum, RA Soslow. MSKCC, New York. Background: Borderline (BT) ovarian tumors are treated differently depending on the surgeon, patient age, the type of borderline tumor and co-morbid conditions. When the tumor appears to be confined to the ovary, these patients typically undergo conservative surgery. To determine whether additional surgery is needed in this situation, it becomes important to understand the extent to which frozen section diagnoses are overturned on review of permanent sections. The purpose of this study was to assess the sensitivity and positive predictive value of an intraoperative ovarian borderline tumor diagnosis at our institution. Design: All patients with an intraoperative or final pathologic diagnosis of ovarian borderline tumor of all histologic subtypes between years 2000 to 2010 were included in the study. Results: A total of 166 patients were included in the study. The median age was 49 years (20.3-91.2 yrs). The sensitivity and positive predictive value of an intraoperative diagnosis of ovarian borderline tumor was 81.6% and 89.9% respectively. 75% of tumors diagnosed as borderline on frozen retained this diagnosis at final pathology (74.6%) while 14 (8.4%) were upgraded from borderline to carcinoma. Twenty cases diagnosed as benign on frozen were upgraded to borderline (12%), while 8 cases (5%) were downgraded from carcinoma to borderline. The rates of undercalling carcinoma as borderline tumor on frozen section varied considerable by histologic type: 5% of tumors diagnosed as serous BTs, 0% of seromucinous BTs, 14% of intestinal mucinous BTs and 80% of small numbers of endometrioid BTs were reclassified as carcinomas on permanent sections. Most under calls were due to sampling error, not interpretive error. Further study of the serous tumors revealed differences related to the presence of micropapillary architecture, with 21% of tumors diagnosed as micropapillary serous BTs reclassified as carcinomas on permanent section compared to 1% of nonmicropapillary serous BTs. Conclusions: One can anticipate an accurate frozen section diagnosis of BT when the tumor is serous or seromucinous and non-micropapillary. This does not provide unmitigated support for performing staging surgeries for these types of borderline tumors when disease appears clinically confined to the ovary, without surface involvement. Significant rates of underdiagnosis can be anticipated with micropapillary serous, intestinal mucinous and endometrioid tumors when diagnosed as BT on frozen section. This provides sufficient support for performing cancer-type staging surgeries at the discretion of the surgeon in these circumstances.
1046 Endometrial Carcinomas with DNA Mismatch Repair Abnormalities: Genotypic Phenotypic Correlations. K Garg, ND Kauff, RA Soslow. MSKCC, New York. Background: Endometrial carcinomas (ECs) are commonly associated with defective DNA mismatch repair, either due to epigenetic (MLH1 promoter methylation) or genetic alterations (germline mutations in DNA mismatch repair genes resulting in HNPCC/ Lynch syndrome (LS)). Correlations between genotype and morphologic phenotype are poorly understood. In this study, we describe the pathologic characteristics of ECs with DNA MMR abnormalities. Design: ECs with abnormal DNA MMR IHC that were tested for DNA MMR mutation and/or MLH1 promoter methylation were included in the study (n=11). Results: Of 11 samples, 7 had absent MLH1 or PMS2 expression. Of these, 4 tumors showed MLH1 promoter methylation; germline testing in the other 3 cases demonstrated a clearly deleterious germline MLH1 mutation in 1 and missence mutations of unclear significance in 2. In the four samples with loss of MSH2 or MSH6 expression, germline testing identified 3 MSH2 mutations and 1 MSH6 mutation. Two of the 11 patients had no personal or family history suggestive of LS while 4 patients met the Amsterdam II criteria for LS (including the 2 patients with MLH1 variants). Six of the 11 tumors were endometrioid (EEC), 1 was clear cell (CC), 1 mixed endometrioid and serous and 3 undifferentiated/dedifferentiated. One endometrioid ca arose in endometriosis. Peritumoral and tumor infiltrating lymphocytes were noted in 2 cases, tumor heterogeneity in 4 cases, lower uterine segment origin in 2 cases, undifferentiated/ dedifferentiated histology in 3 cases and synchronous ovarian clear cell carcinoma (arising in endometriosis) in 1 case. Correlation between genotyping and tumor morphology is shown in Table 1 .
Correlation between genotype and morphologic phenotype Genotype (number of patients) Tumor morphology (patient age in yrs) MLH1 methylation (4) 1 dedifferentiated ca (35), 1 FIGO 1 EEC (49), 1 FIGO 3 EEC (58), 1 CCC (59) MSH2 mutation (3) 2 FIGO 2 EEC (41, 47), 1 mixed endometrioid and serous (50) MSH6 mutation FIGO 1 EEC (42) MLH1 deleterious mutation (1) Dedifferentiated ca (52) MLH1 missense mutations (2) 1 undifferentiated ca (39), 1 endometrioid ca in endometriosis (55) Conclusions: Morphologic and topographic characteristics previously described in DNA MMR defective endometrial carcinomas were frequently seen in this patient group. Abnormalities in MLH1, both genetic and epigenetic, appear to confer a particular predilection for tumors with undifferentiated or dedifferentiated histology. It appears that MLH1 promoter methylation can be seen in relatively young patients. Patients with Lynch syndrome also may be at risk for tumors arising in endometriosis. We have previously studied a group of morphologically ambiguous ECs with overlapping features of type 1 and 2 tumors, for interobserver diagnostic concordance and IHC for p53 and p16, and found that p53 overexpression (OE) correlates with adverse clinical outcomes. In this study, we wanted to assess the molecular abnormalities of these ECs and whether they had a prognostic impact. Design: Twenty three ECs (n=23) with ambiguous morphology that had been stained for p53 and p16 formed the study group. These tumors were subjected to sequenom analysis for hotspot mutations in PIK3CA, KRAS, NRAS, and AKT. Sequencing results for PIK3R1 and PTEN are forthcoming. Results: Of the 23 cases, mutations were detected in 12 (52%). Correlation between mutation status, morphologic impression and IHC for p53 and p16 are shown in table 1.
Correlation between molecular abnormality, consensus diagnosis, IHC for p53 and p16 and clinical outcomes Mutation analysis (number of cases) Consensus diagnosis p53 OE p16 OE RAS mutations endometrioid 3 of 6 (2 DOD) 0 of 6 PIK3CA exon 9 (2) Serous 2 of 2 (1 DOD) 1 of 2 PIK3CA exon 20 (2) 1 serous, 1 endometrioid 0 of 2 (LFU) 1 of 2 RAS/AKT/PIK3CA (1) No consensus diagnosis 0 0 AKT (1) Endometrioid 0 0 No mutations detected (11) 6 serous, 5 endometrioid, 1 no consensus 6 of 11 (3 DOD) 3 of 11
Of the 13 cases with a consensus diagnosis of endometrioid ca, RAS mutations were noted in 6. 3 of these tumors also showed p53 OE and 2 of these patients died of disease (DOD). Of 8 cases with a consensus diagnosis of serous carcinoma, PIK3CA mutations were noted in 3; 2 with exon 9 mutations also showed p53 OE. The prognosis is difficult to assess due to small numbers and patients lost to follow up (LFU).
Conclusions:
A consensus diagnosis of endometrioid carcinoma correlates with presence of RAS mutations, and p53 OE in these cases correlated with worse clinical outcomes. PIK3CA mutations were present in tumors with serous and endometrioid morphology, concurrent p53 OE was seen in cases with PIK3CA exon 9 mutations, but not exon 20 mutations. The impact of PIK3CA mutations on clinical outcome cannot be determined due to small numbers. PIK3CA and RAS mutations can co-exist in ECs.
Evidence for BRCA1 Haploinsufficiency in Expression Profiles from Morphologically Normal Fallopian Tube Epithelium.
S George, A Milea, J Greenaway, C Virtanen, S Shaw, M Sharma, P Shaw. University Health Network, Toronto, Canada. Background: Histological precursors of High Grade Serous Carcinoma have been identified in fallopian tube epithelium of women at genetic high risk of ovarian/tubal/ peritoneal carcinoma. One of the putative precursors, the p53 signature, is also found frequently in women at low risk. The most immediate precursor to invasive disease, serous tubal intraepithelial carcinoma (STIC) is found more frequently in mutation carriers. We have previously reported that tubal epithelium from mutation carriers (FTE-BRCA) has a differential gene expression signature during the luteal phase of the ovarian cycle. The purpose of this study is to determine whether morphologically normal FTE-BRCA has an expression profile different from non-carriers (FTE-non BRCA). Design: Morphologically normal tubal epithelium was microdissected from snapfrozen tissues from 12 BRCA1 mutation carriers undergoing risk-reducing surgery and from 12 control samples. All samples were from pre-menopausal women, and an equal number of samples from the follicular and luteal phases were included. Following RNA extraction, reverse transcription and linear amplification, samples were hybridized to Affymetrix GeneChips. Normalized data was subjected to cluster analysis and differentially expressed genes identified using SAM and GeneSpring. Selected candidate genes were validated by real-time RT-PCR and immunohistochemistry on tissue microarrays (TMA) of normal tubes and ovarian cancers. Stained slides were scanned and digital slides (Aperio Scanner XT) analysed using automated image analysis (TMALab, Genie, Aperio, Inc). Results: 135 genes were differentially expressed, and largely upregulated, with a greater than 2-fold difference and a p-value less than 0.05, in FTE-BRCA compared to FTE-non BRCA. The differences were present in both follicular and luteal phases. The selected target genes are involved in cell proliferation, in DNA damage and in inflammatory signaling. The differential expression of 5 targets was validated by RT-PCR and by immunohistochemistry. Levels of BRCA1 mRNA were not decreased in FTE-BRCA compared to non-BRCA.
Conclusions:
We have demonstrated for the first time that FTE from BRCA1 heterozygotes differs from FTE-non BRCA in the absence of histological lesions. These differences suggest that BRCA1 haploinsufficiency exists in normal FTE-BRCA, and that normal FTE-BRCA may respond differently to the microenvironment. These changes may reflect the earliest molecular changes of serous carcinogenesis, and may be markers of increased cancer risk. Conclusions: There were significant major diagnostic disagreements between reviewers in subtyping of high-grade endometrial carcinoma in more than one third of cases. This did not reflect systematic bias on the part of any single reviewer. Although this study was not designed to look at the reproducibility of diagnosis of low versus high-grade endometrial carcinoma, even this distinction proved to be problematic.
Is There a Need for Pre-Operative Evaluation in an Asymptomatic Patient Population Receiving a Supracervical Hysterectomy?
A Gopinath, S Mandavilli, M Assaad, AC Steinberg. Hartford Hospital, CT. Background: In the United States approximately 550,000 hysterectomies are performed annually with the vast majority done for benign conditions. With the advent of minimally invasive techniques (laparoscopy and robotically assisted laparoscopy), supracervical hysterectomy (SCH)has gained popularity. Urogynecology performs SCH as part of their pelvic reconstruction to decrease the risk of potential complications. Debate has occurred whether in the asymptomatic patient,evaluation (ultrasound,endometrial biopsy) for potential of endometrial pathology is warranted. Urogynecology at our institution does not perform an evaluation in the asymptomatic patients. The aim of this study is:1) find the incidence of incidental uterine carcinoma in SCH specimens 2) evaluate the need for preoperative gynecological workup in asymptomatic patients. Design: Following IRB approval, the pathologic findings in all SCH performed (October 2006-September 2009) in our institution were analyzed. Two groups were established for comparison,procedures performed by 3 urogynecologists(groupI) vs 29 general gynecologists (groupII). Procedures performed by Gynecology-oncology were excluded from the study. Results: 320 (groupI-86 and groupII-234) subjects were included. Mean age of groupI-53.7 (27-77yrs) when compared to group2-45.1 (26-65yrs) demonstrated a difference (p<.001).82 subjects,all in group2, had pre operative endometrial biopsies interpreted at our hospital. In groupII, 1 high grade adenocarcinoma and 1 complex atypical hyperplasia were identified compared to none in groupI (statistically not significant). Other findings in both groups included complex hyperplasia without atypia (1, 0.3%), chronic endometritis (1, 0.3%), benign endometrial polyp (21, 6.5%), leiomyomas (204, 64 %),adenomyosis (113, 35%) and adenomatoid tumor (1, 0.3%).
Conclusions:
In patients receiving supracervical hysterectomy the incidence of carcinoma is very low. In this study no significant difference was identifiable between patients who had some form of evaluation and those who did not. This could be attributed to the fact that, in the patients with abnormal findings on preoperative evaluation referral to the gynecology-oncology surgeons occurred. We conclude that with the probability of occult uterine malignancy being very low the need for expensive preoperative evaluation in an asymptomatic population needs to be questioned. Immunostains were performed for the immune markers CD3 (pan T lymphocyte), CD8 (cytotoxic T lymphocyte), and FoxP3 (regulatory T lymphocyte). For each stain, intraepithelial TIL density in triplicate cores was visually semi-quantitated on a scale from 0 to 3. Overall survival (OS) and disease-free survival (DFS) were derived from clinical and public records. Kaplan-Meier curves were compared by the log-rank test. To correct for multiple comparisons on the same data, p<0.0125 was considered significant. Results: High intratumoral CD3+ TIL density averaged across all tumor sites (N=22 out of 50 patients) was significantly associated with favorable OS (p=0.0037), while high CD8+ and high FoxP3+ TIL density (N=29/50 and 22/50 patients, respectively) showed trends toward longer OS (p=0.0458 and p=0.0182, respectively). This effect was slightly less pronounced if only the TIL density of primary sites was considered. In cases having low FoxP3+ TIL density, a low FoxP3:CD8 ratio (seen in N=8/28 patients) predicted longer OS (p=0.0501). The OS of patients with homogeneously high (N=18) and with heterogeneous CD3+ TIL density (N=11) was significantly longer than that of patients with homogeneously low CD3+ density (N=21) (p=0.0069; Figure 1 ). DFS was not significantly associated with any measure of TIL density in this study.
Lymphocytic infiltration is correlated with overall survival in serous ovarian cancer. This effect is more pronounced when multiple tumor sites are evaluated. While the significance of between-site heterogeneity remains unclear, homogeneously low CD3+ TIL density is an adverse prognostic factor. Background: Anecdotal data suggests that ovarian tumors with BRCA abnormalities often show tumor infiltrating lymphocytes (TILs), and solid or transitional cell-like growth pattern. This study examines the possibility of predicting BRCA dysfunction ("BRCAness") based on the presence of these morphologic features. Design: A consecutive series of 44 ovarian carcinomas were reviewed for tumor subtype, presence of TILs, solid or transitional cell-like growth pattern, and geographic necrosis, without knowledge of BRCA1 and BRCA2 status. TILs were only evaluated in sections from the primary tumor. A prediction of possible BRCA dysfunction was made when a combination of two or more of the above features were present in a high grade serous carcinoma (HSC). The predicted status was then correlated with the actual BRCA1/2 status. Results: Among the HSCs, morphologic prediction of possible BRCA dysfunction was made on 7/10 cases with (70%) BRCA1 or 2 germline or somatic mutation, 9/10 (90%) cases with BRCA1 promoter methylation, and 8/15 (53%) cases without BRCA mutation or methylation (no BRCA loss group). All 9 cases of non-HSCs were predicted as no BRCA dysfunction and did not show BRCA mutation or methylation. There were significantly more BRCA mutation or promoter methylation cases in the predicted BRCA dysfunction group than in the predicted no BRCA dysfunction group (p = 0.002) when considering all cases. However, this difference was not significant when only HSCs were considered (p = 0.095). Within the HSC subtype, TILs were more frequently present in the BRCA1 promoter methylation group (9/10, 90%) compared to other groups (4/10 in BRCA1 or 2 mutation group, 7/15 in no BRCA loss group) (p = 0.015). Transitional-like morphology was more frequently present in the BRCA1 or 2 mutation group (8/10, 80%) compared to the BRCA1 promoter methylation group (4/10) and no BRCA loss group (6/15) (p = 0.037). There was no significant difference in the presence of solid growth pattern or geographic necrosis among the subgroups. There were no false positive cases that underwent unnecessary staging. Underdiagnosis occurred in 14/100 (14%). Agreement between frozen section diagnosis and final diagnosis was observed in 72/100 cases (72%). Agreement in non-benign tumors was seen in 44/ 72 cases (61%). The sensitivity was 100%, 44.9%, and 37.5% for benign, borderline, and primary malignant tumors. The corresponding positive predictive value was 77.8%, 68.4%, and 100%. In univariate and multivariate analysis tumor diameter was the only predictor of underdiagnosis. Conclusions: Intraoperative frozen section diagnosis of mucinous tumors is reliable for benign tumors and metastases, but it has a low sensitivity for borderline tumors and ovarian carcinomas. Surgical management based on intraoperative frozen section diagnosis should be used with caution. Conclusions: ASCUS with equivocal hrHPVT on ThinPrep specimens correlated with more frequent high-grade dysplasia on follow-up cervical histology than did unequivocal positive hrHPVTs, and moreover correlated with more severe dysplasia (i.e., more CIN 3). Therefore, ASCUS-equivocal hrHPVTs should not be repeated as currently recommended but managed similarly to ASCUS-positive hrHPVT. These tests may indicate a higher risk of dysplasia than those associated with unequivocal positive hrHPVTs. Background: Differentiating Cervical Intraepithelial Neoplasia (CIN) from atrophy in postmenopausal women is challenging based on morphology alone. p16 and Ki67 help in distinguishing CIN2/3 from atrophy, and a positive HPV test increases the likelihood of follow-up histologic diagnosis of CIN2/3 in women over age 50. Our goal is to further characterize the utility of p16, Ki-67 and HPV tests in women over age 50, particularly in CIN1. Design: We retrospectively identified consecutive cervical specimens (biopsy, cone, and LEEP) from three one-year time periods (2003, 2004, and 2007) . Included were cases from women ≥ age 50 with benign diagnoses, atrophy, and CIN. Slides were stained with p16 and Ki67. p16 was graded as positive or negative, and Ki67 graded as positive or negative. Medical records were reviewed for cytology, HPV test, and histopathologic diagnoses from time of biopsy to 2010. Results: 97 cervical samples from 86 women (mean age=57) were analyzed and stained. The reason for sampling was either for follow up of abnormal pap smear in 68 (70%) cases or for other reasons (i.g. abnormal biopsy, postmenopausal bleeding). 34 (74%) of CIN1 cases were negative for both p16 and Ki67 (see table) . Of CIN1 cases with positive HPV tests, only 1/11(9%) had positive p16 staining, versus 2/2 (100%) of CIN2/3 cases. 39 women with CIN1 had follow-up data available. Of those, 4 (10%) had subsequent histologic progression to CIN2/3 and none developed invasive disease. Of these four cases, p16 was positive in 1 case, and HPV test was positive in a separate case. Conclusions: In our study, the majority of cases (74%) diagnosed as CIN1 in women ≥age 50 are negative for p16 and Ki67 and do not progress to high grade dysplasia during 3-5 year follow-up. Longer term study, however, is warranted to determine whether cases of p16 and Ki67 negative CIN 1 in this population behave like other benign processes with a low risk of progression, similar to atrophy. A combination of morphology, p16 and Ki67 on cervical specimens in women over 50 years of age, and furthermore, use of these stains on pap smear specimens, in combination with HPV testing may help distinguish CIN from atrophy, and reduce unnecessary invasive follow-up testing.
BRCA Dysfunction in Ovarian Tumor
Increased CD4 Positive T-Cell Recruitment in Primary Chronic
Vestibulitis Suggests Potential Disease Triggers. E Jacobson-Dunlop, C Leclair, M Goetsch, TK Morgan. OHSU, Portland; Oregon Health & Science University, Portland. Background: Chronic vestibulitis is a common cause of localized introital pain and sexual difficulty. In a tightly controlled prospective study, we recently demonstrated that vestibulitis has more chronic inflammation, neural hypertrophy, and mast cells, than normal control vestibular biopsies. The objective of the current study was to test for significant differences in lymphocyte sub-types in vestibulitis compared with controls. Design: We used archived tissue sections from our prior prospective study, which recruited adult premenopausal women from the Program in Vulvar Health at Oregon Health and Science University. Patients had severe entry dyspareunia for at least one year and sampling had been performed on tender and nontender vestibule mucosa. Women designated as having primary vestibulitis (n=10) had noted significant pain from the first attempted vaginal entry. Secondary sufferers (n=10) had de novo pain onset after no prior history of localized entry pain. An unaffected control group (n=4) had no history of entry dyspareunia. Histologic sections were immunostained in duplicate for CD20, CD3, CD4 and CD8. The study set was scored while blinded to phenotype for the average number of positive cells per high-powered 20x objective field. Differences between groups was evaluated by ANOVA with Bonferroni/Dunn post-hoc testing. Results: Tender biopsies from women with primary vestibulitis showed a significant shift in the CD8:CD4 ratio (p<0.01). They had twice as many CD8 positive cells and twenty times as many CD4 positive T-cells than controls. The number of T-cells was not significantly different in secondary vestibulitis compared with controls, but they did have more CD20 positive B-cells. Conclusions: This observation suggests CD4 positive T-cell recruitment may provide a clue to understanding potential triggers in primary disease. The predominance of CD20 positive B-cells in secondary vestibulitis suggests a more subacute disease process. Notably, many triggers for vestibulitis have been evaluated in the past without convincing results, perhaps because these studies did not distinguish between primary and secondary disease. Design: 23 consecutive LG-ESS cases from 23 patients with material available for study were retrieved from pathology files . A tissue microarray (TMA) paraffin block of duplicate 0.6mm cores was prepared. Immunohistochemistry (IHC) for p53, estrogen receptor (ER), progesterone receptor (PR) and CD10 were done according to standard techniques and assigned an Allred score wherein a score >= 3 was considered positive. For Ki67 a percentage of >10% was considered as positive. All H&E stained slides and IHC stained sections of TMA were reviewed and scored by two pathologists. FISH analysis for the JAZF1 rearrangement was performed. For IHC variables and JAZF1 rearrangement, Fisher's exact test and for mitosis, Wilcoxon's rank-sum test was used to compare stage 1 versus higher stage ESS. Results: The average age was 48.4 years and all patients were alive at the time of study except one. Follow-up was available in all but one case. Cases included 13 stage I, 3 stage II, 2 stage III, 1 stage IV, 2 primary ovary, 1 extra uterine pelvic mass. More frequent p53 positivity and more frequent JAZF1 rearrangement were seen in higher stage LG-ESS compared to stage 1 diseases. Other parameters showed very similar results in stage 1 versus higher stage disease (Table) . None of parameters showed difference when group of patients without recurrence was compared to the patients who had disease recurrence, regardless of stage. (CINtec, MTM) and proliferation markers MIB-1 (Dako) and proEx TM C (BD). H&E and immunostained slides were independently reviewed by two pathologists. Diffuse nuclear and cytoplasmic staining of cells for p16 in at least half of the epithelial thickness was interpreted as positive for CIN2, and negative otherwise. Co-expression of nuclear staining for MIB-1 and proExC in cells within at least half of the epithelium was interpreted as supportive of CIN2, and negative otherwise. Results: Histologic Dx of CIN2 (group 2) was supported by 3 stains in 61% (44/72) cervical bx and by 2 stains (p16-) in 13% (9/72). In 26% (19/72) of bx stains failed to support the presence of CIN2. Overall, CIN2 was overdiagnosed in 9% (19/211) cervical bx. Immunoreactivity for p16 was present in 83% (44/53) and absent in 17% (9/53) of true CIN2 lesions. In-situ hybridization (ISH) for HPV was performed in p16 (-) group (9 bx). In 4/9 tissue was insufficient for additional work-up. HPV 16/18 by ISH was (+) in remaining 3/5 and (-) in 2/5. Conclusions: 1) In 25% (53/211) the absence of CIN2 in subsequent excision may be due to small lesion size with complete removal by colposcopic bx, or regression. 2) CIN2 was overdiagnosed in 9% cervical bx in this study. 3) Immunopanel of p16, MIB-1 and ProExC can be useful in separating CIN2 lesions from its benign mimics. 4) While not extremely sensitive for CIN2 (83%), p16 appears highly specific "key" biomarker and critical when dealing with diagnostic challenges. 5) ISH for HPV can be helpful in rare p16 (-) cases. Kip1 expression in a panel of benign (n = 13) and malignant (n = 12) fallopian tubes containing normal epithelium, p53 signatures, tubal intraepithelial carcinoma, and invasive serous carcinoma. We further examined STMN1 expression in 131 high-grade late-stage serous ovarian carcinomas by tissue microarray analysis and a panel of ovarian cancer cell lines by Western blot. Results: STMN1 was expressed in neither quiescent cells nor benign lesions of the fallopian tube epithelium, but was robustly induced with progression to tubal intraepithelial carcinoma. STMN1 induction during early tumorigenesis was accompanied by decreased p27
Kip1 expression, a negative regulator of G 0 -to S-phase transition and direct inhibitor of STMN1. STMN1 was expressed in > 80% of high-grade serous ovarian carcinomas and ovarian cancer cell lines, indicating that expression is retained in late disease stages. Additionally, STMN1 may be a useful proliferative cell marker, independent of MIB1. Conclusions: The dynamics of STMN1 expression observed in early tubal lesions suggest that STMN1 plays a critical role in FTSEC cell cycle progression. Its induction in benign-appearing cells may signal cell cycle entry and identify pre-mitotic cells with proliferative potential. STMN1 expression might contribute to HGPSC pathogenesis by relaying growth signals from oncogenic signal transduction pathways to the cytoskeleton or by potentiating early-stage cell migration and loss of polarity. F Kawakami, H Itami, N Oka, S Semba, Y Mikami, T Sudo, C Ohbayashi, H Yokozaki, T Itoh . Kobe University Hospital, Hyogo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Sysmex Corporation, Kobe, Hyogo, Japan; Kobe University Graduate School of Medicine, Hyogo, Japan; Kyoto University Hospital, Japan. Background: High-grade squamous intraepithelial lesion (HSIL) and adenocarcinoma in situ (AIS) are premalignant uterine cervical lesions, and most of them are human papilloma virus (HPV) associated. For the last few decades a panel of theories mentioned the origin of coexistent HSIL and AIS lesion; however there are still few molecular evidences related to those theories. In this study, we examined HPV subtypes as well as the methylation status of the HPV-16 L1 gene to reveal the difference or affinity of carcinogenetic pathway between HSIL and AIS. Design: A total of 8 HSIL and AIS lesions were removed by conization or hysterectomy. In each case, HSIL and AIS lesions were isolated individually by micro-dissection from deparaffinized tissue sections. Further, high-risk HPV PCR genotyping were performed. Bisulfite-treated DNA was processed to analyze HPV-16-positive cases for the methylation status at the L1 and LCR genes; after a while the methylation status within HSIL and AIS were compared by P-value of Fisher's exact test. Results: Out of 8 cases, 6 (75%) showed same subtype of HPV in both HSIL and AIS: HPV-16, 5 cases; and HPV-18, 1 case. And then 2 (25%) cases contained different subtypes of HPV between HSIL and AIS: HPV-31 (HSIL) and HPV-18 (AIS); and HPV-52 (HSIL) and HPV-16 (AIS). Among the five cases which contained HPV-16 in both HSIL and AIS, no significant difference with one exception in the frequency of CpG island methylation status in the HPV-16 L1 region were observed; likewise only one case within 6796 genomic position was significantly methylated in HSIL compared with coexistent AIS (P = 0.0278). Conclusions: Our finding suggests that same HPV subtype is involved in the individual carcinogenetic pathway in the majority of the cases coexistent HSIL and AIS lesions. Further more, there is no significant difference between HSIL and AIS in the methylation pattern of HPV-16 L1 gene. These facts suggest that, the two lesions largely arise from same progenitor cells in which recombination between HPV and host cell DNA is occurred. While in the minority of the cases, HSIL and AIS may arise individually with different HPV infectious background and collided with each other. Background: Two decades ago, careful studies of chromosomal heteromorphisms and DNA polymorphisms proved that ovarian teratomas are derived from the female host during gametogenesis. When the teratoma arises during meiosis I, chromosomal recombination events result in partial homozygosity in multiple chromosomes. When the teratoma arises during meiosis II, a haploid gamete can either endoreduplicate (resulting in complete homozygosity), or fuse with another haploid gamete (resulting in partial homozygosity). We sought to use these concepts to prove that mucinous carcinomas associated with ovarian teratomas are also germ cell derived. Design: Six cases of mucinous carcinoma associated with ovarian teratomas were identified. DNA was extracted separately from the teratoma, mucinous carcinoma, and normal tissue after scalpel dissection of tissues from unstained formalin fixed, paraffin embedded sections. Twelve polymorphic microsatellite markers were PCR amplified for each sample; the resulting fluorescently labeled fragments were measured by capillary electrophoresis. Alleles from the teratomas and carcinomas were scored for each marker as non-informative (normal tissue homozygous or PCR failure), heterozygous (two alleles present), or homozygous (one allele present in tumor when normal tissue heterozygous). Results: Three cases of mucinous carcinoma showed near complete/complete homozygosity for informative markers (8/9, 9/9, and 10/10, respectively). Two of these had identically homozygous teratomas (the third teratoma was unavailable for analysis). Two carcinoma/teratoma pairs were completely heterozygous for all 8 informative markers. The remaining case had a teratoma homozygous for 2 of 10 informative markers, while the matching carcinoma was definitively homozygous for only one of these markers. Conclusions: Microsatellite polymorphism analysis demonstrates that mucinous ovarian carcinomas genetically match associated teratomas when present. Although this technique does not unequivocally distinguish between homozygosity and loss of heterozygosity (hemizygosity) in the carcinomas, presumed homozygosity across multiple markers in 3 of 6 cases is strong evidence that some mucinous carcinoma/ teratoma pairs arise from an endoreduplicated haploid gamete during meiosis II. Similar testing of a larger set of mucinous ovarian carcinomas may show that a subset of mucinous carcinomas have obliterated a pre-existing teratoma and are germ cell (rather than epithelial) derived.
HPV Implication Pattern in Coexistent HSIL/AIS Lesion.
Synchronous Versus Metastatic Gynecological Cancers:
A Comparative Mutational Profiling Study. S Khelifa, SD Finkelstein, P Hui. Yale University, New Haven, CT; RedPath Integrated Pathology, Pittsburgh, PA. Background: Separation of synchronous ovarian primary cancer from a metastatic uterine cancer to the ovary can be difficult and currently relies primarily on the conventional histological examinations, yet such a separation may have important clinical and therapeutic implications. Comparative mutational profiling (CMP) involves the analysis of loss of heterozygosity (LOH) among lesions to facilitate such differential diagnoses. We evaluated the efficacy of CMP in separating a synchronous ovarian primary vs. a metastatic endometrial carcinoma to the ovary Design: Ten cases of endometrial adenocarcinoma with lesions simultaneously involving the ovary were retrospectively retrieved from our file. All cases were reviewed according to the conventional histological criteria in separation of a synchronous ovary primary with a metastatic endometrial carcinoma involving the ovary. Non-neoplastic tissue and multiple foci of both endometrial and ovarian tumors were microdissected and subject to comparative mutational profiling analysis involving 16 polymorphic loci. Allelic imbalance or LOH at each locus was documented and compared between the endometrial and the ovarian lesions. Results: Among ten cases selected and histologically reviewed, 2 cases of synchronous endometrial and ovarian tumors, 7 cases of metastatic endometrial carcinomas, and 1 case of metastatic ovarian carcinoma were confirmed based on the conventional histological criteria (morphology, bilateral ovarian involvement, depth of myometrial invasion, lymphovascular involvement, and ovarian surface involvement). CMP analysis revealed an excellent correlation with the histological classification of the tumors in 9 out of 10 cases.
Conclusions:
Comparative mutational profiling appears reliable in assessing the relatedness of gynecological cancerous lesions. Such an objective molecular approach has a diagnostic power at least similar to that of the histological evaluation. Additional studies are needed to further confirm the efficacy of CMP in the workup of gynecological tumors simultaneously involving multiple mullerian organs. New molecular tools such as immunostaining for p16 appear to improve diagnostic agreement and predictive value; therefore, we hypothesize that combining p16 and H&E-based diagnoses will significantly change understanding of the relationship between risk factors and cervical dysplasia. Design: Routine H&E, p16, and Ki67 stained slides were prepared from 252 random colposcopic biopsies obtained from Kaiser Northwest, which had at least five years of clinical follow-up (including negative serial Pap tests or surgical excision). Two expert gynecologic pathologists independently reviewed each case blinded to all clinical data. Diagnoses were reported based on H&E only, H&E and p16, and H&E, p16 and Ki67 after sufficient "wash out periods." Kappa statistic and test accuracy were calculated for each method relative to the gold standard based on clinical follow-up. Odds of at least CIN2 were determined in multivariate logistic regression models using a constant panel of risk factors (eg, age, family income, education level) while varying the diagnostic method. Results: H&E plus p16-based diagnoses of CIN2 were more reproducible and accurate than H&E only, consistent with recent reports (see table) . Ki67 staining was not justified. Low family income was only significantly associated with at least CIN2 if using p16 assisted diagnoses (p=0.02 vs. p=0.61). There was a trend toward significant change in the odds of at least CIN2 if the patient had low family income in regression analysis only if using p16 assisted diagnoses (p=0.057). Conclusions: Despite the relatively small sample size in this pilot study, the association between low family income and at least CIN2 became significant when diagnoses were made with H&E and p16, and there was a trend toward significance for the odds of at least CIN2 for women with low family income if using H&E and p16. This shifting relationship implies that more accurate diagnoses provided by p16 staining may lead to more valid risk estimation in future epidemiologic studies. can be considerable overlap with other ovarian epithelial tumors (most often, ovarian serous carcinoma (OSC)) and with metastatic tumors such as renal clear cell carcinoma (RCCC). We studied the pattern of expression of three markers by OCCC, OSC and RCC. In addition to Wilm's tumor 1 protein (WT-1, a mesothelial marker expressed in OSC but uncommonly expressed in OCCC), the immunohistochemical panel includes Hepatocyte Nuclear Factor-1β (HNF-1β) and PAX 2. HNF-1β is expressed in renal tubules and collecting ducts but is not significantly expressed in adult ovaries or testes. It is aberrantly expressed in OCCC, but is rarely expressed in other ovarian epithelial tumors. PAX 2 is expressed in normal endometrium and tubal epithelium. Prior studies have shown its expression in mullerian tumors such as OSC, and have described it as a marker of mullerian origin in metastatic tumors. The aim of our study is to describe the expression of these three markers in OCCC, OSC and RCCC, to facilitate the use of this panel to aid in the diagnosis of morphologically challenging cases. Design: Cases of OCCC (33), OSC (10) and RCCC (6) were retrieved by searching our pathology database. Immunohistochemical stains were performed on formalin fixed paraffin embedded tissue using three antibodies: rabbit polyclonal HNF-1β (Sigma Prestige), rabbit polyclonal PAX 2 (Invitrogen-Zymed Laboratories) and WT-1 (clone 6F-H2, Ventana Medical). We assigned an intensity score (IS) of 0 (negative), 1 (weak), 2 (moderate) or 3 (strong), and a proportion score of 0 (0 to <1%), 1 (≥1 to 5%), 2 (6 to 20%), 3 (21% to 80%) or 4 (>80% Background: Pseudomyxoma peritonei (PMP) can be classified into two subtypes, disseminated adenomucinosis (DPAM), and peritoneal mucinous carcinomatosis (PMCA) according to the cytomorphologic features of peritoneal lesions and clinical behavior. However, differences in the mechanism of disease progression between the two subtypes have not been explained. We suspected that the difference in the expression of adhesion related protein or epithelial mesenchymal transition, which is crucial for invasion, might be related to the difference of progression rates and prognosis between the two subtypes. Design: To compare the expression of adhesion related proteins, we performed immunohistochemical stainings for E-cadherin, vimentin, cytokeratin 7 and 20 between the two subtypes in the peritoneal lesions of PMPs using paraffin sections. The cases were 52 pseudomyxoma peritonei treated at Asan Medical Center during 1995-2010. We counted the number of cellular strips composed of cohesive cell clusters and single isolated cells (SICs) floating in mucin pools separately using 10x10 grid micrometer from Olympus BX51 at 400x magnification field on H&E stained and immunostained sections, and then compared the number of SICs with the expression patterns for E-cadherin, and vimentin in cellular strips and SICs, respectively between the two subtypes. CK7 and 20 were used for identification of tumor cells.
MLH1-Deficient Ovarian and Endometrial Carcinomas Most Often
Results:
Loss of E-cadherin expression was significantly higher in SICs compared to cohesive cellular strips in both subtypes. Median follow up periods was 998 days (range: 14-4631 days). According to the histologic subtypes and the number of SICs, significant difference in the overall survival rates was identified between the two subtypes. The patients having more than 30 SICs/x400 fields had signficantly worse prognosis compared to those having less than 30 SICs, and the number of cases showing more than 30 SICs was significantly higher in PMCA compared to DPAM (p<0.001).
Vimentin expression was increased in the SICs, but vimentin expressing cells were undistinguishable from the macrophage in the mucin pools. S/C ratio based on H&E findings. *Tubulin stains ciliated cells, which was presented as an average of sum of all cases studied. **The numbers represent the average Ki-67 index for all cases studied. Cystadenoma, borderline tumor and LG-Ca diagnosed as ovarian based on conventional criteria
Conclusions:
The immunophenotype of LG-Ca, OEIs, and normal tubal epithelium, are similar, and are notably different from the immunophenotype of OSE. This suggests that LG-Ca are ultimately tubal in origin. Differential patterns of tubulin expression between tubal epithelium and LG-Ca cells suggest that the cancer develops from a clonal expansion of tubal secretory cells, although detailed mechanisms underlying this process remain unclear. Alternatively, LG-Ca may arise through the direct implantation of tubal epithelium onto the ovary to form OEIs, from which the cancer develops. It has been proposed that cells from STICs are shed from the fallopian tube and implant on the ovary developing into a tumor, which simulates a primary HGSC. However, the molecular mechanisms underlying the dissemination of the cells from a STIC are not known. In order to identify the molecules that may be responsible for this critical process, we analyzed the ovarian cancer gene expression and identified several upregulated genes associated with HGSC. Among these, we selected laminin for further study because it has been shown to be involved in cell adhesion, motility and invasion. Design: RT-PCR was used to assess the expression of different laminin isoforms (LAMA2, LAMA3, LAMC1, and LAMC2) in fresh tissue samples from 8 ovarian HGSCs, 9 ovarian cancer cell lines and 12 primary cultures of normal fallopian tube epithelium (FTE). Immunohistochemistry for LAMA3, LAMC1, p53 and Ki-67 was performed on formalin-fixed paraffin embedded tissue sections from 18 STICs, 16 of which were associated with concurrent ovarian HGSCs. LAMA3 and LAMC1 were scored based on intensity of cytoplasm (0 to 3+), and p53 and ki67 based on percentage of positive cells. Results: RT-PCR, showed a statistically significant increase of LAMA2 (p=0.044) and LAMC1 (p=0.0006), and reduction of LAMA3 (p=0.0032) and LAMC2 (p=0.0006) in the HGSCs samples and the ovarian cancer cell lines as compared to controls. LAMA3 was expressed in normal FTE, STICs and HGSCs and was decreased in intensity in 9 (56%) of 16 HGSCs compared to STICs and FTE. Intense LAMC1 immunoreactivity (2+ and 3+) was detected in 17 (94.4%) of 18 STICs and 14 (87.5%) of 16 of the concurrent HGSCs whereas the LAMC1 staining was undetectable or weak (1+) in all FTE from the same patients. Interestingly, LAMC1 immunoreactivity was intense in 7 STICs in which p53 staining was absent and in 5 STICs with low Ki-67 index (<20%). Conclusions: LAMC1 appears to play an important role in the development of HGSC. Since it is involved in cell adhesion, motility and invasion, upregulation of LAMC1 may facilitate shedding and dissemination of STIC cells to the ovaries and other peritoneal and abdominal structures. The presence of LAMC1 immunoreactivity in STICs, especially those with negative p53 staining and low Ki-67 labeling index, suggests that LAMC1 could be a reliable tissue biomarker to identify STICs.
TP53 Mutations in Serous Tubal Intraepithelial Carcinoma and Concurrent Ovarian High-Grade Serous Carcinoma. E Kuhn, RJ Kurman, RA Soslow, G Han, T-L Wang, I-M Shih. Johns Hopkins Medical
Institutions, Baltimore, MD; Memorial Sloan Kettering Cancer Center, New York, NY. Background: Somatic mutation of TP53 is the most common molecular genetic alteration in high grade serous carcinoma (HGSC) of the ovary, occurring in more than 95% of cases. As serous tubal intraepithelial carcinomas (STICs) have been proposed to be the most likely precursor of HGSC, we undertook a study to determine whether STICs harbor TP53 mutations as well. Mutations of TP53 have been reported in STICs and associated HGSC but that study [1] was limited to 5 cases. We therefore performed TP53 mutational analysis in a larger series of STICs and concurrent HGSCs and correlated the mutational status with p53 immunoreactivity. Design: Formalin-fixed paraffin-embedded tissue specimens were obtained from 18 HGSCs with concurrent STICs; 8 of them contained two discrete STICs. Approximately 1,000 cells from STIC and normal-appearing fallopian tubal epithelium were lasercapture microdissected from STICs, while HGSCs were manually microdissected. Genomic DNA was extracted, PCR amplified and sequenced. TP53 mutations were analyzed from exons 4 to 8. Immunohistochemistry (IHC) for p53 was performed in all the cases.
Results: TP53 mutations were detected in 15 (83.3%) of 18 HGSCs. Importantly, TP53 mutations were not detected in the corresponding FTE samples from the same patients, confirming they are somatic mutations in HGSCs. STIC Background: Serous tubal intraepithelial carcinoma (STIC) has been recently recognized as a potential precursor lesion of ovarian high-grade serous carcinoma (HGSC) but reproducibly diagnosing it, even among expert gynecologic pathologists, can be very difficult. Although proliferative activity as indicated by the Ki-67 labeling index has been reported to be increased in STICs, a direct comparison of the Ki-67 index in the STIC to normal-appearing fallopian tubal epithelium (FTE) and the associated ovarian HGSC in the same patient has not been described. In this study we compare the Ki-67 index of FTE, STIC and ovarian HGSC in the same patient to evaluate whether Ki-67 staining can assist in the diagnosis of a STIC. Design: A total of 33 STICs were analyzed, and among them 29 were associated with concurrent HGSC. Nine normal fallopian tubes from postmenopausal patients without neoplastic diseases were included as controls. Histological diagnosis of STICs was made according to previously reported morphological criteria (1). The Ki-67 index (using the Mib-1 antibody) was determined by calculating the percentage of cells showing nuclear immunoreactivity, in three random 20X-power fields. A minimum of 250 cells was counted. Results: Immunoreactivity for Ki-67 in FTE was restricted to a few scattered cells and no statistically significant difference was found between patients with and without HGSC (p>0.05). On the other hand, both STICs and HGSCs had significantly higher Ki-67 indices than normal FTE (p< 0.0001). STICs were uniformly positive for Ki-67, with an index raging between 11.7%-71.1%. Ki-67 immunoreactivity was predominantly located in the basal layer in STICs. Based on the findings in 42 FTE specimens, we propose to use the mean Ki-67 index (2.4%) + 3 standard deviations (2.8% x 3) which approximated 10% as the cutoff to distinguish STICs (including p53 negative ones) from normal FTE (100% sensitivity and 93% specificity). In 29 cases with concurrent ovarian HGSC, the Ki-67 labeling index was higher in STIC vs. HGSC in 12/29 (41.4%) while it was lower in 17/29 (58.6%) (p=0.55). hpfs in SC, tumor necrosis (percent of tumor), lymph node status (LN), vascular invasion (VI), tumor components outside the ovary (OTO), and surgical debulking status. The patients were followed to the most recent visit or their death. We correlated these parameters with disease-specific survival (DSS) using Kaplan-Meier method and Log-rank test. Results: The mean age was 69.0 years (> 60 in 33/47). The tumor, average 13.6 cm, was predominantly located in the left and right ovary in 18 and 24 cases, respectively (similar size in both ovaries in 5). FIGO stage was I in 1, II in 5, III in 40, and IV in 1 patient, respectively. LN metastasis and VI was seen in 6/17 and 29/47 patients, respectively. The CC was high-grade serous in 27, endometrioid in 2, mixed high-grade serous and endometrioid in 17, and mixed high-grade serous and clear cell carcinoma in 1. The mean percentage of CC was 70% (10% to 99%). The SC was heterologous in 34 (72%) and homologous in 13 (28%). The mitoses per 10 HPFs in SC averaged 33. Tumor necrosis was present in 45/47 cases (mean 10%, range 1-40%). Tumor OTO contained only CC in 17, only SC in 1, and both in 29 cases. Optimal and suboptimal surgical debulking was performed in 28 and 6 patients, respectively (degree of debulking unclear in 13). The patients were followed from 1 to 183 months: 6 patients lost to followup, 3 died postoperatively, 29 died from disease, 2 died from other causes, 7 still alive (14 to 183 months). The DSS at 1-year, 2-year, and 5-year was 75%, 56%, and 21% respectively. Presence of SC OTO was a significant prognostic factor (p = 0.03) whereas stage (only 6 patients with stage I-II) and other parameters were not. After adjusting FIGO stage, presence of SC OTO was still a significant prognosticator for patients with stage III-IV disease (p = 0.003) whereas others were not. Conclusions: Most POMMMTs occurred in older patients with an advanced stage at diagnosis. Presence of SC OTO was a significant adverse prognostic factor. Specific tumor components OTO should be listed in pathology report.
Conclusions
Frequent Loss of Progesterone Response Competence in Isolated
Non-Cycling Glands of Normal Secretory Endometrium. BE Lane, NM Monte, J Elvin, GL Mutter. Brigham and Women's Hospital, Boston, MA. Background: Small numbers of isolated non-cycling (atrophic, proliferative, or very poorly developed secretory) endometrial glands are commonly (45%) seen within the surface layer of progesterone-exposed normal secretory endometrium. We hypothesize that these glands have either lost the progesterone receptor, or developed downstream defects elsewhere in the progesterone response pathway. We here compare expression of a panel of progesterone response genes in these outlier glands to those in background secretory glands. Design: 20 cases of normal, mid-secretory (23-24 days) endometrial curettings with two or more outlier non-secretory glands on H&E stain were immunostained for mitotic activity (MIB1), and three makers normally downregulated in response to progestins (estrogen receptor,"ER", progesterone receptor,"PR", and PAX2). For each marker, outlier glands were scored as high expressors (indicating defective progesterone associated downregulation) or normal expressors at the low level of the secretory background.
Results:
All or most outlier glands maintained high expression of ER, PR or PAX2 in 83% (15/18), 95% (18/19), and 84% (16/19) of informative cases, respectively, when compared to the diminished levels in background secretory endometrium. Increases in outlier gland mitotic activity (MIB1) were seen in 55% (11/20) of cases. Figure  1 shows marker results for outlier (arrows) compared to adjacent normal (asterisk) background glands. Conclusions: Acquisition of hormonal incompetence is a common event in small numbers of endometrial glands, which present on routine stains as a dyssynchronous minor element in an otherwise normal secretory endometrium. Outlier glands maintain high levels of ER, PR, and PAX2 expression, in contrast to the low levels in normal background. Affected glands have an increase in mitotic activity. This cannot be explained simply by loss of the progesterone receptor itself, but rather reflects a defective progesterone response within affected glands. The etiology is unknown, but might be explained by a low frequency of inactivating events (mutation, deletion) occurring within the progesterone response cascade during cyclic endometrial gland regeneration. Background: Conventional endocervical adenocarcinoma in situ (cAIS) is typically strongly and diffusely positive for p16 and has a high Ki67 index in keeping with its frequent association with high risk HPV infection. The intestinal variant of AIS (iAIS) is less common, and its relationship to HPV infection and biomarker expression has not been thoroughly studied. The purpose of this study was to evaluate the frequency and pattern of p16 and Ki67 expression and the HPV status in iAIS in comparison to cAIS. Design: Fifty-four cases of AIS (14 iAIS, 40 cAIS) were retrieved from our archives. The age of the patient at diagnosis as well as coexisting squamous lesions were recorded. HPV DNA analysis and immunohistochemistry for p16 and Ki67 were performed on cases with available tissue. Results: The average age at diagnosis was significantly older in iAIS (age 45) versus cAIS (age 34) (p-value = 0.005). In contrast, coexisting squamous intraepithelial lesions were more common in the cAIS than the iAIS (35%, 14/40 versus 23%, 3/13). 15/19 (79%) cAIS showed strong and diffuse staining for p16. Conversely, only 5/12 (42%) iAIS had diffuse strong positivity. 10/10 (100%) cAIS showed >75% nuclei staining for Ki67. In contrast, this degree of staining was only present in 4/11 (36%) cases of iAIS. HPV DNA analysis revealed that 6/7 (86%) of iAIS cases were positive for HPV; five were type 18 and 1 was type 33. Conclusions: iAIS is strongly associated with HPV infection, sharing a similar pathogenesis with cAIS. However, the distinctly older age is unique, suggesting that age-related factors might influence cell differentiation in these lesions. The less intense staining for p16 and Ki-67 distinguish this variant from cAIS, and this must be taken into account when using these biomarkers to resolve problematic endocervical lesions with intestinal differentiation. (Sieben 2006) , presumed to arise within mullerian epithelium in the ovarian cortex or peritoneal surface.Epithelial hyperplasia has been reported in fallopian tubes (FT) of patients with SBT (Robey 1989) but its significance is unknown.This study explored 4 parameters possibly linking FTs and SBTs: 1) differentiation characteristics of SBTs, 2) frequency of candidate precursors (secretory cell outgrowths in the FT (SCOUT)) relative to controls, 3) existence of SCOUTs exhibiting ciliated differentiation, and 4) a shared immunophenotype between SCOUTs and SBTs. Design: 48 SBTs were culled from department files and stained for evidence of ciliated (p73) and secretory (HMFG2 or PAX8) differentiation and PAX2 expression.FTs from 34 SBTs and 65 benign controls were examined for PAX2 (-) SCOUTs. Results: All SBTs stained for p73 and HMFG2 or PAX8, consistent with origin from a cell capable of secretory and ciliated differentiation.SCOUTs were seen in 110/398 (27%) FT cross-sections from SBTs vs 18/161 (11%) in controls (p=<0.001).SCOUTs were heterogenous, ranging from largely secretory (84/110) to mixed ciliated and secretory (26/110). Some SCOUTs had papillary architecture and in two cases, multiple foci of papillary SCOUTs with mixed ciliated and secretory differentiation. All SBTs had heterogeneous PAX2 staining; 35% were >80% positive, 56% were 20-80% positive, and in 9% of SBTs, less than 20% of the cells stained for PAX2.
Conclusions:
This study shows for the first time that the FT hosts discrete epithelial alterations that are more frequently associated with SBT, have the capacity for both ciliated and secretory cell differentiation, frequently lack PAX2 expression, and share disturbances in PAX2 expression with SBTs.These findings suggest a precursor condition originating in the FT in a field of multifocal gene dysregulation, a subset of which might gain a growth advantage over pelvic/ovarian surface mesothelium, leading to SBT. If confirmed, this model could explain the origins of both low and high grade pelvic serous neoplasms.
Diagnostic Utility of JAZF1/JJAZ1 Fusion Gene in Endometrial
Stromal Sarcoma of the Uterus. S-R Lee, J Choi, HK Kim, Y Lee, K-R Kim. University of Ulsan College of Medicine, Seoul, Korea. Background: Diagnosis of endometrial stromal sarcoma (ESS) is usually not problematic in most cases because of their characteristic histopathologic findings. However, when the tumors have extensive secondary differentiation, including smooth muscle, myxoid, fibrous, ovarian sex cord-like/epithelioid, or endometrioid glandular differentiation, correct diagnosis can be very difficult. Recently, the presence of the JAZF1/JJAZ1 gene fusion in endometrial stromal sarcoma has been described, but the incidence has been variably described, and the applicability of the fusion gene in the difficult cases has not been cofirmed. In this study, we analyzed the prevalence of JAZF1/JJAZ1 gene fusion in classical low-grade endometrial stromal sarcomas (n=15) and those with various secondary differentiation (n=13) to examine the applicability of JAZF1/JJAZ1 gene fusion in the diagnosis of difficult cases of ESS showing secondary differentiation. Design: JAZF1/JJAZ1 fusion transcript were analyzed using nested RT-PCR in 28 cases including classical low-grade ESSs (n=15), those with smooth muscle differentiation (n=3), endometrial glandular differentiation (n=2), and with osseous metaplasia (n=1), undifferentiated endometrial sarcoma (UES) (n=5), UES with sex cord-like differentiation (n=1), combined low-grade ESS and UES (n=1). Results: The fusion transcript was detected in 18 (85.7%) of 21 low-grade ESSs and in 2 (28.6%) of 7 UESs, and the positive cases of low-grade ESSs included 14 classical ESS, one with smooth muscle differentiation (33%), two with endometrial glandular differentiation (100%), and one with osseous metaplasia (100%), and two UESs combined with classical low grade ESS. Direct sequencing analysis of DNA in 2 cases confirmed a fusion of JAZF1 and JJAZ1 genes forming a new amino acid (glutamic acid), which was previously described in the literature. Conclusions: JAZF1/JJAZ1 fusion gene was identified in a significant proportion of low-grade ESS regardless of the presence or absence of secondary differentiation, thus, this method can be useful in the diagnosis of difficult cases of ESS. Background: Endometrial stromal sarcoma (ESS) is a genetically heterogeneous group of uterine sarcomas; about half harbor JAZF1 rearrangement while the genetics of the remaining half is undefined. We recently identified a novel translocation-induced genetic rearrangement involving YWHAE as the pathognemonic abnormality in a subset of ESS and we describe here the histologic features of this genetic subtype of ESS. Design: A total of 11 ESS with YWHAE rearrangement was identified through multiinstitutional review of cytogenetics data and FISH screening. The histology and the immunophenotype (ER, PR and CD10) was examined in 8 primary tumors and 3 metastatic tumors, in comparison to 20 JAZF1-rearranged ESS. Results: All YWHAE-rearranged primary ESS had epithelioid areas in which the tumor cells were arranged in a nested pattern with fine stromal capillary network. The cellularity ranged from highly cellular with a small round blue cell appearance to moderately cellular with tumor cells possessing a moderate amount of eosinophillic cytoplasm. In contrast to ESS with JAZF1 rearrangement which usually display small nuclei with < 5MF/10HPF, the YWHAE-rearranged epithelioid cells had larger nuclei with more irregular contour, and all cases showed more than 10 MF/10HPF in addition to tumor necrosis. 5 of the 8 YWHAE-rearranged primary ESS contained an admixed cytologically-bland mitotically-inactive spindle cell component in a fibrous/ fibromyxoid background. In 3 YWHAE-rearranged ESS, only the metastatic tumors were examined: these included two lung metastases with mitotically active epithelioid areas (one with admixed spindle cell component), and one vaginal metastasis where the tumor showed only a low-grade appearance. Immunohistochemically, the spindle cell component (in both primary and metastatic tumors) consistently exhibited ER and PR immunoreactivity with variable CD10 positivity while the epithelioid cell component lacked ER, PR and CD10 immunoreactivity. Staging information was available for 6 primary tumors, of which five were associated with advanced-stage disease (FIGO stage 3) at presentation.
The Histologic Features of Endometrial Stromal Sarcomas Characterized by YWHAE Rearrangement -Distinction from Usual LowGrade Endometrial Stromal Sarcoma with JAZF1 Rearrangement. C-H Lee
Conclusions:
We describe a new molecularly-defined subset of ESS, containing YWHAE oncogenic rearrangement, and exhibiting higher-grade histologic features than those in classic ESS with JAZF1-rearrangement. Background: Cervical cancer screening with Pap cytology and HPV DNA testing is highly sensitive in predicting cervical precancerous lesions (CIN2/3). However, patients with CIN2/3 or even carcinoma can be missed during the screening. To evaluate the factors that resulted in the screening failure, we compared history of Pap cytology and HPV DNA testing results in patients with cervical squamous cell carcinoma (SQC). Design: We conducted a computer-based search for a 5-year period and collected the results of surgical pathology, ThinPrep Pap, and Hybrid Capture 2 (HC2) HPV DNA testing from patients with cervical SQC. HPV DNA testing using PCR was performed on the surgical specimens from the cases with negative HC2 test. Results: 234 patients with SQC were identified, including 35 cases of microinvasive SQC. The average age was 48 years (22 to 84 years). The clinical or Pap findings leading to the diagnostic biopsies are detailed in 28 patients had HC2 HPV DNA tests within 5 months before the histologic diagnosis. HC2 HPV DNA was tested positive in 24 patients (86%), while negative in 4 patients (14%). However, HPV DNA was detected by PCR in the surgical specimens from the 4 patients with a negative HC2 test. Conclusions: HSIL was the most frequent abnormal cytology to trigger the histologic diagnosis of SQCs. 44% of cases had at least one negative Pap test within 3 years prior to the histologic diagnosis. We found a fractional (14%) false negative HC2 HPV rate in patients with cervical SQC, which is similar to the false negative HC2 HPV rate (11%) recently reported in the Kaiser Permanente system after cytology and HPV co-testing. False negative HC2 HPV results argue against the proposed cervical cancer screening with primary HPV screening and secondary Pap cytology.
Uterine/Cervical Embryonal Rhabdomyosarcoma in Adult
Women. F Li, M Gupta, BM Ronnett. Johns Hopkins Hospital, Baltimore, MD. Background: In its classical form, embryonal rhabdomyosarcoma (ERMS) is a vaginal tumor occurring in young girls and is often not considered in the differential diagnosis of uterine and cervical spindle cell tumors in adult women. Experience with consultation cases indicates a need for improved recognition of this tumor. Design: Clinicopathologic and immunohistochemical features of 12 cases of ERMS identified in women >20 years of age were evaluated, with the goal of improving recognition of this tumor outside of its classical setting. Results: Patient age ranged from 23 to 86 years (mean, 49.4 ; median,48.5), with 2 patients aged 20-29 years, no patients aged 30-39 years, 5 patients aged 40-49 years, and 5 patients >50 years of age. Tumors originated in the cervix in 7 cases and in the endometrium in 5. These were diagnosed by biopsy in 4, curettage in 1, polypectomy in 6, and hysterectomy in 1. All endometrial tumors and 5 of 7 cervical tumors occurred in women >40 years of age. Tumors were characterized by a spindle cell proliferation in which tightly packed hypercellular foci composed of cells with minimal cytoplasm were scattered throughout an edematous hypocellular spindle cell proliferation, often with condensation beneath epithelial surfaces. Apoptotic bodies and mitotic figures were evident, usually in the hypercellular foci. In 4 tumors, rare to few entrapped endocervical or endometrial type glands were present but these tumors lacked the classical features of adenosarcoma. All tumors coexpressed desmin and myogenin to some degree (desmin was diffuse in 9 and focal in 3; myogenin was diffuse in 6 and focal in 6). Proliferative activity, as assessed by Ki-67 expression, was notably elevated in all tumors, typically concentrated in the hyperpcellular foci. Conclusions: ERMS has a broader clinical profile than classically expected and can occur as a uterine (endometrial) or cervical tumor in adult women. Thus, ERMS should be considered in the differential diagnosis of uterine/cervical spindle cell tumors, regardless of patient age. The hypocellular background can suggest a low-grade tumor but recognition of characteristic hyperceullular foci in which desmin and myogenin are coexpressed and proliferative activity is elevated is useful for establishing the diagnosis. It is generally believed that uterine leiomyosarcomas (uLMS) arise de novo, rather than from a precursor lesion. However, recently it has been hypothesized that uLMS may arise from preexisting leiomyoma like areas, especially with cellular or atypical morphology. The aim of this study was to focus on the genetic aspects of diagnostically challenging smooth muscle tumors with special interest of atypical uterine leiomyomas (uLM) and uLMS. Design: 16 uLM (of usual typ, hormonally treated, infracted), 11 atypical uLM and 15 uLMS were evaluated morphologically, immunohistochemically and by array CGH. Results: As expected, copy number changes were rarely seen in uLM. The only recurrent aberration was loss of chromosome 19 material, which was observed in 7 out of 16 (44%) cases. In contrast, in atypical uLM the number of copy number changes increased significantly involving almost all chromosomes. The most frequent changes (>35%) included gains on chromosomes 1q, 11q, 16p and 17q and a loss of material on chromosome 13q. In uLMS there was a further increase of copy number changes. Here frequent alterations included losses on 1p, 3p, 6p, 10q, 13q, 14q and 16q, and gains of 1q, 11q and 17p. Conclusions: By comparing three morphologic different uterine smooth muscle tumors we observed a continuous increase of copy number changes from uLM to atypical uLM and uLMS. Between the group of atypical uLM and uLMS several overlapping copy number changes were identified. This suggests that similar or identical pathways may be involved in the evolution of these tumors.
Molecular and Genetic Characterization of Diagnostically
Old Versus New FIGO Staging Systems in Predicting Overall Survival in Patients with Uterine Leiomyosarcoma: A Study of 86 Cases. D Lim, W-L Wang, C-H Lee, T Dodge, B Gilks, E Oliva. National University Health
System, Singapore, Singapore; M.D Anderson Cancer Center, Houston, TX; Vancouver General Hospital, BC, Canada; Massachusetts General Hospital, Boston. Background: Uterine leiomyosarcoma (LMS) has traditionally been staged using the FIGO system for endometrial cancer. Recently, a new FIGO staging system (modified from the AJCC soft tissue sarcoma staging system) has been proposed. We aimed to compare whether the old or new FIGO staging system is more accurate in predicting overall survival (OS) in patients with LMS. Design: 86 patients diagnosed with uterine LMS in two tertiary institutions between 1984 and 2010 were retrospectively staged using the old and new FIGO systems. OS was calculated from the date of diagnosis to date of death or last follow up. 5 year survival rates for both groups were estimated using the Kaplan-Meier method. Median OS was also analyzed. Results: 27 patients were downstaged and none were upstaged using the new FIGO system. Five and 4 patients with old FIGO stages 2 and 3 respectively were downstaged to stage 1 while 18 with old stage 3 were downstaged to stage 2. The median follow-up time was 23.5 months (range, 1 to 216). 30 patients (35%) died of disease. Background: Distinction of LMS from leiomyoma is based on: 1) nuclear atypia, 2) mitotic rate and 3) TCN. Unlike ischemic-type necrosis which may be seen in benign and malignant smooth muscle tumors (SMTs), TCN is thought to be unique to LMS. The distinction between these two types of necrosis can be challenging, especially during early stages, when necrotic foci are limited or when they exhibit overlapping features. The aim of this study was to assess the interobserver variability in the interpretation of TCN in uterine LMS. Design: 34 LMS were retrieved and a representative H&E slide showing one or more areas of necrosis was selected from each case. Pathologists from 6 different institutions subspecializing in gynecologic pathology performed a blinded, independent review of the slides. Using the current WHO criteria for assessment of TCN, they had to classify the necrotic foci into: 1) TCN, 2) no TCN or 3) indeterminate for TCN. Agreement among the panelists was categorized as: full agreement-all pathologists in agreement; partial agreement-4 or 5 pathologists in agreement; no agreement-≤ 3 pathologists placing the case into the same category. Results: Full agreement regarding the presence or absence of TCN was reached in 12 cases (35%) (7 thought to show TCN); partial agreement in 16 (47%); and no general consensus in 6 cases (18%). Overall, the level of agreement was fair (k=0.3948). In 8 of the 34 cases (23.5%), ≥ 1 pathologist made a diagnosis of "TCN" and ≥ 1 pathologist made the diagnosis of "no TCN" in the same case. The number of cases diagnosed as "indeterminate for TCN" by each pathologist ranged from 0 to 10 with a mean of 5.8. In 20 cases, at least 1 pathologist diagnosed "indeterminate for TCN" (59%); at least 2 were undecided in 10 (29%), and at least 3 in 4 cases (12%). Four pathologists diagnosed "indeterminate for TCN" in 1 case.
Conclusions:
The level of interobserver agreement amongst experienced gynecological pathologists in the assessment of TCN in uterine LMS is only fair. These results further reiterate the importance of assessing for both nuclear atypia and mitotic activity when differentiating between benign and malignant SMTs and not relying solely on the presence of TCN. Background: Sex cord-stromal tumors (SCSTs) of the ovary comprise less than 10% of all ovarian tumors. The majority are ordinary fibromas, others types being uncommon or rare. The differential diagnosis of the predominantly spindled and cellular SCSTs, particularly sarcomatoid granulosa cell tumors (GCTs), cellular fibromas (CFs) and thecomas (THs), is often difficult due to their close histologic resemblance and absence of reliable ancillary tests. Recently, the single somatic mutation FOXL2 402C→G (C134W) was reported in approximately 95% of adult-type granulosa cell tumors and in 15% of thecomas, but was absent in other ovarian tumors. However, the morphologic subtypes evaluated in these studies were not specified. Most GCTs are easily diagnosed based on morphologic and immunohistochemical features, and the challenge resides in the differentiation of the sarcomatoid variant from other SCSTs. This study evaluates the potential diagnostic application of FOXL2 mutational analysis, specifically in the setting of spindled and cellular SCSTs. Design: A total of 86 ovarian tumors, including 12 sarcomatoid GCTs, 27 GCTs of other subtypes, 30 CFs, 9 THs and 8 SCSTs of other categories (4 Sertoli-Leydig cell tumors, 2 steroid cell tumors, and 2 unclassified SCSTs) were retrieved from the archives of the Mayo Clinic. Reticulin, inhibin and calretinin were performed in all cases. The diagnoses were based on blind review of the HE slides and the aforesaid stains by two pathologists with expertise in gynecologic pathology. DNA was extracted from formalin-fixed, paraffin-embedded tissue sections followed by polymerase chain reaction and direct sequencing of the FOXL2 gene.
FOXL2 Mutational Analysis in the Differential
Results: The median age of the patients was 55 years old (range 14 to 69). Tumor size ranged from 0.5 to 39 cm. FOXL2 402C→G (C134W) was detected in 23 of 27 non-sarcomatoid GCTs (85.2%), 6 of 12 of sarcomatoid GCTs (50%) and 2 of 9 THs (22.2%). The mutation was not detected in any of the CFs and SCSTs of other categories. Mutational analysis was repeated in all GCTs lacking the mutation and the results were confirmed.
Conclusions:
The frequency of FOXL2 402C→G (C134W) in similar to that reported in the literature for non-sarcomatoid GCTs and THs. However, it is significantly lower for sarcomatoid GCTs, which had detectable FOXL2 mutations in only half of the cases. Therefore, mutational analysis may prompt re-evaluation of the tumor classification criteria for sarcomatoid SCSTs. Additional studies are warranted to establish the application of molecular testing in the diagnosis of GCTs. Results: The median age of the patients was 24 years old (range 9 to 58). Tumor size ranged from 2.3 to 29 cm. All dysgerminomas were diffusely positive for OCT4, KIT, PLAP and D2-40; less than 10% stained for CD30 and less than 5% for AE1/AE3, CAM5.2 and hCG. Yolk sac tumor was the only lesion positive for AFP; a diffuse pattern was present with the exception of 2 cases that showed focal expression. All yolk sac tumors were also positive for AE1/AE3 and CAM5.2; KIT was expressed in 84,6%, PLAP in 77%, D240 in 38,4%, OCT4 in 18% and inhibin in 7,6% of cases. All choriocarcinomas stained positively for hCG and keratins; two were also positive for inhibin and one for CD30. All immature teratomas with the exception of one case were positive for both or either synaptophysin and GFAP; chromogranin was expressed in 1/3 and calretinin in 1/4 of cases. Only one of the mixed mGCT contained embryonal carcinoma, which was diffusely positive for CD30, OCT4, PLAP, D2-40 and keratins, and negative for KIT and inhibin. The other mixed mGCTs showed dysgerminoma, yolk sac and immature teratoma components, which had an immunoprofile similar to the pure tumors in these categories.
The immunohistochemical profile of ovarian mGCTs is similar to the one described for mGCTs of the testis; and, therefore, it can be used in this setting with the same level of reliability. Finger) , a zinc-finger transcriptional repressor plays an important role in cell cycle regulation. We investigated the PLZF expression in ovarian benign epithelium, borderline tumors with or without micropapillary foci, and in low-grade, and high-grade serous carcinoma. Design: 55 routinely processed specimens, comprising benign ovary (n=10), serous cystadenoma or adenofibroma (n=10), serous borderline tumor (n=10), serous borderline tumor with micropapillary foci (n=10), high grade serous carcinoma (n=10), and low grade serous carcinoma (n=5) were subjected to citrate-based Ag retrieval followed by exposure to streptavidin-biotin reagents and diaminobenzidine. Results: In normal ovarian surface, PLZF staining was nuclear and was positive in 80-100% of epithelial lining cells. Nuclear staining was also seen in serous cystadenofibroma, in 90-100% of epthelial cells. In contrast, serous borderline tumors displayed cytoplasmic and perinuclear rather than nuclear staining, with about 10-20% of tumor cells staining. In micropapillary foci, cytoplasmic PLZF staining further decreased to 3-5 % epithelial cells on the long slender micropapillae (Fig. 1 A -F) .
PLZF Immunostaining Distinguishes Low-Grade and High-Grade
Staining of low-grade serous carcinoma was easily distinguished from high grade serous carcinoma: the former displayed cytoplasmic PLZF expression in 5-10% of tumor cells, whereas the latter were completely non-staining (Fig.2 A-D) .
Conclusions: PLZF immunostaining distinguished ovarian normal, low grade neoplastic and high grade malignant epithelia. Our findings are consistent with basic studies that have defined a mechanism of nuclear export of PLZF corresponding to de-repression of cell proliferation. These findings define a new means of distinguishing ovarian serous tumors. Downregulation of PLZF may contribute to uncontrolled serous epithelial cells proliferation; therefore it may play an important role in ovarian serous tumor pathogenesis.
Immunohistochemical Expression of Two Upper Gastrointestinal (GI) Markers (CK17 and DPC4) in Primary and Metastatic Mucinous Ovarian
Neoplasms. JM Lloyd, AM Krasinskas, M Chivukula. UPMC, Pittsburgh, PA. Background: In mucinous neoplasms of ovary, diagnosing metastatic disease can be challenging, especially in the setting of an occult primary. Morphologic and immunohistochemical parameters exist to aid in this distinction; however, they are not entirely specific. Cytokeratin (CK) 17 is a basal-type cytokeratin expressed in pancreaticobiliary carcinomas, whereas DPC4 (SMAD4) is a tumor suppressor that is inactivated in up to 40% of pancreatic adenocarcinomas. This study aims to determine the expression of CK17 and DPC4 in primary and metastatic mucinous ovarian tumors. Design: DPC4 and CK17 expression were determined by immunohistochemistry (IHC) on primary low malignant potential (LMP) and invasive ovarian mucinous tumors (IMT-O), and metastatic mucinous ovarian tumors (MMT-O) (upper gastrointestinal in origin). Primary cholangiocarcinomas (CC), primary breast mucinous carcinomas (MT-B), and primary pancreatic neoplasms (PMT) were also stained. The intensity of staining (IS) was graded as negative-0, weak-1, moderate-2, and strong-3, and the proportion of positive staining cells (PS) was recorded as none (0), 1-5% (1), 6-20% (2), 21-80% (3), and 81-100% (4). A cumulative score (CS) was derived from PS and IS, and ranged from 0 to 7. CS was divided into negative (0), weak (1-2), moderate (3-5), and strong (6-7). Results: Conclusions: 1. Moderate-strong DPC4 expression is seen in primary LMP and invasive mucinous carcinomas. 2. Our study is the first to evaluate CK17 in ovarian neoplasms; moderate staining is seen in more than half of primary ovarian LMP and invasive mucinous tumors. 3. All primary mucinous carcinomas of breast demonstrate strong DPC4 expression (100%) and all are negative for CK17. 4. Though metastatic tumors to ovary show stronger DPC4 than CK17 expression, in determining the origin of a mucinous tumor of ovary, a combination of both marker expression favors metastatic disease from a pancreaticobiliary primary over an ovarian or breast primary.
CDX2 Is a Useful Marker To Distinguish Ovarian Primary Carcinoid from Gastrointestinal Neuroendocrine Tumors (NET).
JM Lloyd, H Xu, C Zhao. UPMC, Pittsburgh, PA; University of Rochester, NY. Background: Primary ovarian carcinoids are the second most frequent monodermal teratomas. They occur in a pure form (15%) or combined with other teratomatous components (85%). Primary ovarian carcinoids and metastatic tumors share similar morphologic features. They can be designated as primary with relative ease when they occur in association with other teratomatous components. However, when they occur in a pure form, metastatic disease must be excluded. Gastrointestinal (GI) NET (carcinoid) are more common with the majority arising from small intestine (SI) (29%) and appendix (25%). CDX2 is a nuclear transcription factor critical for intestinal differentiation, and is a relatively specific marker of intestinal epithelium. To the best of our knowledge, CDX2 expression has not been assessed in primary ovarian carcinoids (and is known to be expressed in a subset of GI NET). The aim of this study is to evaluate the expression of CDX2 by immunohistochemistry (IHC) in a large series of primary ovarian carcinoids and primary GI NET. Design: CDX2 expression was determined by IHC on 28 primary pure ovarian carcinoids, 13 primary ovarian carcinoids arising in association with benign teratomas, 2 ovarian carcinoids metastatic from SI and 70 GI NET (11 stomach, 10 duodenum, 20 SI, 12 appendix, 17 colorectal). Nuclear staining in >5% of cells was considered positive. Results: None of the 28 primary ovarian carcinoid tumors are positive for CDX2, whereas 49/70 (70%) cases of GI NET and 2/2 (100%) SI NET metastatic to ovary showed strong nuclear staining (diffuse or focal) ( Table 1) . Two primary carcinoids mixed with benign teratomas showed only weak positivity. Conclusions: CDX2 positive carcinoid tumors involving the ovary are unlikely to represent primary ovarian carcinoids and are more likely to be metastatic from the GI tract in the absence of other associated teratomatous elements. CDX2 positivity can be seen in primary ovarian carcinoids that occur in association with benign teratoma suggesting that some of these tumors may arise from GI derived epithelium within the teratoma.
Va l i d a t i o n o f D i a g n o s t i c C r i t e r i a f o r E n d o m e t r i a l Adenocarcinoma.
A Lo, S Khutti, K Mittal. New York University School of Medicine, NY. Background: We previously identified morphologic criteria for endometrial biopsies which showed increased sensitivity and specificity for distinguishing endometrial adenocarcinoma (EA) from complex atypical hyperplasia (CAH). In the current study we evaluated the application of these criteria to endometrial biopsies received at our institution between 2007 and 2010. Design: We searched the pathology database at NYULMC for all endometrial biopsies with subsequent hysterectomy received between January 2007 and August 2010 which were diagnosed as either CAH or EA, FIGO grade I. Slides for each identified case were retrieved, and were reassessed for the presence or absence of adenocarcinoma without the knowledge of hysterectomy findings. A diagnosis of EA was made if the biopsy possessed either 1)areas of >95% glandular crowding that were 3 mm or larger in aggregate diameter or 2) any cribiform architecture. We compared our diagnosis with that of the resection. Results: We identified 95 patients that fulfilled all of the criteria for inclusion. On assessment of the slides using the previously discussed criteria, we diagnosed 50 of these cases as EA. On resection, 42 of these patients had EA (42/50, 84%); the remainder had CAH or contained no residual atypical lesion. In 45 cases we diagnosed CAH; 36 of these cases had CAH on resection. The remaining 10 cases were diagnosed as adenocarcinoma and adenocarcinoma in situ on resection (7/45, 15.5% and 3/45,6 .6% respectively). These figures produced a sensitivity of 84% and a specificity of 80% for the diagnosis of endometrial adenocarcinoma (p<.0001).
Conclusions:
The findings of this study validated previously derived criteria for diagnosing endometrial adenocarcinoma. The criteria used in this study had a higher sensitivity and specificity for predicting endometrial adenocarcinoma in hysterectomy specimens than any of the previously published criteria. The probability of finding endometrial adenocarcinoma in cases diagnosed as CAH was lower than that reported in other published series. Use of these criteria should lead to more accurate classification of cases in the spectrum of complex atypical endometrial hyperplasia to well differentiated endometrial adenocarcinoma. Background: Tubulin, the major building block of microtubules, functions as structural and mobile elements in mitosis, intracellular transport, and in the cytoskeleton. Recent studies have shown that increased tumor expression of the class III beta-tubulin isotype (b3T), correlates with poor clinical outcomes in patients with various malignancies. These include breast, ovarian, gastric, and non-small cell lung cancers. Studies suggest that these poor clinical outcomes, in the setting of b3T overexpression, are related to resistance to tubulin-binding chemotherapeutic agents, such as taxanes and vinca alkaloids, used in the treatment of these malignancies. Treatment of endometrial cancer may also be treated with tubulin-binding agents. The purpose of this study is to investigate b3T expression in endometrial tumors. Design: Endometrial cancer cases were identifed from the hospital database for a 3 year period. General information, including patient demographics, tumor characteristics, chemotherapeutic agents used, and survivor data, was collected using pathology reports, clinical records, and tumor registry data. Residual formalin fixed paraffinembedded tissue, archived in the Department of Pathology, was retrieved for each tumor and subjected to immunohistochemical staining for b3T. Slides were evaluated for the presence of staining and scored semiquantitatively on a 4-tiered scale based on percentage of total tumor area staining and intensity of staining. Results: Ninety-six uterine cancer cases were stained for b3T. The majority (n=64) were adenocarcinomas (45 endometrioid, 10 serous, 9 endometrioid with mucinous differentiation). Approximately half (46.8%) of adenocarcinomas showed b3T over expression. The majority of sarcomas (85.7%) were negative for b3T. Among carcinosarcomas, 64.3% showed b3T over expression, almost exclusively in the carcinomatous component. When comparing b3T positive to b3T negative tumors, no statistically significant differences were seen among demographic characteristics, stage or grade of tumors, or among chemotherapeutic modalities. However, tumors showing b3T over expression were more likely to have lymphovascular invasion (47.9% vs. 14.6%, p=0.001) and a worsened uterine cancer specific survival. Conclusions: Differential class III beta-tubulin staining patterns are seen in endometrial cancers across all histologic subtypes. Further investigation is warranted to further characterize the correlation between class III beta-tubulin positivity and clinical outcomes. Background: Lynch syndrome is an autosomal dominant condition caused by germline mutation in one of the DNA mismatch repair genes (hMLH1, hMSH2, hMSH6 and hPMS2), and is associated with increased risk for multiple malignancies, with colorectal carcinoma and endometrial carcinoma being the most common. Patients with Lynch syndrome are also at increased risk for ovarian malignancies, with a lifetime risk estimated at 10-12%. We analyzed the prevalence of DNA mismatch repair gene defects amongst primary malignant epithelial tumors of the ovary, using immunohistochemical staining for DNA mismatch repair (MMR) proteins. Design: Tissue microarray (TMA) consisting of 342 primary malignant epithelial tumors of the ovary collected at Vancouver General Hospital were stained for hMLH1, hMSH2, hMSH6 and hPMS2. Positive staining for MMR proteins on TMA were verified on whole section slides for 25 randomly selected cases. Results: Of the 342 primary malignant epithelial tumors of the ovary, loss of expression of MMR proteins was more commonly seen in the non-serous carcinomas, specifically: mucinous (1/8 cases), endometrioid (3/29 cases), clear cell (3/29 cases) and undifferentiated (1/9 cases) carcinomas, and mixed carcinomas with an endometrioid, clear cell and/or undifferentiated component (3/5 cases). The frequency of MMR protein loss was significantly higher in non-serous cases versus high-grade serous carcinomas (11/80 cases or 13.8% vs. 9/217 cases or 4.1%, p=0.007). No loss of MMR protein expression was identified in borderline tumors (22 cases), low-grade invasive serous carcinoma (9 cases) or malignant Brenner tumor (3 cases). All 25 cases positive for MMR gene products on TMA also stained positive when retested on whole section slides. Conclusions: Our study demonstrated loss of expression of MMR proteins in 13.8% of ovarian carcinomas of non-serous types. These results raise the possibility of selective genetic screening for Lynch syndrome in patients with these types of ovarian carcinoma. Tumors Using CK7, EMA, CA125, SALL4 , and AFP Antibodies. D Maeda, S Ota, Y Takazawa, M Fukayama. Graduate School of Medicine, The University of Tokyo, Japan. Background: The distinction between ovarian clear cell adenocarcinomas (CCAs) and yolk sac tumors (YSTs) is of significant clinical importance, because treatment options for CCAs ans YSTs are completely different. However, it is often challenging to make a histological distinction between these tumors. Among the variety of histological patterns of ovarian YSTs, hepatoid and glandular histological patterns are known to closely resemble CCAs. In this study, we aimed to identify a useful panel of immunohistochemical markers for differential diagnoses of ovarian CCAs and YSTs. Design: We studied 94 ovarian CCAs and 14 ovarian YSTs that had been surgically removed in four major hospitals in Tokyo between 1986 and 2010. Immunohistochemical analyses were performed on a representative section from each case, using antibodies against the following: CK7, EMA, CA125, SALL4, AFP, GPC3, and Hep Par 1. Immunostaining was interpreted as positive when at least 5% of the cells were immunoreactive. Positive expression was further classified as 1+ (5-14%), 2+ (15-49%), or 3+ (≥50%). Results: All 94 CCAs (100%) were positive for CK7 and EMA, with more than 90% of the cases showing diffuse (3+) immunoreactivity for each antibody. Of the 14YSTs, three each (21%) showed focal (1+) positivity for CK7 and EMA, respectively. Most (63/94; 67%) CCAs, but only one YST (7%), showed positive immunostaining for CA125. One CCA (1%) was positive for SALL4, a newly introduced germ-cell tumor marker. In contrast, all 14 YSTs (100%) showed diffuse (3+) nuclear immunoreactivity for SALL4. All of the YSTs, but none of the CCAs, were AFP-positive. However, the extent of AFP reactivity varied among the YSTs (1+: 2 cases, 2+: 5 cases, 3+: 7 cases). Positive staining for GPC3, another marker for hepatic tumors, was observed in 41 of 94 CCAs (44%) and in all 14 YSTs (100%), while Hep Par 1 immunoreactivity was occasionally observed in CCAs (27%) and YSTs (43%). Conclusions: Our results suggest that positive immunostaining for CK7, EMA, and CA125, and negative immunostaining for SALL4 and AFP support a diagnosis of CCA, whereas positive reactions for SALL4 and AFP, and negative reactions for CK7 and EMA favor a diagnosis of YST. GPC3 immunostaining appears to be of limited value in distinguishing CCAs and YSTs, as a significant number of CCAs were GPC3-positive. Similarly, Hep Par 1 is not useful for differentiation, although it is interesting that approximately 30% of CCAs and 40% of YSTs expressed this hepatic marker.
Prevalence of DNA Mismatch Repair Protein Loss in 342 Primary
Immunohistochemical Differentiation of Ovarian Clear Cell Adenocarcinomas and Yolk Sac
Clinicopathological Significance of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma. D Maeda, T-L Mao, M Fukayama, T-L Wang, I-M Shih. Graduate School of Medicine,
The University of Tokyo, Japan; National Taiwan University Hospital, and College of Medicine, Taipei, Taiwan; Johns Hopkins Medical Institutions, Baltimore, MD. Background: Recent genome-wide analysis has demonstrated that somatic mutations in ARID1A are the most common molecular genetic changes in ovarian clear cell carcinoma (CCC). ARID1A mutations which occurred in approximately half of CCC cases, lead to deletion of the encoded protein and inactivation of the putative tumor suppressor. Design: In this study, we first correlated ARID1A mutation status and ARID1A immunoreactivity then applied immunohistochemistry to determine if there is any clinicopathological features associated with the loss of ARID1A expression in a total of 149 CCC cases collected from the University of Tokyo Hospital, National Taiwan University Hospital and the Johns Hopkins Hospital. Results: We demonstrated that loss of ARID1A expression was associated with ARID1A inactivating mutations in CCC (p= 0.0073). Specifically, all 9 CCCs harboring ARID1A mutations showed undetectable or very weak immunoreactivity while negative staining could also be observed in one of 3 CCCs with wild-type ARID1A. ARID1A immunoreactivity was undetectable or very week in 88 (59%) of 149 CCCs. There was no statistically significant difference of ARID1A negative and positive cases in terms of histopathological features (structural patterns, nuclear atypia, cystic vs. adenofibromatous), age, clinical sage, overall survival, and frequency of lymph node metastasis. However, we observed that loss of ARID1A expression correlated with lower chance of peritoneal dissemination (p<0.05). Conclusions: In conclusion, this study provides the first analysis of ARID1A mutations and clinicopathological features and we demonstrate that mutations in ARID1A resulted in loss of ARID1A protein expression in CCC and there was no significant difference of ARID1A positive and negative cases in all the clinical parameters examined except for frequency of peritoneal dissemination. Background: Long term survival for ovarian cancer is poor (<30%). Patients undergo debulking surgery followed by platinum-taxane based chemotherapy. Most patients respond well initially, however relapse with chemoresistance is frequent. Tumour hypoxia is a factor in chemoresistance via HIF-1 (hypoxia inducible factor-1) pathway activation. Recent reports indicate an inverse relationship between resistance to cisplatin and paclitaxel across a variety of tumour cell lines. This study aimed to examine whether hypoxia could play a role in this inverse relationship in two ovarian cancer cell lines, A2780 and its cisplatin-resistant derivative, A2780cis. Design: Cell lines were grown in RPMI 1640 media (10% FBS, 1mM glutamax and 1% penicillin/streptomycin) at 37°C, 5% CO 2 . Hypoxic exposure was carried out in an Invivo hypoxic chamber at 0.5% O 2 . Drug resistance following hypoxic exposure was determined using MTT assays. Dose response curves, IC 50 values and Student t-test values were determined by GraphPad software. Experiments were performed in triplicate with significance at p<0.05. Results: A2780cis were 5-fold more resistant to cisplatin than A2780s (IC 50 10µM vs. 2µM, p<0.001). Conversely A2780cis were more than 10-fold more sensitive to paclitaxel than A2780s (IC 50 250pM vs. 3.4nM, p<0.01). Exposure to acute hypoxia (4 h) prior to drug treatment significantly increased resistance to cisplatin in both cell lines. However, acute hypoxia before paclitaxel treatment increased sensitivity to the drug in A2780s, while increasing resistance in A2780cis. Chronic hypoxia (5 days) before treatment increased sensitivity to both cisplatin and paclitaxel in A2780s. Conclusions: A2780 and A2780cis have an inverse relationship between resistance to cisplatin and paclitaxel. This relationship can be further potentiated by exposing the cells to hypoxia prior to drug treatment. Genes involved in this process may include HIF-1, p53 and BRCA; known to play a role in cisplatin and paclitaxel resistance whilst also regulated by hypoxia.
Expression Analysis of Newly Identified EMT Genes in High Grade
Serous Carcinoma of the Ovary and Uterus. BD McMillen, X Yang, J-J Wei. Northwestern University, Chicago, IL. Background: The pathobiology of high-grade serous carcinoma (HGSC) of the ovary is currently not well understood, and is an area of active investigation. In a recent study, we identified a group of epithelial-mesenchymal transition (EMT) genes that are directly or indirectly regulated by the oncogene HMGA2 in ovarian surface epithelial (OSE) cells. To test whether HMGA2-mediated aggressive tumor growth in HGSC acts through regulation of EMT genes, we decided to examine whether these EMT genes are expressed in HGSC. These genes have never been studied in depth regarding the pathogenesis of ovarian tumors. Design: Our study includes 96 serous tumors, including 56 ovarian high grade serous carcinomas (OSC), 18 serous borderline tumors (LMP) and 22 uterine serous carcinomas (USC). We examined HMGA2 and its target EMT gene expression, including ID1, LUM, POSTN, and STC2 by immunohistochemistry. Associated markers p53, ER, PR and Ki-67 were also included. Results: In ovarian surface epithelial cells (OSE), four EMT associated genes (ID1, LUM, POSTN, and STC2) are regulated by HMGA2. In this study, we found that HMGA2 positive HGSC had significant down regulation of ID1, LUM and POSTN, and up regulation of STC2 in comparison to HMGA2 negative HGSC. The findings are consistent with our predictions based on gene expression in OSE cell lines. Importantly, we found HMGA2 and its EMT genes are positively associated with lymph node metastasis, suggesting an increased propensity towards aggressive behavior in tumors expressing these genes. There was significant difference of EMT gene expression between tumor cells and surrounding stroma. Lastly, HGSC from both ovary and uterus showed a very similar gene expression pattern. Conclusions: HMGA2 and its associated EMT genes are significantly dysregulated in HGSC and they are positively correlated with lymph node metastases. Differential expression of these EMT genes between tumor cells and surrounding stroma suggests a functional role in aggressive tumor growth in HGSC. In particular, distinct expression patterns of these EMT genes in HGSC may provide novel markers for the study of HGSC. Background: Metastatic mucinous carcinomas in the ovary are readily recognized when they display characteristic features (bilateral involvement, moderate tumor size, surface involvement, nodular growth, an infiltrative pattern) but are capable of simulating primary ovarian mucinous tumors. Metastatic pancreaticobiliary tract adenocarcinomas present a particular diagnostic challenge due to their ability to exhibit borderline-like and cystadenomatous growth patterns which can be misinterpreted as underlying primary ovarian precursor tumors. Design: Clinicopathologic features of 35 metastatic pancreaticobiliary tract adenocarcinomas in the ovary were analyzed. Immunohistochemical analysis of Dpc4 expression was performed on 33 cases and clinical follow-up was obtained. Results: Mean patient age was 58 years (median, 59; range, 33-78) . In 15 cases (43%), the pancreaticobiliary tract and ovarian tumors presented synchronously and in 2 cases (6%) the ovarian tumors presented prior as the first manifestation of disease. Ovarian tumors were bilateral in 31 cases (89%). Mean and median sizes were 10.6 and 9.5 cm, respectively (range, 2.5-21 cm). Nodularity was present in 22 cases (63%) and surface involvement was identified in 14 cases (40%). An infiltrative pattern was present in 28 cases (80%), most often admixed with borderline-like and cystadenomatous areas but as the exclusive pattern in 11 cases (31%). Conversely, borderline-like and cystadenomatous patterns were identified in 24 cases (69%) and as the exclusive patterns (either pure or combined with one another) in 7 (20%). Dpc4 expression was lost in 20 of 33 tumors analyzed (61%). Of 25 patients with follow-up, 23 died of disease (mean/median time, 9/6 months; range, 1-39) and 2 were alive with disease (at 1 and 25 months). Conclusions: Frequent bilateral ovarian involvement, moderate tumor size, nodularity, and infiltrative patterns are useful features for identifying these ovarian tumors as metastatic; however, many also exhibit borderline-like and cystadenomatous patterns which, when dominant and combined with synchronous presentation, make recognition as metastases challenging. Loss of Dpc4 expression provides the most useful immunohistochemical evidence for establishing the pancreaticobiliary tract as the most likely source of these metastases. Kyoto University Hospital, Japan; Brigham and Women's Hospital, Boston, MA; Kitano Hospital, Osaka, Japan; Kyoto Medical Center, Japan; Nagahama City Hospital, Shiga, Japan; Kansai Medical School, Hirakata Hospital, Osaka, Japan. Background: Uterine leiomyosarcoma may rarely have heterologous differentiation, resulting in the presence of components of rhabdomyosarcoma, osteosarcoma, or liposarcoma. Those with adipocytic differentiation have been described in single case reports under a variety of names including lipoleiomyosarcoma, and thus morphologic diversity and clinicopathologic features remain undetermined. Design: Seven cases of uterine leiomyosarcoma with adipocytic components ("lipoleiomyosarcoma") were reviewed to determine clinicopathologic features and morphologic characteristics. Results: The patient age ranged from 41 to 63 years (mean; 50.3, median: 44). All cases had features of ordinary leiomyosarcoma, but five also showed epithelioid features and/or myxoid changes. Three cases showed a mixture of spindle cells and mature adipocytes with bland nuclear morphology, and thus in areas resembled lipoleiomyoma or spindle cell lipoma. In addition, two cases harbored components resembling pleomorphic lipoma, one of which was associated with lipolieomyoma-like component. Adipocytic component was well-differentiated and/or cytologically pleomorphic, and in two cases showed myxoid changes. In these two cases mature adipocyte-like or epithelioid cells with multiple intracytoplasmic vacuoles were embedded in the myxoid matrix. Features of prototypical myxoid/round cell liposarcoma were not identified.
Ovarian Metastases of
Immunohistochemically the tumors in all four cases were positive for alpha-smooth muscle actin, h-caldesmon, and/or desmin. CD34 and S-100 protein were negative in leiomyosarcomatous component but CD34 were positive in areas of adipocytic component in three tumors, and S-100 protein in two. Adipocytic component was confirmed to be positive for CDK4 and MDM2 in four and two tumors, respectively. All four patients with follow-up information had recurrent disease within 2 years (interval; 2-16 months). Conclusions: Adipocytic differentiation in leiomyosarcoma is frequently associated with myxoid and epithelioid features, and may harbor lipoleiomyoma-and/or bizarre leiomyoma-like component, resulting in diagnostic difficulty, particularly with limited sampling. Background: Lynch syndrome (LS) is characterized by a high lifetime incidence of colorectal cancer and endometrial cancer. Given recent recommendations for universal, cost effective screening of all patients with newly diagnosed colorectal cancer using mismatch (MMR) protein immunohistochemistry (IHC), we evaluated for LS endometrial cancer in the general population. Design: 387 consecutive cases of primary endometrial cancer at a single institution (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) were evaluated for LS regardless of age, family history or histologic features. Evaluation methods consisted of IHC for the MMR proteins MLH1, MSH2, MSH6 and PMS2, followed by real-time PCR (Methylight) DNA methylation analysis for cases with MLH1/PMS2 deficiency. A subset of tumors also had microsatellite instability and/or gene sequencing data, but this was not part of the study design. Results: Twenty-six LS-associated endometrial cancers were identified: 2 MLH1/ PMS2, and 24 with MSH6 and/or MSH2. Only 26% occurred in women <50 years of age (range, 39-88 years), one of which was in a prophylactic hysterectomy specimen for prior diagnosis of LS. Two had associated colorectal carcinoma, but there were no simultaneous ovarian carcinomas. 48% were grade 1; 26% grade 2; and 26% high grade. Most were endometrioid (n=21), with 2 mixed endometrioid/mucinous, 1 mucinous, 1 serous, 1 clear cell, and 1 carcinosarcoma. 3 were in the lower uterine segment; 9 had tumor infiltrating lymphocytes. Conclusions: Screening using current Bethesda guidelines and recently suggested pathologic guidelines misses a substantial proportion of patients with MMR protein deficient endometrial cancer and many patients with LS. Based on recent recommendations for universal screening of newly diagnosed colorectal carcinomas, these data also support universal screening of all newly diagnosed endometrial cancer. A cost effective algorithm using only 2 MMR antibodies as an initial screen is proposed.
Expression of Mismatch Repair Proteins in Endocervical Adenocarcinomas: A Review of 79 Cases Including Minimal Deviation Adenocarcinomas and Problematic Lower Uterine Segment Tumors.
AM Mills, S Liou, CS Kong, TA Longacre. Stanford University, CA. Background: Endometrial carcinoma is one of the most common malignancies seen in Lynch Syndrome (LS). Recently, the prevalence of LS has been noted to be much higher (29%) in patients with endometrial tumors localized to the lower uterine segment (LUS) when compared to the general endometrial cancer population (1.8%) (Westin et al, J Clin Oncol, 2008) . In this location, distinction from endocervical primary may be difficult, particularly when atypical morphology is present, immunohistochemical stains are inconclusive, and evidence of HPV-infection is lacking. While clinical studies do not suggest an association between LS and endocervical carcinomas, mismatch repair protein (MMR) testing has not been performed in large numbers of these tumors. In this study, we examined expression of MMR proteins in endocervical adenocarcinomas and problematic LUS tumors of uncertain origin. In addition, we focused on cases of minimal deviation adenocarcinomas (adenoma malignum) which may present diagnostic difficulties due to their HPV-negative status and unconventional morphologies. Design: Expression of MMR proteins (MSH2, MSH6, MLH1, PM2) was assessed on a tissue microarray containing 33 endocervical adenocarcinomas and 36 problematic LUS cases. The endocervical adenocarcinomas consisted of 20 invasive and 13 in situ cases. Problematic LUS cases consisted of uterine tumors for which a site of origin could not be assigned due to discordance among radiographic, gross, and morphologic findings. Representative whole slides from 10 cases of minimal deviation adenocarcinoma were also stained with all 4 MMR proteins Results: All 33 endocervical adenocarcinomas and all 10 minimal deviation adenocarcinomas demonstrated intact expression of the 4 MMR proteins. A single problematic LUS case showed loss of MSH2 and MSH6. Although this tumor was clinically thought to represent an endocervical primary based on its location in the cervix and lower uterine segment, the tumor's immunohistochemical profile (p16 negative, vimentin negative, hormone receptor positive) was more compatible with endometrial origin. Conclusions: Conventional endocervical adenocarcinomas and minimal deviation adenocarcinomas do not exhibit MMR protein deficiency by immunohistochemistry, indicating that these mismatch repair genes are intact in these tumors. These findings suggest that endocervical adenocarcinoma is almost certainly not a feature of LS and that loss of MMR proteins in a LUS tumor argues strongly against endocervical origin. Background: MLH1 protein deficiency due to epigenetic silencing of MLH1 by promoter hypermethylation occurs frequently in endometrial carcinomas, but the clinicopathologic features of these tumors have not been well characterized. Design: Fifty-four endometrial carcinomas with deficient MLH1 immunohistochemical expression resulting from MLH1 promoter methylation identified by real-time PCR (Methylight) DNA methylation analysis were studied. Tumors were assessed for histologic type, grade, lymphovascular invasion, tumor infiltrating lymphocytes, depth of invasion, concurrent hyperplasia, tumor location, and stage. Results: The average patient age was 64.8 years (range: 42-88). The majority (86%, 44/51) of tumors were located in the uterine fundus. Four tumors were located in the fundus with extension into the lower uterine segment (LUS) while 3 tumors were limited to the LUS. While most tumors (81%, 44/54) showed pure endometrioid histology, 19% (10/54) also demonstrated mucinous differentiation. No serous, clear cell, or carcinosarcoma histologies were identified. Most tumors were either grade 1 (41%, 22/54) or grade 2 (42%, 23/54); only 9 cases were high grade. One endometrioid case showed predominantly grade 1 tumor immediately juxtaposed with a focus of undifferentiated carcinoma. Advanced FIGO stage was seen in 13% of grade 1, 24% of grade 2, and 44% of grade 3 carcinomas. Tumor-infiltrating lymphocytes were present in 33%. At least 35% had concurrent hyperplasia and in no instance was the hyperplastic component associated with loss of MLH1. Conclusions: Sporadic endometrial carcinoma with MLH1 promoter hypermethylation occurs predominantly in the uterine fundus, is associated with endometrioid or mucinous histology -often with associated hyperplasia, and exhibits a similar grade distribution to non-MLH1 methylated endometrial cancer. Despite decreased high-risk histology, MLH1-methylation appears to be associated with an increased rate of advanced-stage disease.
Size of Endometrial Adenocarcinoma and Non-Cancerous Tissue in Biopsy Have Predictive Value for Finding Endometrial Adenocarcinoma in Hysterectomy.
K Mittal, S Sasturkar, A Salem. NYU School of Medicine, New York, NY. Background: In a significant number of cases, a hysterectomy following a diagnosis of endometrial adenocarcinoma in endometrial biopsy does not show carcinoma. In this study we evaluated if the amount of carcinoma in biopsy or the presence and extent of non-cancerous tissue in biopsy correlates with the likelihood of finding endometrial adenocarcinoma in hysterectomy. This is of particular interest in Grade I Endometrial adenocarcinoma where conservative management with progestins may be a choice. Design: Endometrial adenocarcinoma grade I cases diagnosed at NYU Medical center from 2003 to 2006 were reviewed without the knowledge of subsequent hysterectomy findings. The size of tissue with endometrial carcinoma was semi-quantitatively assessed using a ruler placed directly on the slide. The measurements were expressed as approx. aggregate diameter of cancerous tissue present. Similar measurements were taken for the non-cncerous tissue in each biopsy.
Results:
The aggregate size of the carcinoma in biopsy was predictive of presence of endometrial carcinoma in hysterectomy specimens. There were a total of 49 cases of endometrial adenocarcinoma. Carcinoma was seen in hysterectomy in 33 of 34 (97%) patients with tumor diameter of 7 mm or greater versus 10 of 15 (66.6%) patients with tumor diameter of less than 7 mm in biopsy (p=0.007). The extent of benign tissue present in the biopsy also correlated with the likelihood of finding endometrial carcinoma in hysterectomy. Carcinoma was seen in hysterectomy in 30 of 31 patients where only carcinoma was seen in biopsy versus 13 of 18 patients where non-cancerous endometrial tissue was also present (p=0.02). Carcinoma was seen at hysterectomy in only 1 of the 4 cases with non-cancerous tissue with aggregate diameter greater than 15 mm. Conclusions: The findings of this study suggest that absence of endometrial carcinoma in some hysterectomy specimens where biopsy had previously shown carcinoma may be due to the focal nature and small size of the carcinoma in these particular patients. In endometrial biopsy specimens, the small size of the carcinoma tissue (less than 7 mm in diameter) and the presence of non-cancerous endometrial tissue may be used to identify such cases. The findings of this study may be useful in counseling individual patients with biopsy diagnosis of endometrial carcinoma about the likelihood of finding endometrial carcinoma in hysterectomy.
Hedgehog Pathway Expression and Clinical Outcome in Endometrial Carcinoma (EC).
W Mneimneh, MA Ashraf, CE Sheehan, JS Ross. Albany Medical College, NY. Background: The expression of hedgehog pathway proteins including including Sonic (Shh) and Desert (Dhh) have been associated with embryonic development and human neoplasia. Hedgehog pathway signaling has not been linked to clinical outcome in EC. Design: Formalin-fixed, paraffin-embedded tissue sections from 128 endometrial carcinoma, including 104 endometrioid carcinoma (EC), 12 uterine papillary serous carcinoma (PSC) and 12 malignant mesoderm mixed tumor (MMMT), were immunostained by automated methods (Ventana Medical System, Tucson, AZ) using goat polyclonal Shh and Dhh antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). Cytoplasmic immunoreactivity was scored based on staining intensity (weak, moderate, strong) and percentage of positive cells (focal <= 10%, regional 11-50%, diffuse >50%). Results were correlated with clinicopathologic variables. Results: Immunoreactivity for Shh and Dhh were predominately cytoplasmic. Strong diffuse Shh and Dhh overexpression was observed in 20% and 19% of tumors overall; and 21% and 23% ECs, 17% and 0% PSCs, and 17% and 0% MMMTs, respectively. Shh overexpression correlated with advanced stage (34% advanced vs 15% early, p=0.024) and depth of myometrial invasion (38% invading to more than 50% of the myometrium vs. 17% to less than 50% vs. 0% no invasion, p=0.024). Dhh overexpression also correlated with advanced stage (37% advanced vs 17% early, p=0.033) and depth of myometrial invasion (33% invading to more than 50% of the myometrium vs. 19% to less than 50% vs. 0% no invasion, p=0.04). A significant co-expression was identified between Shh and Dhh (p=0.012). On multivariate analysis, disease recurrence (p=0.004) and advanced stage (p=0.03) independently predict shortened survival. Conclusions: Overexpression of both Shh and Dhh occurs in EC and is associated with depth of tumor invasion and pathologic stage. Further studies of the hedgehog signaling pathway in EC appears warranted. Background: Clusterin, a multifunctional glycoprotein, is ubiquitously produced in mammalian tissues. While clusterin has been shown to play significant roles in many aspects of human tumor biology, such as cell proliferation, apoptosis, chemoresistance and angiogenesis, the relationship of clusterin expression with angiogenesis in ovarian cancer has not been studied. Design: Immunohistochemical (IHC) staining for clusterin, VEGF and VEGF-R were performed on a Tissue Microarray (TMA) containing 181 primary ovarian epithelial cancer. These 181 tumors consisted of 119 serous carcinoma, 23 mucinous carcinomas and 39 other types of carcinoma (endometroid, mixed mullerian, clear cell, Brenner, and undifferentiated). A total of 170 cases were available for evaluation for all 3 markers. The levels of protein expression for these 3 genes were scored based on staining intensity and percentage of immunopositive cells and were correlated with one another. Results: Among these 170 cases, clusterin, VEGF and VEGF-R were overexpressed in 94 (55%), 97 (57%) and 48 (28%) of the cases respectively. Among 94 tumors that overexpressed the clusterin, VEGF and VEGF-R were increased in expression in 66 (70%) and 29 (30%) cases respectively. By contrast, among 76 tumors without significant clusterin expression, overexpression of VEGF and VEGF-R were seen in only 31 (40%) and 19 (25%) of the cases. Conclusions: Overexpression of clusterin in epithelial ovarian cancer appears to be correlated with increased tumor angiogenesis, consistent with the established role of clusterin as an oncogene in the biology of ovarian cancer.
Clusterin Overexpression Promotes Angiogenesis in Primary
Mucinous Adenocarcinoma of the Endometrium Confers Increased
Risk of Lymph Node Metastases. F Musa, B Adams, K Holcomb, E Pirog. Weill Cornell Medical College, New York, NY. Background: Mucinous adenocarcinoma of the endometrium (MUC) is a rare histological variant of endometrial carcinoma accounting for less than 10% of endometrial tumors. The tumor develops in a background of hyperplasia and mucinous metaplasia of the endometrium. Few studies have characterized its clinical behavior. The aim of this study is to compare the risk factors and clinical course of MUC relative to endometrioid adenocarcinoma. Design: A case-control study was performed which included patients treated for endometrial cancer at the New York Hospital -Cornell Medical Center between 1996 and 2006. Mucinous adenocarcinoma was defined as tumor with more than 50% of mucinous-type epithelium. 41 cases of were identified. Each case was matched by age and histological grade with two controls of endometrioid histology. Cases and controls were compared with regard to known risk factors for endometrioid carcinoma and the extent of disease at diagnosis. Chi-square tests were used to compare proportions and student T-tests for the comparison of means. Multivariate regression was used to identify the independent predictors of lymph node metastases. Overall survival was calculated using the Kaplan-Meier method and compared with the Log-rank test. P< .05 was considered significant for all tests. Results: No significant difference was found between cases and controls with regard to ethnicity, body mass index, history of diabetes mellitus, hypertension, prior hormone replacement, and tamoxifen use. Prior oral contraceptive use was significantly less common among women with MUC compared to controls (6.5% vs 32.3%, P= .01). No significant differences in myometrial invasion (MI) > 50% or the presence of lymphvascular space invasion was found between cases and controls, however 17% of patients with MUC had lymph node metastases compared to 3% of controls (P= .01). Multivariate analysis controlling for both tumor grade and depth of MI identified mucinous histology as an independent predictor of lymph node metastasis (P =.02). Adjuvant radiation or chemotherapy was used in 60% of cases compared to 42% of controls (P =.05). No difference in recurrence or survival was identified between the two groups. Conclusions: Mucinous adenocarcinoma of the endometrium is associated with an increased risk of lymph node metastases that is independent of tumor grade and depth of MI. Comprehensive surgical staging including retroperitoneal node dissection should be considered in all patients with this diagnosis.
Absence of V600E B-RAF Mutation in MLH1-Negative Endometrial
Carcinoma. E Musulen, AM Munoz-Marmol, C Sanz, C Carrato, JL Mate, A Ariza. Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. Background: Lynch syndrome (LS) is caused by germline mutations in the mismatch repair (MMR) system genes, of which those involving the MLH1, MSH2 and MSH6 genes are the most frequent. Among LS-associated neoplasms, colorectal carcinoma (CRC) is the most common and endometrial carcinoma (EC) the second most common. To compare the pathogenesis of these two neoplasms, we have prospectively studied a population screening EC series for the molecular alterations known to occur in LSassociated CRC. Design: Seventy-eight surgically resected primary ECs were prospectively studied. Immunohistochemistry for MMR gene proteins (MLH1, MSH2, and MSH6) was performed in all cases. This was followed by microsatellite instability (MSI) analysis, with amplification of five different microsatellites (NR21, NR24, NR27, bat25, and bat26), and V600E B-RAF gene sequencing study in MLH1 (-) cases. Bethesda criteria were evaluated and MMR genes mutational analysis was performed in every case. Results: Of the 78 EC patients studied, 6 were under 50 years of age, 30 were between 51 and 60, and 42 were older than 61. Twenty EC cases were found to be unstable. Of them, 14 were MLH1 (-) and showed wild-type (WT) B-RAF; 3 were MSH2 (-) and MSH6 (-); and 3 were MSH6 (-). No V600E B-RAF mutation was detected in any of the cases studied. Conclusions: In conclusion, the absence of V600E B-RAF mutation in MLH1 (-) EC cases would indicate that in EC this mutation is not related to hypermethylation in the same way as it is in CRC. Therefore, algorithms for molecular studies of these two neoplasms should reflect this difference. Owing to their overall bland cytology and frequent microglandular architecture, these lesions are difficult to differentiate from benign MGH of endocervix, particularly in the small volume endometrial curettings/biopsies. This study aims to determine a useful immunohistochemistry (IHC) panel for distinguishing MUC-AD of endometrium from MGH of endocervix. Design: A total of 23 cases of MUC-AD of endometrium were selected from our institution's pathology database between the years 2006 to 2010. Eleven cases of MGH of endocervix were used as control group. All cases were stained for p63, p16, vimentin, CEA, CD10, and Ki-67 antigens. Staining intensity and the percentage positivity for each stain was evaluated. Results: None (0%) of the MGH endocervix cases were positive for p16 whereas, 21/23(91.3%) MUC-ADs of endometrium cases showed moderate to strong nuclear and cytoplasmic staining for p16 in ≥50% of tumor (avg. staining, 76.4%). Nuclear staining for p63 was noted in all(100%) the MGH cases (avg. staining, 93.2%) in a distinct continuous, linear and basal pattern. Although, 20/23(87%) MUC-ADs of endometrium showed nuclear positivity for p63, the pattern was focal, random and scattered (avg. staining 16.1%). CEA highlighted the surface and apical cytoplasm of the mucinous epithelium in all (100%) the MUC-ADs of endometrium (avg. staining, 62.8%). However, 4 of 11 MGH cases (36.4%) also expressed positivity for CEA (avg. staining, 17%). Ki-67 staining index was >5% in only 1/11(9%) cases of MGH of endocervix, in contrast to 17/23(73.9%) cases of MUC-ADs of endometrium. All 23(100%) cases of MUC-ADs showed basal cytoplasmic/membranous epithelial staining for vimentin (avg. staining, 70.2%). However, 4 of 11(36.4%) MGH cases also showed positivity in ≥50% of epithelial cells. CD10 was positive in stromal cells of 23/23(100%) cases of MUC-ADs of endometrium and 7/11(63.6%) cases of MGH. Conclusions: A combined IHC panel of p16, p63 and Ki-67 is useful in distinguishing MUC-ADs of endometrium from MGH of endocervix. Diffuse and strong expression of p16, lack of continuous, linear and basal staining for p63, and increased Ki-67 index (>5%) strongly favors a diagnosis of MUC-ADs of endometrium over MGH of endocervix. CD10, CEA and Vimentin are non-contributory in this context. The exact mechanism of diffuse p16 expression in MUC-ADs of endometrium is unclear. Background: The role of the fallopian tube in high-grade pelvic serous carcinoma (HGSCA) includes a benign precursor (p53 signature) with altered expression of p53, HMGA2 and PAX2. A second entity, secretory cell outgrowth (SCOUT), shares loss of PAX2 with p53 signatures and serous tubal intraepithelial carcinoma (STIC), which in turn have increased expression of Cyclin E, Ki-67, p16, FAS and RSF-1. This study expanded the list of genes altered in HGSCA development to more precisely define the components of this sequence. Design: Whole-genome transcriptome analysis of laser micro-dissected paired cancer and tubal epithelium revealed loss of ALDH1 and upregulation of EZH2 (Xian unpublished). To determine their tissue specificity, tissue sections from HGSCA (n=16) and controls (n=65) were studied, and secretory cell outgrowths (SCOUTs; 30), p53 signatures (21), and STICS (33) were selectively stained with antibodies to p53, p16, PAX2, ALDH1 and EZH2. Results: Fallopian tubes from HGSCA and controls averaged loss of PAX2 at frequencies of .56 and .11 per section respectively (p < .001). Coordinated loss of PAX2 and ALDH1 was seen in 70%; ALDH1 was also independently down-regulated in other SCOUTs. Concordant loss of PAX2 and ALDH1 was seen in 80% of p53 signatures exceeding 30-50 cells; expression was normal in very small p53 signatures (less than 20 cells). Loss of ALDH/PAX2 persisted in 80% of STICs but foci of staining were common in STICS and HGSCA. EZH2 stained scattered rare normal cells and a small number in SCOUTs and p53 signatures, and was increased in 33/33 TICS. p16 staining was positive in 12 of 14 TICs but patchy in 7/12. Conclusions: The fallopian tubes of HGSCA exhibit two independent but related phenomena that may signify disruption of both genetic and epigenetic pathways. First, a globally distributed multifocal loss of PAX2 and ALDH1 expression is significantly associated with HGSCA and persists through the carcinogenic spectrum. Second, these two gene perturbations intersect in the fimbria with p53 mutations, where the transition to malignancy involves up-regulation of EZH2 and other biomarkers. Elevated EZH2 staining is a useful parameter for confirming STIC. Very small p53 signatures may not belong in the serous carcinogenic sequence. Background: Mesonephric adenocarcinoma (MA) is a rare subtype of uterine cervical carcinoma (CA).Secondary to overlapping histologic features with other subtypes of cervical CA (endometrioid and clear cell carcinoma), proper recognition can be challenging.Immunohistochemistry (IHC) is frequently utilized to assist with proper classification.It has been suggested that the use of PAX-2 may distinguish benign and mesonephric cervical lesions from cervical CA on the basis that PAX-2 was lost in usual type cervical CA.This study evaluates the expression of PAX-8 and PAX-2 as well as other traditional IHC in a series of MA.In situ hybridization (ISH) for high risk HPV is also evaluated. Design: Six cases of MA were retrieved from our institutional files spanning 1991-2008. Pathology material was reviewed in all cases to confirm diagnosis.All cases were investigated by IHC for PAX2, PAX8, and p16. ISH for high risk HPV was performed on all cases.Previously performed IHC was also reviewed as part of the study.Clinical information was obtained from patients' (pts) charts. Results: Pts ages ranged from 41-57 years (median 46).The most common presenting symptoms included: vaginal bleeding, 4 cases; menorrhagia, 1 case; and cervical polyp, 1 case. Five pts underwent hysterectomy; in cases where the stage was known (n=4), all were stage 1.Follow up ranging from 12 to 60 mos was available in 5 pts.All are currently free of disease.The immunoperoxidase results are summarized in table 1. For p16, 2 cases had patchy and 2 cases had focal staining.Staining for calretinin was focal in 2 cases and diffuse in 1.Vimentin staining was focal in 2 cases and diffuse in 3 cases.Staining for CEA was focal in the 2 positive cases. Staining for estrogen receptor was weak in the 2 positive cases.ISH for high risk HPV was negative in all 6 cases. Conclusions: MA expresses both PAX-2 and PAX-8 suggesting that these markers could be useful to distinguish MA from usual types of cervical CA.The tendency of MA to express vimentin in conjunction with patchy or focal p16 can be misinterpreted as an indication of endometrial origin.In contrast to previous reports, the majority of the cases (66%) in this study were negative for CD10 and only 50% of cases were positive for calretinin.Therefore, these markers may have a limited role in the evaluation of MA. Results: Greater than 50% of tumor in NELS was identified in 14 of 17 cases (82%) that recurred, compared to only 4 of 16 cases (25%) that did not recur (p = 0.0016). ER was positive and PR was negative in most cases in both groups. Significant p53 staining was found in 12 of 15 cases (80%) that recurred and in 7 of 14 cases (50%) that did not recur (p = 0.128). Of the 10 cases that had greater than 50% of tumor in NELS and significant p53 staining, 9 cases (90%) recurred. Of the 4 cases that had less than 50% of tumor in NELS and p53 staining of less than 90%, all 4 cases (100%) did not recur.
Summary of Immunoperoxidase
Findings in MA Stain Positive Negative PAX-2 5 1 PAX-8 5 1 p16 4
Clusterin Overexpression Promotes Cell Proliferation and Inhibits
Of the 15 cases with discordant results, less than 50% of tumor in NELS but significant p53 staining or greater than 50% of tumor in NELS but p53 staining less than 90%, the pattern of invasion was more predictive than p53 staining (60% vs 40%). Conclusions: 1. HGSCa with greater than 50% of tumor in NELS recur in a short time.
2. Significant p53 staining is found in cases that recur but without statistical significance.
3. When the amount of tumor in NELS and p53 expression agree, there is at least a 90% predictive value. 4. In cases that lack agreement between the amount of tumor in NELS and p53 expression, there is a slightly increased predictive value of the amount of tumor in NELS. There were no cases which did not identify any pelvic lymph nodes (left or right), and only one case where no para-aortic nodes were identified. 78 cases (53.42%) had less than the minimum number of pelvic and para-aortic lymph nodes required in the GOG 0210. Of the 78 cases, 54 were type 1 endometrial carcinoma, and 24 were type 2 endometrial carcinoma.
Number of Lymph Nodes in Staging for
Conclusions:
The minimum number of lymph nodes required by the GOG to accept patients into Protocol 0210 is often difficult to attain. In our study the majority of cases that failed to reach the minimum number were obese patients with type 1 endometrial carcinoma, in which dissection of para-aortic lymph nodes may have been technically challenging. Moderate staining(H score >100)for PRA, PRB and pAkt was seen in 79%, 84%,and 62% of initial biopsies,respectively.Expression levels of all markers(PRA, PRB, pAkt, p4EBP1)were greater in the initial biopsy than after treatment (p<0.05).Strong(H score >200) expression of PRB in the initial biopsy was significantly associated with resolution(83% vs. 44% resolution,p=.035). Conclusions: Our data suggests that progestin therapy appears to reduce expression of PRA, PRB, pAkt, and p4EBP1 in CAH and G1EAC, and hence,may influence activation of the pAkt/PTEN pathway.Strong PRB expression in both the initial and first follow-up biopsies with CAH or Grade 1 EA has the potential to predict response to progestin treatment.Staining for PRB in a patient's initial diagnostic biopsy therefore may provide additional information to assist in counseling patients regarding their individual likelihood of resolution of G1EAC and CAH with progestin therapy. Background: Accurate diagnosis of premalignant endometrial disease, EIN, requires learning new diagnostic criteria and resolving its many mimics. PAX2, a gene clonally inactivated in three quarters of EIN lesions, is a potential tool for educational and/ or diagnostic use. When informative, PAX2 can precisely delimit lesion extent and facilitate appreciation of lesion characteristics relative to background. We had two trainees diagnose routinely stained ("H&E") biopsies and then measured the effect of subsequently viewing a PAX2 stain on their interpretation. Design: H&E recuts and PAX2 immunostained sections from 52 endometrial biopsies originally diagnosed as EIN were assembled (by GLM and NM) as a study set, and presented to two pathology fellows (MQ and AL, "subjects") for review. 71% (37/52) of the EINs were known to be PAX2 null. The subjects first diagnosed H&E slides using standard EIN criteria, recording those features that complicated diagnosis. PAX2 stains were then reviewed in all cases and problems and benefits of their interpretation noted. Results: Results of 52 cases and two reviewers totalled 104 diagnostic passes. H&E diagnoses included EIN (82%), and crowded glands subdiagnostic of EIN (12%). Diagnostic areas seen on the original slides were depleted in some recuts. The most common features confounding H&E EIN diagnosis were altered differentiation ("metaplasia", 14%), separation of EIN and background glands within different tissue pieces (13%), large lesions lacking comparison normal endometrium (11%), and secretory background (8%). Trainees were more likely to consider PAX2 staining helpful when there was a secretory background, or foci of EIN lacked adjacent normal tissue in the diagnostic fragment. PAX2 staining confused the subjects where interpretation of PAX2 immunoreactivity was unclear (14%), and when non-diagnostic tissue fragments contained PAX2 null glands (11% Background: Vasculitis includes a heterogeneous group of disorders with the common histologic findings of vascular wall inflammation. Systemic or localized disease (e.g., renal vasculitis) has serious consequences. The incidence of gynecologic vasculitis (GynV) and its significance is little known. Design: We performed a retrospective review of vasculitis cases affecting the female genital tract accessioned in our institution between 1990-2010. Fifty-two cases were identified. Histopathologic evaluation, clinicopathologic review and follow-up was performed. Results: Age of the patients ranged from 37 to 85 years (mean 55.2 years, median 51 years). None had prior symptoms or were diagnosed with generalized vasculitis, while one patient had prior diagnosis of fibromyalgia. Most patients presented with abnormal bleeding and were treated for conditions unrelated to vasculitis, including patients with hysterectomy for uterine tumors (n=34); ovarian tumors (n=15), cervical dysplasia (n=2), uterine prolapse (n=1), cesarean section complications (n=1), and unknown reasons (n=1). All patients had hysterectomy while 5 in addition had unilateral salpingooophorectomy and 37 had bilateral salpingo-oophorectomy. Vasculitis was confined to the cervix in 23 cases, endo-myometrium in 6 cases, ovaries 7 cases, fallopian tubes 3 cases, adnexal soft tissue 3 cases and diffuse (vasculitis involving more than one organ) 10 cases. The different types of vasculitis were: necrotizing 16 cases, predominantly lymphocytic 14 cases, granulomatous 5 cases, and non-specific in the remaining 17 cases. Only 2 patients had serologic tests: ESR, ANA, Anti-double stranded DNA and Anti-centromere. Only the patient with fibromyalgia was ANA +, but negative for the remaining tests. None of the patients with GynV received corticosteroids or additional treatment. Fourteen patients were lost to follow-up less than 1 month after surgery. Follow-up available for the remaining patients ranged from 2 month to 19.5 years (mean, 5.5 years). Seventeen patients had malignant tumors; two died of disease. During follow-up, two patients developed invasive ductal carcinoma (breast), one patient developed MGUS, and another was diagnosed with Hashimoto disease and ulcerative colitis. None of the patients developed systemic vasculitis. Conclusions: GynV is rarely associated with systemic vasculitis. Potential GynV causes include: previous surgical interventions and vascular inflammation secondary to local malignancy. In the absence of symptoms of systemic vasculitis, serologic screening and systemic therapy is not required. Design: A search of the anatomic laboratory information system was performed to identify morcellation procedures on gynecologic specimens from 1-1-01 to 1-1-10. All findings were recorded. Pre and postoperative information was obtained from the electronic medical records when available (IRB# BH-10-077).
Results: A total of 889 cases were reviewed (64 had non-morcellated components). The two most common diagnoses were leiomyoma (719 cases, 81%) and adenomyosis (327 cases, 37% Background: Because Lynch Syndrome more frequently affects patients with synchronous (rather than single) colorectal cancer, intuitively, the same principle would seem to apply to women with synchronous gynecologic primaries. Current literature is inconsistent regarding the prevalence of microsatellite instability (MSI) in this population, with reported rates between 0 and 47%. Moreover, it is unknown whether it is appropriate to test one or both tumors in synchronous cases. This study aims to answer these questions in an unselected series of women with presumed synchronous endometrial and ovarian endometrioid adenocarcinomas. Design: Histopathologic review of 42 candidate synchronous endometrial and ovarian endometrioid adenocarcinomas over a 12-year-period produced 27 cases in which there was consensus among three pathologists regarding endometrioid histology and synchronicity based on published criteria. Bilateral ovarian tumors were tolerated in the absence of a parenchymal growth pattern (9 cases), in which cases, both were tested. All formalin-fixed, paraffin embedded tumors were tested by MSI PCR (Promega MSI Analysis System, v1.2, Promega Corporation, Madison, WI.) and immunohistochemistry (IHC) for DNA mismatch repair (MMR) proteins MLH1, PMS2, MSH2, and MSH6. Results: All synchronous cases (tumor pairs/trios) had identical results for any one woman. Twenty-one cases were microsatellite stable with normal IHC. Six of 27 (22%) cases were microsatellite unstable (microsatellite instability-high, MSI-H). Five of these cases demonstrated loss of MLH1 and PMS2 expression; the remaining MSI-H case demonstrated normal MMR expression. Conclusions: The incidence of MSI-H synchronous endometrioid adenocarcinomas closely matches the incidence of MSI in patients with single endometrial cancer (approximately 20%). Because IHC loss of MLH1 and PMS2 is often associated with somatic MLH1 promoter hypermethylation in the tumor, only a fraction of these patients are predicted to have a germline mutation (i.e., Lynch syndrome). The results suggest that screening patients with synchronous endometrioid tumors is no better or worse than screening a general population with only uterine cancer. In addition, the findings indicate that a single specimen may be acceptable for molecular screening in synchronous cases. Background: According to the current treatment guideline of uterine cervical cancer, postoperative adjuvant treatment is indicated in patients having parametrial invasion in the radical hysterectomy specimens. Despite the importance of parametrial invasion, histological decision of parametrial invasion is often subjective because "parametrium" is a loosely defined structure and the definitive landmark has not been determined.
Design:
To define a precise landmark of "parametrium", we scrutinized cervical wall and cervico-parametrial junctions on H&E and trichrome-stained sections of type III radical hysterectomy specimens from patients with FIGO stages IB/IIA (n=22), and IIB (n=66), and compared the applicability of 3 landmarks, 1) thick & large calibered blood vessels, 2) presence of adipose tissue/loose connective tissue on the H&E sections, and 3) compact muscle layers on trichrome stainings in the decision of parametrial invasion. We also compared the applicability of those 3 landmarks in the longuitudinal (n=37) and modified transverse sectioning (n=29). Results: In the 22 FIGO stage IB/IIA cases, inner two thirds of cervical wall was composed of either compact/hapharzardly arranged muscle bundles (55%) or sparse/ hapharzardly arranged smooth muscle bundles containing abundant interstitial connective tissue stroma (45%), while outer one third of the cervical wall was consistently composed of continuous and compact muscle layers, which were clearly distinguishable from parametrium. In the decision of parametrial invasion among 66 FIGO stage IIB cases, only a single case (2%) was difficult to decide by using smooth muscle layer on trichrome staining, while 30% and 8% were difficult to decise by using large calibered blood vessels and apipose tissue/loose connective tissue, respectively. In the decision using 3 different landmarks, modified transverse sectioning gave better tissue orientation for the relationship between cervical wall and parametrium. Conclusions: Trichrome staining for identification of compact muscle layer of cervical wall is a simple and useful method for the decision of parametrial invasion status of cervical cancer in the difficult cases, and modified transverse sectioning was very helpful to obtain important pathological informations in the radical hysterectomy specimens. Background: Previously, using cDNA microarray gene expression, we found that aldolaseC was among numerous genes upregulated in uterine serous carcinoma in comparison to endometrioid adenocarcinoma. Aldolase is a critical enzyme in the glycolytic pathway. Most cancer cells use this pathway for generation of ATP as a main source of their energy supply. Clotrimazole, an antifungal agent, has been proven to induce a dose-dependent detachment of aldolase from the cytoskeleton, leading to cell damage and destruction. Our aims are to evaluate the value of aldolaseC in endometrial carcinoma (EC) and to determine the impact of clotrimazole in inhibition of cell viability and alteration of cell structure in EC cell line. Design: To accomplish the first aim, aldolaseC protein expression using immunohistochemistry analysis was performed on 350 paraffin-embedded EC tissues. Next, fresh frozen tissue from 70/350 samples were available to evaluate the aldolaseC mRNA level using Taqman RT-PCR. For the second aim, endometrial cancer cell line cell (HEC1) and colonic cancer cell line (CT26) (as a control) with and without treatment with clotrimazole were evaluated for cell viability by tryptan blue dye and for cell structure by transmission electron microscope at different times. Results: AldolaseC protein was expressed in 78% EC cases. High aldolaseC mRNA levels were associated with low tumor grade (p=0.002), serous subtypes (p=0.006) and longer overall survival (p=0.051). Treatment of cancer cell lines with clotrimazole induced detachment of cancer cells from culture plates. Total cell death was seen 4 hrs post-treatment in CT26 and 24 hrs in HEC1. The effect of clotrimazole on HEC1 at 4 hrs manifested as small discontinuities of the cell membrane, swollen mitochondria with loss of cristae and very granular cytoplasm. At the 24 hrs time point, cell death had occurred evidenced by loss of integrity of the plasma membrane, leading to cell rupture. Conclusions: Although preliminary, our data is the first to shed light on the value of aldolaseC in EC. We provided evidence of the effect of clotrimazole in EC cell viability and cell structure. We hope our results will open the door for future in vivo investigation and raise the option of clotrimazole as a new therapeutic agent in EC patients 1132 Morphologic Patterns Associated with BRCA1 and BRCA2 Genotype. R Soslow, G Han, N Olvera, D Levine. Memorial Sloan-Kettering Cancer Center, New York, NY. Background: It has been hypothesized that ovarian tumors with BRCA dysfunction might have a distinctive histologic appearance, often referred to as "BRCAness." Data suggest that, like tumors with BRCA1 mutation, those showing solid and/or transitional cell-like features may be prognostically superior to other high grade serous carcinomas; and tumors with prominent infiltrating lymphocytes have been reported in the setting of BRCA dysfunction. Design: The existence of BRCAness was studied by reviewing H&E slides from 43 high grade serous ovarian carcinomas, included in The Cancer Genome Atlas (TCGA), with known BRCA1 and BRCA2 status. Genetic subgroups represented were: BRCA1 germline mutation; BRCA1 somatic mutation, BRCA1 promoter methylation; BRCA2 germline mutation; BRCA2 somatic mutation; BRCA unaffected. Tumor architecture, tumor infiltrating lymphocytes (TILs), and the presence and extent of necrosis were recorded for each case. TILs were only evaluated in sections from the primary site (i.e. Fallopian tube or ovary). Histologic review was performed without knowlege of genotype. Results: A combination of either solid or transitional cell-like architecture with tumor infiltrating lymphocytes was present in 13/31 cases (42%) with BRCA1 or BRCA2 abnormality, as compared with only 1/12 (8%) in the BRCA unaffected group. This phenotype was most commonly encountered in the BRCA1 promoter methylation group (7/13; 54%). None of the 4 BRCA1 somatic mutants showed this phenotype. TILs were found in 18/31 cases (58%) with BRCA1 or BRCA2 abnormality, as compared with only 2/12 (17%) in the BRCA unaffected group. TILs were found predominantly in cases with BRCA1 abnormality (16/23; 70%), including BRCA1 germline mutation (3/4). Geographic necrosis was also more common in cases with BRCA1 or BRCA2 abnormality (14/31; 45%) as compared with 2/12 (17%) in cases with intact BRCA1 and 2. Subgroups with the highest prevalence of geographic necrosis were BRCA1 germline mutants (3/4) and BRCA2 germline mutants (3/4). Conclusions: BRCAness is not a specific trait, but it is characteristic of cases with BRCA1 and 2 dysfunction. Solid and transitional-cell like architecture, along with TILs and geographic necrosis are seen in significant numbers of these cases. None of these findings is specific for either BRCA1 or 2 germline mutation. may provide an efficient and low cost initial screen to select patients for targeted therapies, specifically, PARP inhibition. This methodology will also narrow the pool of patients who may benefit from screening for hereditary cancer syndromes and might provide prognostically relevant information. Design: One section from each of 43 high grade serous ovarian carcinomas included in The Cancer Genome Atlas (TCGA) with known BRCA1 and BRCA2 status was evaluated with a commercially available monoclonal antibody against BRCA1 (clone MS110) after optimization and IRB approval. Genetic subgroups represented were: BRCA1 germline mutation; BRCA1 somatic mutation, BRCA1 promoter methylation; BRCA2 germline mutation; BRCA2 somatic mutation; BRCA unaffected. A semiquantitative estimate of the extent of tumor cell nuclear labeling was recorded and correlated with genetic status. Using a cutoff of 5% (negative versus positive) separated tumors into distinct groups. Results: Negative results (loss of BRCA1 expression) were recorded in: all 4 BRCA1 germline mutants; 3/6 cases with BRCA1 somatic mutation; 11/13 cases with BRCA1 promoter methylation; 1/4 BRCA2 germline mutants; 0/4 BRCA2 somatic mutants; and 0/12 BRCA unaffected cases. Equivocal results, generally stemming from weak or absent internal positive controls, were recorded in every category but BRCA1 germine mutants, and totalled 6/43. Conclusions: This study suggests that the use of a commercially available antibody against BRCA1 in a small series may have clinical utility. Background: Sulindac, a commonly used NSAID, has been investigated as a potential novel therapeutic for different forms of cancer, including colon and breast. A recent study looked at the molecular action of this drug on the HPV18 infected cervical cell line, HeLa, and demonstrated that not only could it induce apoptosis but also degrade one of the main oncoproteins, E7. Design: This study aimed to validate the previous findings and to extend the analysis to other cervical carcinoma cell lines with differing origins, HPV status and viral DNA content. Three cervical cancer cell lines were examined, the adenocarcinoma derived HPV18 positive HeLa, the squamous cell carcinoma derived HPV16 positive SiHa and the HPV negative C33A. Results: Sulindac had a time and dose dependent growth inhibitory effect on all three cell lines. However, the most potent response was observed in the HeLa cells, with the IC 50 value approximately 200µM less than the other two cell lines. Analysis of the HeLa cells demonstrated that this activity occurred predominantly through induction of apoptosis but additionally by cell cycle arrest. We confirmed post-transcriptional degradation of the HPV18 viral oncogene E7. This decrease was dose dependent and appeared to correlate with an observed G1 arrest. In addition, it was demonstrated that a decrease in COX activity may be partially responsible for the anti-proliferative activity of sulindac. Conclusions: This data indicates that the antineoplastic activities of sulindac are multifaceted. Since most cancers progress through the action of multiple pathways, drugs that simultaneously block several pathways might be particularly effective as therapeutic agents. Therefore, these results suggest that NSAIDs may offer potential as novel therapeutics for cervical cancer. University of Tuebingen, Germany; University Hospital of Bonn, Germany. Background: The transcription factor Sox2 is involved in the maintenance of embryonic stem cell pluripotency and is expressed in several carcinoma types such as adenocacinoma of the lung and squamous cell carcinomas (SCC) of various origins. The gene SOX2 is located at chromosome 3q26, a region that is a frequently amplified in serous ovarian carcinoma. This study aims to explore the potential role of Sox2 in ovarian carcinogenesis by correlating Sox2 protein expression and gene amplification with different histological types of ovarian carcinomas, tumor grade and clinical outcome. Design: 209 consecutive cases of ovarian carcinoma (149 serous, 38 endometrioid, 11 clear cell, 5 mucinous and 6 transitional cell carcinomas) were analyzed by immunohistochemistry in a tissue microarray for nuclear expression of Sox2. FISH analysis for gene amplification of SOX2 was performed for the serous carcinomas. Overall survival was compared by Kaplan-Meier Analysis
BRCA1 Immunohistochemistry in a Genotypically
Results: 57% of all carcinomas showed detectable Sox2 positive cells with no significant difference between the major histological types (serous 58.4%, endometrioid 57.9%, clear cell 45.5%). Overall, Sox2 expression was more frequent in less differentiated tumors (G1: 38.9%, G3: 63.4%, p= 0.04). Low level gene amplification was detected in 22% of cases and did not correlate with gene expression levels. Surprisingly, analysis of the largest homogenous group (high-grade serous, stage II-IV) showed a favourable effect of Sox2 expression on overall survival (median 40 months vs. 25 months, p= 0.008). Conclusions: Sox2-positive cells can be detected by immunohistochemistry in a majority of ovarian carcinomas, with increasing frequency in high-grade tumors. However, within the group of high grade serous carcinomas Sox2 expression is associated with a significantly better prognosis, suggesting that in this specific tumor entity activation of certain stemness-pathways may unexpectedly predict favourable outcome. . Although vimentin and inhibin are commonly used as markers for LCTs, these are non-specific; there are currently no specific and sensitive IHC markers for ovarian LCTs. Based on the steroidogenesis pathway, we identified three potential new LC IHC markers: CYP11A1, STAR and SULT1E1. The aim of our study was to further characterize the expression of these enzymes in ovarian LCTs. Design: Paraffin embedded material from 3 LCTs was examined by IHC for the expression and localization of CYP11A1, STAR and SULT1E1. Normal testicular tissue, 7 LCT of the testis and 10 Sertoli Leydig cell tumors (SLCT) were used as controls. Staining intensity was scored on a scale of 0-3 with 0 being no staining and 3 being the most intense staining. Results: All 3 LCTs revealed cytoplasmic staining for SULT1E1 (3=33%, 2=67%, 1=0%, 0=0%), CYP11A1 (3= 67%, 2=0%, 1=33%, 0=0%), and STAR (3 =0%, 2=67%, 1=33%, 0=0%). In the control group, Leydig cells in both testicular LCTs and normal testis revealed cytoplasmic staining for CYP11A1, STAR and SULT1E1. Sertoli cells and germ cells in normal testis and Sertoli cells in SLCT were negative for all three markers. The Leydig cell component of SLCT expressed all three markers. Conclusions: Our findings support that the three markers CYP11A1, STAR and SULT1E1, components of the biosynthetic pathway of testosterone production, are useful to identify ovarian LCTs and are more specific than the currently used markers inhibin and vimentin. As none of the new markers are expressed in either Sertoli cells or germ cells, this panel can help to distinguish LCTs from other sex cord-stromal tumors as well as from germ cell tumors. Background: Type II endometrial carcinoma includes high grade, non-estrogen driven tumors with a molecular pathway distinct from Type I (endometrioid type). Histologically, it consists of serous and clear cell carcinomas with some morphologic overlap. Although Type II represents 9-14% of endometrial cancers it is associated with aggressive clinical course and accounts for 48% of deaths. Her2/neu oncoprotein is an established target for therapy in breast cancer and has an emerging role in the treatment of gastric cancer. The aim of this study is to determine the proportion of Her-2/neu overexpression in Type II endometrial carcinoma and the association between this receptor and stage at presentation. Design: We identified a set of 36 clear cell endometrial carcinomas and 34 serous endometrial carcinomas accessioned from 2000-10. Cases were reviewed independently by two gynecological pathologists. Her-2/neu oncoprotein over-expression was determined by immunohistochemistry. Only a strong and complete membranous staining pattern was considered positive. Clinical information was retrieved from the electronic medical records. Results: Overall Her-2/neu overexpression was found in 11/70 (15.7%) endometrial Type II cases; 6/34 (18%) of the serous carcinomas, and 5/36 (14%) of clear cell carcinomas. Typically the expression was focal, in less than half of the tumor cells. 61/ 70 patients underwent full surgical staging. In the remaining 9 cases, staging was based on a more limited surgical procedure. Of the fully staged patients, 12 had extrauterine involvement at time of surgery and 49 did not. Her-2/neu expression was not associated with extrauterine disease (p >0.05). Conclusions: Our study demonstrates that Her2/neu oncoprotein is overexpressed in about 16% of Type II endometrial cancer. The proportion of this subset is similar to that observed in breast cancer. This observation opens the door for inclusion of novel targeted therapies directed against Her2/neu in clinical trials for aggressive type of endometrial cancer. (Saito, 2009) and that it may be a favorable prognostic factor in ovarian neoplasms (Fujiwara, 2010) . We wanted to examine its role in early endometrioid carcinoma progression. Design: Archived formalin fixed paraffin embedded endometrial tissues were obtained from 535 cases in 207 patients who either did or did not progress to carcinoma. Specimens were sampled mostly in triplicate as 1.1 mm cores for tissue microarray construction. Immunoperoxidase staining of TTF-1 antibody (Dako, Carpinteria, CA) was performed using a Dako autostainer. Scoring was performed by a single pathologist blinded to diagnosis and was recorded by intensity (0 to 3+) and percentage of glandular cells expressing TTF-1. A positive result was considered in any case with 1+, 1% or more cells with TTF-1 nuclear expression. Patients who developed non-endometrioid carcinoma, did not have a follow-up surgical case, and did not have informative TTF-1 information (e.g., no lesional epithelium for evaluation) were excluded from the analysis. Results: 392 cases from 134 patients composed of benign endometrium (n=216), simple and complex hyperplasia (n=45), simple and complex atypical hyperplasia (n=25), and endometrioid carcinoma (n=106) were examined for TTF-1 nuclear expression. Significant differences of expression were noted in benign endometrium versus adenocarcinoma and non-atypical hyperplasia versus carcinoma (p=0.0007 and p=0.0530, respectively, Mann-Whitney U test). Absence of TTF-1 expression in benign endometrium and simple hyperplasia cases was associated with progression to cancer (p=0.00018, log-rank test). This association was not significant in hyperplasia alone, with or without atypia, although the numbers were small. TTF-1 was further shown to be an independent predictor of progression to cancer in multivariate analysis including cancer family history, diabetes, hypertension, body mass index, cancer diagnosis age, and age of menopause (p=0.0004, HR=0.089, 95% CI 0.023-0.339).
CYP11A1, STAR and SULT1E1 Expression in Ovarian Leydig
Conclusions:
The absence of TTF-1 expression in benign endometrium and simple hyperplasia is an independent early predictor of endometrioid carcinoma suggesting that TTF-1 expression may play a protective role in benign and "early" endometrial lesions. The role of TTF-1 in advanced endometrial lesions remains to be elucidated. Background: Clinical studies demonstrated that early stages uterine serous carcinoma (USC) had almost similar outcome in comparison to early stages high grade endometrioid adenocarcinoma (EAC)-G3. The aim of this study is to explore the genetic fingerprints of these tumors that may explain their similar outcome. Design: A transcriptome analysis was performed using the human genome wide illumina bead microarrays carrying 48,000 genes to profile stage I USC (n=11) vs. stage I EAC-G3 (n=11) and vs. stage I EAC-G1 (n=11), respectively. The expressions of 15 genes were selected for validation and determined using Taqman RT-PCR gene expression. Results: We identified 988 differentially expressed genes (DEGs) between USC and EAC-G3 with 522 genes specific to USC and 1,499 DEGs between USC vs. EAC-G1 with 1,063 genes specific to USC. The up-regulated genes specific to USC were genes involved in cell proliferation, invasion and metastasis (SNCG), cell adhesion (MSN), tumor progression (LMNA), cell cycle (TBX2) and tumor development, growth and angiogenesis (IRS2). The down regulated genes were involved in suppressing tumor metastasis (NME5), reduce cell growth (ALCAM), tumor suppressor (CEACAM1), and slow cancer progression (TFF3). Although, many of these genes were novel genes to USC, they were found in other cancer types such as liver, colon, breast and lung cancers. Over-regulation of some genes had been proven to predict poor prognosis such as SNCG and IRS2 in colon cancer, and downregulation of NME5 to be a predictor of metastatic potential in breast cancer. In addition, genes like ALCAM and SNCG were implicated to be associated with chemoresistance in pancreatic and uterine cancer. Conclusions: We found that stage I USC has relatively similar gene fingerprints in comparison to EAC-G3 than to EAC-G1. Numerous novel DEGs and their transcripts found to be specific to USC might have potential prognostic and therapeutic impact on patients with uterine cancer. However, our results should be confirmed by larger studies to evaluate the usefulness of some genes as biomarkers in endometrial cancer. Nevertheless, we believe that our findings shed meaningful insights into the clinical study of endometrial cancer patients that warrant further investigation.
Differentially Expressed Genes in Early Stages
1140 Stem Cell Marker Expression in Endometrial Carcinoma. J Tarragona, M Santacana, J Valls, E Oliva, J Palacios, X Matias-Guiu. Hospital Universitari Arnau de Vilanova, University of Lleida, IRB Lleida, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Massachusetts General Hospital, Boston. Background: It has been suggested that cancers contain minor populations of neoplastic stem-cells that are capable of tumor initiation. Cancer stem cells (CSC) are postulated to be responsible for resistance to hypoxia and have been associated with resistance to radiation therapy. CD133, CD44, CD59, CD9, Oct-4 and ALDH1 have been suggested as stem cell markers in different malignancies but only CD133 has been proposed as a marker for the stem cell population in endometrial carcinoma (EC). However, the immunohistochemical profile of CSC in EC has not been fully elucidated.
Design: CD133, CD44, CD59, CD9, Oct-4 and ALDH1 expression was assessed in three tissue microarrays (TMA) constructed from 70 paraffin-embedded blocks of normal endometrium (NE) in different phases of the menstrual cycle, 157 primary EC and 16 vaginal post-radiation recurrences. CD133, CD44, CD59, CD9, Oct-4 and ALDH1 expression was correlated with stage, histological type and grade of primary EC, and was also compared between primary EC and post-radiation recurrences. Results: CD44, CD9 and CD59 immunostaining was higher in the secretory than in the proliferative phase (p=0.0007, p=0.01, p=0.02, respectively). CD44, ALDH1 and CD59 immunostaining was higher in EC compared to NE (p=0.01429, p<0.00001, p<0.00001, respectively) . A decreasing trend of CD44 and CD9 expression was observed with higher histologic grade (CD44 p=0.05, CD9 p= 0.015). CD44 (mean=29.11), ALDH1 (mean=7.96), CD59 (mean=56.9) and Oct-4 (mean=11.8) expression was lower in post-radiation recurrences when compared to primary EC (mean=122.86, 63.73, 118.1, 65.98, respectively) . There was no significant correlation between CD133, CD44, CD59, CD9, Oct-4 and ALDH1 expression and tumor stage. Conclusions: Some stem cell markers (CD44, ALDH1 and CD59) show increased expression in EC when compared to NE, suggesting a role in tumor development and progression. Moreover, CD44, CD9, ALDH1, CD59 and Oct-4 might not be good predictors of radiation resistance in EC. Background: Proteomics confirm the presence of different proteins in normal tissues and tumors and provide a direct measure of the quantity present. By identifying proteins associated with a malignant process proteomics provide the information how to interfere with the action of those proteins and how to find a drug that may inactivate that action. We compared protein expression in uterine leiomyomas (LM) and leiomyosarcomas (LMS) in search for targets related to histologic features of malignancy and an aggressive behavior. Design: The IRB approved study included 14 LMS and 14 LM, identified in our file between 2002 and 2006. The selected formalin-fixed paraffin-embedded tissues were processed using a heat-induced / enzyme-mediated digestion methodology and analyzed in triplicate by LC-MS/MS on a linear ion trap mass spectrometer. Tandem mass spectra were searched against the UniProt human protein database and differences in protein abundance between the samples were derived by summing the total CID events that resulted in a positively identified peptide for a given protein accession across all samples (spectral counting). The spectral count data were normalized for each protein accession by calculating the percent contribution of the spectral count values for each protein accession against the total number of peptides identified within a given sample. Results: The tumor samples were tested for the presence of 216 proteins and 39 were detected using stringency criteria based on an 80% population of samples with two or more peptides for identifications. Out of 16 proteins that show statistically significant upregulated expression in LMS compared to LM, the following are known to be associated with malignancies: 60S acidic ribosomal protein P1, Ezrin, Fructose-bisphosphate aldolase A, Isoform 1 of Heterogeneous nuclear ribonucleoprotein K, Lamin-B1, Protein disulfide-isomerase, Tubulin alpha-1A chain. Of the 11 proteins showing statistically significant down-regulated expression, some (Actin, Alpha-actinin-1, Isoform 1 of Filamin-A, Isoform 1 of Sorbin and SH3 domain-containing protein 1, Transgelin) appear also to be associated with malignancies. Conclusions: The statistically significant difference in expression of various proteins between LMS and LM may aid the histologic evaluation of smooth muscle tumors and help to identify tumors with more aggressive behavior. In addition the proteomic analysis may lead to a potential identification of a new treatment. Complications associated with H1N1 infection included preterm labor, preterm birth, and pregnancy loss, potentially reflecting effects of the H1N1 virus on the placenta. We sought to determine if placentas from women infected with H1N1 during pregnancy showed evidence of increased inflammation, fetal-derived lesions or other placental pathologies. Design: Women were enrolled under IRB approved protocols who had H1N1 infection during pregnancy confirmed by antigen swab test or PCR. None were acutely infected at the time of delivery. Control subjects were matched for gestational age at delivery, parity and delivery mode. All placentas underwent gross and microscopic pathologic examination and were scored for the presence or absence of inflammation, vascular lesions, meconium and other findings. Fisher's exact test was used for statistical analysis and a p-value of <0.05 was considered significant. Results: Placentas from H1N1-infected women (n=16) and controls (n=17) were examined. Gestational age (GA) ranged from 35 2/7 to 41 5/7 weeks and placental weights ranged from 330 to 630 grams. To control for GA, the fetal to placental weight ratios were determined and were not different between H1N1 cases and controls (7.28±1.27 vs. 6.89±1.15; p=0.37). No significant differences in inflammation were observed. Acute inflammation of the membranes was seen in 4 H1N1 and 7 control placentas (p=0.46), while chronic membrane inflammation was seen in 2 H1N1 and 1 control placenta (p=0.6). Chronic villitis was observed in 2 H1N1 placentas and 5 controls (p=0.40), while umbilical cord or chorionic plate vascular inflammation was seen in 4 H1N1 placentas and 6 controls (p=0.7). Interestingly, 6 H1N1 placentas had intervillous or subchorionic thrombi, compared to 2 controls (p=0.12) and 3 H1N1 placentas had intimal fibrin cushions compared to 1 control (p=0.11), for an overall occurrence of 9 fetal vascular lesions in H1N1 placentas compared to 3 in controls (p=0.03). Conclusions: There were no significant differences in maternal inflammation (membranes) or fetal inflammation (umbilical cord and chorionic plate vessels) between the H1N1 and control groups. In contrast, placentas from women infected with H1N1 during pregnancy showed a higher incidence of fetal-derived vascular lesions, suggesting that fetuses exposed to H1N1 may undergo changes that increase risk for vascular lesions.
Pathologic Characteristics of Endometrial Carcinoma in Women 40
Years of Age and Younger. C Uram-Tuculescu, E Dragoescu. Virginia Commonwealth University Health System, Richmond. Background: Endometrial carcinoma (EC) is the most common invasive gynecologic cancer. Arising mainly in postmenopausal women, it is uncommon before 40 years (y) of age. Previously considered to have favorable histology and excellent outcome, recent studies suggest that EC arising prior to age 40y (EC<40y) may have unfavorable histology and extrauterine disease. The etiology of EC<40y is considered to be primarily unopposed estrogen stimulation in the setting of obesity and anovulatory cycles with a smaller number of cases attributed to microsatellite instability (MSI) as an inherited risk factor. The aim of this series is to analyze the pathologic features of EC<40y in our academic center. Design: All cases of EC<40y diagnosed at our center between January 2005 and September 2010 were retrieved and information from the pathology reports at the time of surgery was recorded. For patients who elected for uterine conservation/medical treatment, results from endometrial biopsy/curettage were used. Status of MSI, estrogen (ER) and progesterone (PR) by immunohistochemistry was retrieved. Body mass index (BMI) of each patient was recorded. Results: 15 cases of EC<40 y were identified, representing 13.2% of all 113 EC diagnosed during this interval. Women ranged in age from 20 to 40y (mean=34.8). 4 patients elected uterine conservation/medical treatment; 3 had FIGO I endometrioid adenocarcinoma and 1 had serous carcinoma in an endometrial polyp. 86.6% of women were obese (BMI>30), mean BMI=45 (range . Of the 7 cases tested, 4 were ER positive (57.1%) and 3 PR positive (42.8%). MSI testing in 3 cases showed positive staining in 2 cases and MSH2/MSH6 negative result in 1 case submitted for mutational analysis. Conclusions: EC<40 y is uncommon (13.2% of all EC) and is not an indolent disease. In our series 45.4% of patients had advanced disease, LVI, positive pelvic cytology and 72.7% had large tumors. 86.6% of EC<40y were endometrioid type. The majority of patients were obese and MSI studies were initiated by the clinician in a minority of cases. (HGSC) . There also exists a spectrum of lesions that are putative STIC precursors, namely "p53 signature," which lacks nuclear atypia, and tubal intraepithelial lesion in transition (TILT), which exhibits atypia, but falls short of STIC. A recent study (Carlson, et al.) reported suboptimal interobserver concordance when morphologic guidelines, but not immunohistochemistry (IHC), were used for categorization. The current study tested an algorithm to enhance interobserver concordance, with the ultimate goal of developing a classification scheme that can be used for diagnostic standardization.
Design:
Empirically derived morphologic criteria were tested using a panel of 6 pathologists who independently examined 67 lesions in round 1. An around-the-scope training session and IHC (using p53 and Ki-67) were added to morphologic examination, followed by independent assessment of 42 cases in round 2. Results: By CGH, the most common regions of gain in all ECs were 1q21-q41, 1q telomere, 8q24, 8q telomere and 3q27-q29. The most frequent regions of loss were 19p telomere, 9q33.2-q34, 18q 21, 17p12 and 16q22-q24. Differences were observed in the overall frequency and specific regions of gains and losses between EM and NE tumors. A four probe combination of 1q25, 8q24, 8p11 and 20q13 provided the most optimal sensitivity and specificity for the detection of EC in paraffin-embedded tissue sections. Cutoffs for abnormality of each probe were: ≥14% of cells with gains of 1q25 or ≥10% of cells with gains of 8q24 or ≥6% of cells with gains of 20q13 or ≥4% of cells with gains of 8p11. These cutoffs detected of 45/52 cases with EC or ACH (sensitivity 87%) and were negative in all 17 specimens with hyperplasia without atypia or benign endometrium (specificity 100%). The probe set detected 2/3 (67%) of ACH, 10/15 (67%) EM grade 1 tumors, 9/10 (90%) grade 2 tumors and all of grade 3 (n = 10) and NE tumors (n = 14).
Conclusions:
This study revealed specific regions of gain and loss that are common in EM and NE EC. A four probe FISH set appears to have high sensitivity and specificity for the detection of EC. However, prospective studies are needed to determine the analytical performance characteristics and clinical utility of this FISH assay. Conclusions: STIC is early stage of HG-PSC and it has distinct microRNA expression and it can be discriminated by its unique microRNA signature from FT and HG-PSC. Top dysregulated microRNAs in HG-PSC have a high agreement with published data. We were able to identify a subset of oncogenic microRNAs differentially expressed between FT, STIC and PSC. This novel finding will provide molecular tools for the further analysis of tumorigenesis of STIC and will benefit in searching for new biomarkers (microRNA target genes) for STIC.
microRNAs and Their Target Gene Networks in Uterine
Leiomyomas. J-J Wei, Z Liu, J Zavadil, P Soteropoulos, H Ye. Northwestern University, Chicago, IL; UMDNJ-New Jersey Medical School, Newark, NJ; New York University, NY. Background: Human uterine leiomyomas (ULMs) are characterized by dysregulation of a large number of genes and microRNAs. It is thus important to examine the roles played by the highly dysregulated microRNAs through regulation of specific target genes in tumorigenesis of ULMs. To explore the broader relationship between other dysregulated microRNAs and their target genes exhibiting aberrant expression in ULMs, global analysis of microRNA and target gene expression in ULMs is helpful to identify the potential candidates of microRNAs for tumorigenesis and growth of ULMs. Design: Among 70 cases with ULMs, 45 cases were conducted for global microRNA expression analysis (Ambion); 5 cases for global gene expression analysis (Affymetrix); 8 cases for comparative genomic hybridization (CGH); 36 cases for immunohistochemistry; 14 cases for senescence; and 24 cases for validation. Uterine leiomyoma and myometrial cell lines with stable overexpression of lentiviral miR-29b, miR-296, miR-200a and let-7c were prepared for analysis of predicted target gene and tumor growth. Relationship of selected mRNAs in ULMs and target gene functional pathways were analyzed by GeneSpring GX11, TM4 Microarray Software Suite, DAVID and Gene set enrichment analysis. Results: miRNA and mRNA expression were examined in paired sets of ULMs and matched myometria. Patterns of inverse association of microRNA with mRNA expression in ULMs revealed an involvement of multiple candidate pathways, including transcriptional reprogramming, cell proliferation control, MAP kinase, TGF-β, WNT, JAK/STAT signaling, remodeling of cell adhesion, cell-cell and cell-matrix contacts. Two distinct microdeletion detected by GCH might be responsible for loss of miR-15 and miR-200a clusters. These miRNAs directly regulated IGF signaling pathway, EMT pathway, and some oncogenes. These miRNAs are tumor suppressors and significantly inhibit leiomyoma cell growth in vitro. Some miRNAs may participate in the leiomyoma aging process. Those miRNAs that are associated with smooth muscle differentiation are significantly dysregulated in ULMs. Conclusions: The levels of the most dysregulated microRNAs in ULMs show an inverse association with the expression levels of many predicted target genes, and that they may affect multiple homeostatic pathways and functions. Some but not all of them can be validated as functional targets of specific microRNAs in vitro. Dysregulated miRNAs are associated with leiomyoma growth, differentiation and aging process. Background: Over-expression of MCM 2 and 7 have been shown to correlate with aberrant S-phase induction and persistent HPV infection. To further improve accuracy in identifying abnormal cells and true disease from BD SurePath liquid-based cervical (LBC) cytology specimens, a new automated test, that combines the morphology of a standard SurePath Pap with protein biomarker immunostaining on a single slide (hereafter referred to as SurePath Plus), was developed. This research study evaluated the performance of SurePath Plus in identifying CIN2+ disease. Design: This study included 996 cytology specimens ranging from NILM to HSIL. All LSIL and HSIL cases had biopsy results. As biopsies were not obtainable for all NILM and ASCUS cases, a negative HPV test was used as a surrogate for disease negative status. For each sample, 2 slides were produced, one prepared as a SurePath Pap and a second SurePath Plus slide prepared using a BD PrepStain Plus instrument that combines cell deposition with optimized immunocytochemical processing and Pap counterstaining. All slides were scored using standard Bethesda 2001 criteria. The SurePath Plus slide was further evaluated for the presence of nuclear immunostaining in morphologically abnormal cells. The distribution of cases within the various morphologic categories and their biopsy status were compared.
Results:
Comparison of the SurePath Plus slides to the SurePath Pap slides, using a cytology endpoint, resulted in a 153% increase in the HSIL+ detection rate (123 cases) and a corresponding decrease in detection rates for LSIL (23% decrease, 58 cases) and ASCUS (54 % decrease, 207 cases). The biopsy endpoint analysis resulted in a significant increase in the number of CIN2+ cases associated with HSIL+ cytology and a corresponding reduction in the amount of CIN2+ within the LSIL and ASCUS groups for the SurePath Plus Test when compared to the SurePath Pap. Specifically, the number of CIN2+ cases within the HSIL+ group increased 154% (77 cases), while the number of CIN2+ cases decreased by 62% (52 cases) within the LSIL and 62% (13 cases) for the ASCUS population. Conclusions: This study reports the successful development of reagents, assay, and instrumentation that combine biomarker specific immunostaining with standard Pap counterstaining. The use of the SurePath Plus test leverages the advantages of both biomarker expression and morphologic assessment on a single LBC slide. Within this biopsy confirmed research cohort, the SurePath Plus test resulted in a more accurate detection of high grade disease.
1149
The Clinical Significance of "Squamous Intraepithelial Lesion (SIL) of Indeterminate Grade" as a Distinct Cytologic Category. D Wong, C Teschendorf, GY Lin, F Hasteh. University of CA, San Diego. Background: "Squamous intraepithelial lesion of indeterminate grade" (SIL) was introduced in the 2001 Bethesda System for cervical lesions that lie between low-grade or high-grade lesions without discussion of follow-up or its clinical significance. At our institution we use the SIL terminology for such borderline lesions, which is similar to "low grade squamous intraepithelial lesion cannot exclude high-grade squamous intraepithelial lesion (LSIL-H)" utilized by some studies. In this study, we evaluated the follow-up of these borderline lesions collected over a 3 year period and compared them to the follow-up results of low-grade or high-grade squamous intraepithelial lesions (LSIL or HSIL) on Pap smears. Design: A computer-generated review of cervical pap smears (100% Surepath) diagnosed as SIL from 01/2007 through 01/2010 revealed 152 cases. Histologic outcomes (cervical biopsy, endocervical curettage, loop electrosurgical excision procedure) or follow-up pap smears with available high-risk HPV serologies were obtained for 127 (84%) of these cases. Control groups of 150 cases with a Pap smear diagnosis of LSIL or HSIL with histologic follow-up were selected sequentially from this same time period. Patients with <6 months follow-up and no follow-up were excluded. If multiple follow-up specimens were available the highest degree of dysplasia was used. Results: On follow-up, HSIL (cervical intraepithelial neoplasia (CIN) grade 2 or 3) was identified in 21% (27/127) of SIL cases, 8.7% (13/150) of LSIL cases and 69% (104/150) of HSIL cases. LSIL (CIN 1) was identified in 30.7% (39/127) of SIL cases, 59% (89/150) of LSIL cases and 17% (26/150) of HSIL cases. ASC-US (atypical squamous cells of undetermined significance) was identified in 20.5% (26/127) of SIL cases with most positive for high-risk HPV at 61.5% (16/26). In comparison, the ASC-US rate was similar for both the LSIL and HSIL control groups (7.3% and 6.7% respectively). A diagnosis of benign was identified in 27.6% (35/127) of SIL cases, 24.7% (37/150) of LSIL cases, but only 6.7% (10/150) of HSIL cases. The histologic outcomes between the SIL, LSIL and HSIL groups are statistically different (p<0.001).
Conclusions:
The results showed that patients with the cytologic diagnosis of "SIL of indeterminate grade" have histologic outcomes which are intermediate between and statistically significantly different from patients with either a LSIL or HSIL diagnosis. Our findings support prior studies evaluating the follow-up of patients with LSIL-H and support retaining SIL as a unique category in the Bethesda system. Background: K-ras gene product in the EGFR pathway is critical in the development of many types of malignancy including lung, colon and endometrial cancer. Often, K-ras mutation-associated lung, pancreatic, colon or ovarian cancer display mucinous differentiation. Previous studies showed that K-ras gene mutation can be found in 10-40% of endometrial carcinoma. Endometrial carcinoma includes many histological subtypes with variable pathogenesis. To our knowledge, the correlation of K-ras mutations with carcinoma with significant mucinous differentiation of uterus has not been reported before. The current study is aimed to investigate the prevalence of K-ras gene mutations in the mucinous carcinoma and endometrioid carcinoma with significant mucinous differentiation (MC&ECMD) and compare it with endometrioid carcinoma (EC). Design: With IRB approval, specimens of MC&ECMDs and ECs were searched from the archival files of the Department of Pathology, W&I Hospital. Thirteen MC&ECMDs and eight ECs were selected for this study. Genomic DNA was extracted from formalinfixed paraffin-embedded tissue sections that were macrodissected to ensure more than 80% of tumor cells. PCR amplification for K-ras codons 12 and 13 were performed (RIH, RI), followed by sequencing using capillary electrophoresis (Sequencing Facility, Yale University, CT). The sequencing results were analyzed by "Sequence Scanner v1.0" program. Results: K-ras codons 12 and 13 mutations were detected in 10 of 13 (76.9%) MC&ECMDs with the most prevalent mutation being G12D (codon 12, GGC > GAC) (4/10, 40%). Only 2 of 8 ECs (25%) were positive for K-ras mutation, all being G12D. Statistically significant difference of K-ras mutation was noted between MC&ECMDs and ECs (P< 0.05, Fisher's exact test). Overall G12 D mutation is the most prevalent mutation detected in this study (6/12, 50%).
